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1.2. Anterior eye development 
 
1.2.1. Morphological development 
 
During vertebrate gastrulation, the endoderm and mesoderm interact with and destine 
overlying ectoderm to become head ectoderm with lens-forming bias (Saha et al., 1989). The 
optic vesicle, an evagination of the brain, activates this bias and induces the head ectoderm to 
become a lens placode. The lens placode invaginates to form the lens, whereas the optic 
vesicle forms the optic cup that will develop into the retinal layers, including the ON. Lens-
derived signals induce overlying ectoderm to become corneal ectoderm that rests on a basal 
lamina and that secretes multple layers of collagen (Gilbert, 2006).  
 
At the 6th week of gestation mesenchymal cells of both ocular neural crest (NC), as well as of 
paraxial mesoderm origin, migrate along the collagen matrix to fill the space between corneal 
ectoderm and the lens. Most of the cells form several layers of loosely aggregated cells that 
condense and differentiate into corneal endothelium (reviewed by Cvekl and Tamm, 2004). 
The differentiation of the corneal endothelium is critical for the separation of the lens from the 
cornea and subsequent anterior chamber formation (Reneker et al., 2000; Flügel-Koch et al., 
2002). New mesenchymal cells continue to migrate to the future corneal stroma. By the 12th 
week of gestation, glycosaminoglycan and collagen fibril secreting fibroblasts appear 
(reviewed by Qazi et al., 2009). Glycosaminoglycans are the ground substance of the cornea, 
whereas the small in diameter and spatially highly ordered collagen fibrils confer corneal 
transparency (Maurice, 1957; Benedek, 1971). A new group of mesenchyme cells invade the 
future anterior chamber angle and differentiate into stroma of the iris and ciliary body (CB). 
Beginning from weeks 15 - 20 of gestation until birth, anterior chamber or iridocorneal angle 
invading mesenchyme cells develop into the trabecular meshwork (TM) and Schlemm´s canal 
(SC) (reviewed by Cvekl and Tamm, 2004), the structures that build up the aqueous humour 
(AH) outflow pathway. The above described key anterior eye development steps can also be 
found in mouse embryos between E12.5 and E19.5 as illustrated in Fig. 1.2. 
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Figure 1.2: Illustration of mouse anterior eye development. A) After the lens has detached from the corneal 
ectoderm/surface epithelium (SE) at E12.5 - E13.5 (at 6th week of gestation in human), mesenchymal cells (Me) 
of both ocular NC, as well as of paraxial mesoderm origin, migrate along a collagen matrix into the space 
between the corneal ectoderm and the lens (L). B) At E13.5 – 14.5 the mesenchymal cells condense to several 
flat layers separated by extracellular matrix. In human, the mesenchymal cells condense and differentiate into 
corneal endothelium already at this stage. C) At E14.5 – E15.5 all layers of the cornea (corneal epithelium 
(CEp), corneal stroma (CS) and corneal endothelium (CEn)) have formed, allowing the separation of the lens 
and the formation of an anterior chamber (AC). New mesenchyme cells migrate into the future anterior chamber 
angle (black arrows). D) At E15.5 the anterior edges of the optic cup extend to form the iris and CB. Invading 
mesenchyme cells form the stroma of these structures (SIr and SCB). The last vawe of mesenchymal cells 
migrate into the anterior chamber angle between E17 and E19 (between 15th and 20th week of gestation in 
human), resulting in the formation of the TM and SC. LV = lens vesicle, Re = neural retina, PE = pigmented 
epithelium, EF = embryonic fissure, HA = hyaloid artery. Adapted from Cvekl and Tamm, 2004. 
   
 
 
 
Introduction  13 
 
1.2.2. Signalling molecules 
 
The mature anterior eye is made up of tissues originating from the four embryonic lineages 
neural ectoderm (epithelial layers of CB and iris), ocular surface ectoderm (lens, corneal 
epithelium, limbus, conjunctiva, harderian and lacrimal glands, eyelid epidermis), NC 
(corneal stroma and endothelium, conjunctival and eyelid mesenchyme, stroma of iris and 
CB) and mesoderm (SC and blood vessel endothelium), that interact in a complex way during 
morphogenesis. These mechanisms are strictly controlled by spatial and temporal regulation 
of the expression of various transcription factors, as well as by integration of different 
signalling pathways. The transcription factor paired box 6 (PAX6/Pax6 in human/mouse) is a 
key transcription factor in the synchronization of eye development in vertebrates. Its restricted 
spatial expression in the head ectoderm confers bias for the invagination and formation of the 
lens (Li et al., 1994). Spatial and temporal regulation of Pax6 expression in widespread 
regions of the eye regulates the spatial and temporal expression of downstream key 
transcription factors. In addition, Pax6 has cell-autonomous roles in migration and 
differentiation of NC-derived cells of the cornea (stroma, endothelium) and TM (Baulmann et 
al., 2002; Collinson et al., 2003).  
 
The lens-derived transcription factors MAF (v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog), FOX (forkhead box) E3 and PITX (paired-like homeodomain) 3, as well 
as the transcription factors PITX2 and FOXC1 that are expressed in the anterior eye ocular 
mesenchyme cells themselves, are crucial controllers of normal anterior eye development. 
Mutations in their genes are known to cause different subtypes of anterior segment dysgenesis 
(ASD) including Peters´ anomaly, Axenfeld-Rieger´s syndrome, aniridia and embryotoxon. 
ASD phenotypes show anomalities in anterior mesenchyme-derived structures like iris, cornea 
and the anterior chamber angle, which may result in the absence of an anterior chamber, 
corneal opacity or, due to dysgenesis of the AH outflow tissues in the anterior chamber angle, 
an elevated intraocular pressure (IOP) (reviewed by Cvekl and Tamm, 2004). It has been 
proposed that ASD relys on defects in the migration and differentiation of mesenchymal NC 
cells (Kupfer and Kaiser-Kupfer, 1978). The fact that phenotypes of different ASD subtypes 
may be overlapping and that the same mutation may show different phenotypes, shows the 
complexity of ASD. Mouse models have shown that some secreted signaling molecules 
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transforming growth factor-ß (TGF-ß) and bone morphogenetic protein 4 (BMP4) lead to 
defects that closely resemble those seen in ASD (Chang et al., 2001; Sanford et al., 1997; 
Flügel-Koch et al., 2002), which raises the possibility that their expression may be controlled 
by above described key transcription factors.  
 
Since Pax6-mutant mice have a defect retinoic acid (RA) signaling (Enwright and Grainger, 
2000), there have been speculations about to what extent the effect of PAX6 on eye 
development is modified via retinoids. It is well established that vitamin A (retinol) is 
indispensable for eye development (Hale, 1933). RA is synthesized in the retina and the 
corneal ectoderm, though it signals via retinoic-acid receptor (RAR) heterodimers in the 
periocular mesenchyme and NC-derived mesenchyme to affect the gene expression of key 
transcription factors involved in anterior eye morphogenesis (Matt et al., 2005). Experiments 
with Pitx2- and Dkk2-mutant mice showed that the RA signalling in the NC mesenchyme was 
able to control Wnt signalling of the NC, as well as that of the overlying corneal ectoderm 
(Gage et al., 2008).  
   
 
1.3. The TM 
 
1.3.1. AH outflow  
 
AH drainage through the anterior eye produces an IOP of 16 - 17 mm Hg that is optimal for 
maintaining shape and thus optical properties of the eye. AH transports oxygen and nutrients 
to, as well as waste products from, the avascular lens, cornea and TM. AH is thought to have 
a role in the delivery of antioxidants, as well as in the immune response (reviewed in Civan, 
2008). AH is produced by the ciliary body in the posterior chamber and flows through the 
pupil into the anterior chamber. From here, most of AH is drained through the conventional or 
the trabecular outflow pathway, whereas the rest of AH is conducted through the 
unconventional or uveoscleral outflow pathway with a negligible contribution to the IOP 
Introduction 
 
(Johnson and Erickson, 200
where the AH is drained into
 
        
 
Figure 1.3: Diagramm showing th
outflow pathways. AH is produce
into the anterior chamber. A pa
contribution to the IOP. The bulk
resistance and thus is responsible 
venous system. B) is a magnificati
 
 
1.3.2. TM architecture 
 
AH is drained through the T
the TM is made up of the uv
and the juxtacanalicular tissu
 
0). The conventional pathway includes the
 the episcleral venous system (Fig. 1.3A, B).
e conventional or trabecular, as well as the unconven
d in the CB epithelium in the posterior chamber and
rt of the AH escapes through the uveoscleral pa
 of the AH is drained through the TM, the tissue t
for the build-up of IOP. The AH from both pathways
on of the squared area in A). Adapted from Lütjen-Dr
M by a pressure gradient. Beginning from t
eal and corneoscleral meshworks (UTM and
e (JCT) (Fig. 1.4B).  
15 
 TM and SC, from 
  
 
tional or uveoscleral AH 
 flows through the pupil 
thway with a negligible 
hat builds up an outflow 
 flows into the episcleral 
ecoll, 2000. 
he anterior chamber, 
 CTM, respectively) 
Introduction  16 
 
 
 
 
Figure 1.4: A) The conventional AH outflow pathway is made up of the TM between the anterior chamber and 
the SC. B) Beginning from the anterior chamber, the TM is made up of the uveal and corneoscleral meshworks 
(UTM and CTM, respectively) and the juxtacanalicular tissue (JCT). The JCT, as well as the lining between the 
JCT and the inner wall endothelium of SC are thought to be the sites that generate outflow resistance. The fluid 
flow into SC is controlled by pouchings and pores of the inner wall endothelium of SC (small arrows). SS = 
scleral spur, CM = ciliary muscle. Magnification bars: 20 µm (A), 5 µm (B). Light micrograph of a meridional 
section through the TM as presented in Tamm, 2009. 
 
 
UTM and CTM are made up of layers of trabeculaer lamellae. The core of the lamellae 
contain dense elastic fibers that are surrounded by a sheath of flat trabecular cells that resides 
on a basal lamina and that thickens with age. The cells can phagocytize dispensable material 
like iris-derived pigment particles and extracellular material (reviewed by Tamm, 2009; 
Acott, 1994). The lamellae of the UTM and CTM show a relatively ordered spatial 
organization with numerous open spaces between the lamellae. This gives the UTM and the 
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CTM a highly porous structure with a negligible contribution to fluid flow resistance 
(reviewed by Johnson, 2006).  
 
In contrast, the cells of the JCT are organized more irregularly and are attached to each other, 
to extracellular matrix (ECM) or to the SC endothelium. Structural elements of the ECM are a 
network of elastic fibers and fibronectin-based cell-matrix connections between the ECM and 
SC endothelium. Matricellular proteins of the JCT ECM that are involved in structural ECM 
modulation are thrombospondin-1 (Flügel-Koch et al., 2004) and SPARC (secreted protein, 
acidic and rich in cysteine) (Rhee et al., 2003). The POAG associated myocilin, one of the 
most highly expressed proteins in the TM (Tomarev et al., 2003) can associate with fibrillar 
elements of the JCT ECM (Ueda et al., 2000).   
 
 
1.3.3. Generation of outflow resistance 
 
The JCT and the inner wall endothelium of SC have proven to be the sites of build up of AH 
outflow resistance. Since the spaces between the cells and the ECM are the route for AH 
outflow through the JCT, the amount and quality of the ECM are crucial regulators of the 
resistance (reviewed by Acott and Kelley, 2008). JCT ECM turnover is controlled by the 
growth factors TGF-ß2, CTGF (connective tissue growth factor), BMP4 and BMP7 
(Fuchsofer and Tamm, 2009), as well as by glucocorticoid (GC) and prostaglandin derivatives 
(Johnson et al., 1990; Bahler et al., 2008). It is thought that AH flow into the SC is controlled 
by emerging outpouchings (giant vacuoles) and pores of the SC inner endothelium (Figs. 1.4B 
and 1.5), whereas the flow resistance itself is generated in the JCT ECM or the SC basement 
membrane (BM) (reviewed by Johnson, 2006). 
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Figure 1.5: AH flow into the SC is controlled by emerging outpouchings (giant vacuoles) and pores (arrows) of 
the SC inner endothelium. Scanning electron micrograph as presented by Johnson, 2006.  
 
 
Tendons and elastic fibers structurally connect the ciliary muscle (CM) and the scleral spur 
(SS) with the TM ECM (Fig. 1.4A). The SS contains innervated myofibroblast-like cells 
(Tamm et al., 1995) that contain actin filaments (Tamm et al., 1992). Both CM and SS cell 
contraction affect TM architecture, probably in opposite directions (reviewed by Tamm, 
2009). 
 
 
1.3.4. Pathology 
 
Glaucoma is the definition of a complex group of neurodegenerative disorders that are 
characterized by optic neuropathy leading to gradual visual loss, and that in its irreversible 
end phase is the second leading cause of blindness worldwide (reviewed by Leske, 2007). 
Classically, the optic neuropathy is thought to develop as a consequence of an elevated IOP 
due to an elevated AH outflow resistance through the TM. The fact that normal-tension 
glaucomas exist and that the inheritance of glaucoma is complex, show the complexity of the 
disease (reviewed by Armstrong and Smith, 2001).  
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Three main classes of glaucoma are primary open-angle glaucoma (POAG), primary acute 
closed angle glaucoma (PACG) and primary congenital glaucoma (PCG). In PACG and PCG 
an increased AH outflow resistance through the TM rely on defects in anterior chamber angle 
morphology (reviewed by Ray et al., 2003; Kupfer and Kaiser-Kupfer, 1979). Glaucoma can 
also be manifested as a symptom of other eye malformations like different forms of ASD 
(reviewed by Cvekl and Tamm, 2004).     
 
 
1.3.4.1. POAG 
 
Due to normal morphology of drainage structures in POAG, and since an elevated IOP due to 
increased AH outflow resistance through the TM is asymptomatic, the disease is not 
manifested until loss of visual fields, a timepoint where apoptosis of optic nerve head (ONH) 
cells already has begun. POAG is the most common form of glaucoma and can, dependent on 
the age of onset of the disease, be divided into the juvenile and adult forms. 13 - 25 % of 
POAG cases are inherited in an autosomal dominant or recessive pattern, though with varying 
clinical expression and penetrance of disease (Becker et al., 1960; Kellerman and Posner, 
1955).  
 
Age-related changes of the TM are the most important factors leading to POAG, which 
explains the fact that mostly elderly people are affected. An altered histological structure of 
the outflow pathway like a decrease in the number of cells, as well as an accumulation of 
ECM have been reported (reviewed by Armstrong and Smith, 2001). Electron microscopy has 
revealed an accumulation of collagen and fine fibrillar material. The fine fibrils, that are 
embedded in a glycosaminoglycan matrix, form sheaths around the elastic fibers of the JCT. 
The sheaths can thicken to form so called plaques (Lütjen-Drecoll and Rohen, 1981). 
Additional glaucomatous changes of the JCT are the presence of numerous large cells 
containing many mitochondria and lysosomes, but no endoplasmic reticulum (ER) or Golgi 
apparatus (Rohen et al., 1993). 
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1.3.4.2. Secondary forms of open-angle glaucoma (OAG)  
 
OAG can develop secondary due to dysfunction of autoregulation of ocular blood flow, which 
affects IOP and normal metabolism in eye tissues, including ONH and TM (reviewed by 
Moore at la., 2008). Corticosteroid treatment (including the GC dexamethasone) of 
inflammatory and allergic eye conditions increase IOP to a degree that correlates with the 
patient´s steroid responsiveness (Armaly, 1965), a trait that in turn is inherited (Armaly, 
1967). An established risk factor for developing OAG is a thinner than normal central corneal 
thickness (Gordon et al., 2002), an inheritable trait (reviewed by Dimasi et al., 2009). The 
mechanisms that link the secondary factors to OAG are far from clear.   
 
 
1.3.5. Treatment of glaucoma 
 
Since the molecular mechanisms that generate an elevated AH outflow resistance through the 
TM are to be unraveled, treatment of tension-glaucoma has focused on the symptom; i.e. in 
lowering IOP. Treatments include reduction of production of AH by the CB (e.g. carbonic 
anhydrase inhibitors) or facilitation of AH outflow through the anterior chamber angle. The 
latter can be achieved by stimulating a contraction of the parasympathetically innervated CM 
and subsequent relaxation of the TM (e.g. parasympathomimetics), or by enhancing the 
outflow through the uveoscleral route (e.g. prostaglandin F receptor agonists) (reviewed by 
Costagliola et al., 2009). The final alternative to cure raised IOP are surgical methods like 
laser trabeculoplasty (reviewed by Coakes, 1992), filtration surgery (Anand et al., 2007) or 
CB ablation (Mastrobattista and Luntz, 1996).        
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1.3.6. Glaucoma genetics 
 
Chromosomal linkage analyzes of families affected by inherited forms of POAG have 
identified many disease-associated chromosomal loci. Mutated forms of the genes for 
myocilin (MYOC) and optineurin (OPTN) can act as causative (reviewed by Ray et al., 2003), 
whereas mutated forms of the genes for CYP1B1 (CYP1B1) (cytochrome P450, family 1, 
subfamily B, polypeptide 1) and WDR36 (WDR36) (WD repeat domain 36) can act mainly as 
modifying (reviewed by Vasiliou and Gonzalez, 2008; reviewed by Challa, 2008) genes in 
POAG etiology. The many involved loci and the different nature of involved proteins again 
demonstrate the complex nature of both the genetics, as well as the molecular mechanisms 
lying behind glaucoma. 
 
 
1.4. Myocilin 
 
1.4.1. History   
 
The locus GLC1A (GLC, 1 and A stand for glaucoma, primary open angle and first linkage 
for POAG, respectively) in the region 1q21 - 31 on chromosome 1 was identified to be 
responsible for the juvenile form of OAG in 1993 (Sheffield et al., 1993). Since increased IOP 
had been recognized as being a consequence of GC treatment (Armaly, 1963; Becker, 1965), 
research now focused on the effects that GCs exerted on human TM cells in culture, a 
recognized good model in studying cellular in vivo processes (reviewed by Wordinger and 
Clark, 1999). Reported effects were alterations in ECM protein composition (Dickerson et al., 
1998), cytoskeleton (Clark et al., 1994) and gene expression (Kawase et al., 1994). In 1997, 
Polansky et al. showed that prolonged GC-treatment of cultured human TM cells induced the 
expression of a new 57 kD protein, named trabecular meshwork induced GC response (TIGR) 
protein. In the same year TIGR was cloned from CB (Ortego et al., 1997) and retina (Kubota 
et al., 1997). As Stone et al. (1997) mapped TIGR to the region 1q23 - 24 within the GLC1A 
locus and showed that mutations within TIGR cause glaucoma in 3.9 % of POAG patients, as 
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1.4.4. Myocilin protein forms 
 
Myocilin contains many sites that confer the possibility for post-translational modification. 
The many N-glycosylation sites found within myocilin produce bands that vary in size from 
53 – 57 kD (reviewed by Resch and Fautsch, 2009), and which also may be responsible for 
band sizes that reach MWs of up to 66 kDa. In addition to the many N-glycosylation sites, 
myocilin contains sites for O-glycosylation, glycosaminoglycan initiation, hyaluronan-
binding, and phosphorylation (Nguyen at al., 1998; Fingert et al., 1998).  
 
Myocilin is a hydrophobic protein that can be found in AH in larger than 250 kD aggregates 
(Russell et al., 2001), probably composed of myocilin aggregating with itself and other 
proteins. Leucine zipper motifs are involved in homo- and heterodimerization of proteins 
(Hurst, 1996). In vitro, myocilin can dimerize and oligomerize through its leucine zipper 
domain (Fautsch and Johnson, 2001), as well as form intra- and intermolecular disulfide 
bonds through its five cystein residues (Fautsch et al., 2004).  
 
 
1.4.5. mRNA expression pattern 
 
Myocilin mRNA is found at high levels in most ocular tissues including TM, CB, sclera, 
choroid, cornea, iris, retina and ONH (reviewed by Tamm, 2002). Very high expression is 
seen within TM, sclera (Adam et al., 1997), CB and iris (Ortego et al., 1997). Mouse myocilin 
mRNA has a similar expression pattern, with very high expression within CB epithelium, 
anterior portion of sclera and TM (Takahashi et al., 1998), tissues that are involved in 
production and drainage of AH.  
 
Outside the eye myocilin mRNA can be found in skeletal muscle, heart, small intestine, and to 
a lesser extent in mammary gland, thymus, prostate, testis, colon, stomach, thyroid, trachea 
and bone marrow (Ortego et al., 1997; Adam et al., 1997; Fingert et al., 1998). Tiny amounts 
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of myocilin mRNA has also been found within Schwannoma tumours that affect the myelin 
sheath of vestibular nerves of the brain (Ohlmann et al., 2003). The myocilin mRNA 
distribution pattern outside the eye is akin in mouse (reviewed by Tamm, 2002), with the 
addition that myocilin mRNA has been detected in adult mouse brain, including the 
ependymal lining of the ventricles and the choroid plexus (CP) (Swiderski et al., 1999). In rat, 
myocilin mRNA is abundantly expressed in the sciatic nerve (Ohlmann et al., 2003). 
 
 
1.4.6. Protein expression and localization 
 
Expression of myocilin protein correspond its mRNA distribution pattern. High amounts of 
myocilin are detected in all parts of the TM, Sclemm´s canal endothelium, CM, CB 
epithelium, in all layers of the cornea and corneal sclera, iris, vitreous humour, retina and 
ONH (Karali et al., 2000; Ueda et al., 2000). Within the JCT, the part of the TM with the 
highest AH outflow resistance, myocilin localizes to the ECM space, and to a lesser extent to 
the cytoplasm of TM cells (Konz et al., 2009). Within the JCT ECM, myocilin associates with 
the fine fibrils and associated glycoprotein matrix that surround the elastic fibers, and which 
are able to thicken and form plaques (Ueda et al., 2002). Myocilin also associates with the 
elastic fibers themselves (Ueda et al., 2000) and collagen (Tawara et al., 2000) and is, in its 
secreted glycosylated and aggregated form, a major constituent of AH (Russell et al., 2001). 
Intracellularly, myocilin is reported to localize to intermediate filaments (IFs), mitochondria, 
and intracellular vesicles (Ueda et al., 2000), and after dexamethasone-treatment to the ER 
(Wentz-Hunter et al., 2002), the Golgi apparatus and the microtubule motor protein kinesin 
(Clark et al., 2001) of cultured human TM cells.  
  
The expression of myocilin in the mouse eye correspond the expression pattern in the human 
eye. During development, expression of myocilin is first detected in the axons of the retinal 
ganglion cells at E17.5, whereas expression in the anterior eye is not visible until postnatal 
day (P) 10. TM, CB epithelium, iris with stroma, as well as corneal endothelium and stroma 
are positive for myocilin staining at P12 - P14. Thus, in the eye, myocilin expression 
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commence with the time of the morphological maturation of respective tissue (Knaupp et al., 
2004). 
 
Outside the eye, myocilin is expressed in the sciatic nerve. In rat, the site of expression within 
the sciatic nerve was shown to be the myelin sheath (Ohlmann et al., 2003). Myocilin has 
been detected within fibroblast-like cells of the outer fibrocartilagenous annulus fibrosus of 
the intervertebral disc (Gruber et al., 2006), the ECM-rich joint ligament between adjacent 
vertebrae. Within rat kidney glomeruli, myocilin is found constitutively within podocytes, and 
during induced mesangioproliferative glomerulonephritis, a condition characterized by an 
excess production of ECM (Floege et al., 1991), in the cytoplasm and ECM of mesangial cells 
(Goldwich et al., 2005).   
 
 
1.4.7. Function 
  
70 different mutations in myocilin are responsible for 2 – 4 % of POAG cases, and in as many 
as 36 % of patients suffering from the juvenile onset OAG (Schimizu et al., 2000). Over 90 % 
of the mutations reside within exon 3, the rest are found within exon 1. Most of the mutations 
within exon 3 and 1 reside within the conserved olfactomedin and myosin-like domains, 
respectively (reviewed by Zachary and Fautsch, 2009). The majority of MYOC mutations are 
missense mutations, leading to an aa substitution that may affect protein structure and 
function, whereas the most frequently occurring single mutation is a nonsense mutation that 
results in a truncated 368 aa protein (reviewed by Tamm 2002). The single mutations usually 
show specific clinical features regarding IOP, frequency, age of onset and severity of disease 
(Alward et al., 1998). Since patients with only one copy (Wiggs and Vollrath, 2001) or 
homozygous deletion of > 90 % (Lam et al., 2000) of MYOC are healthy, and since myocilin 
knock-out mice have a normal phenotype (Kim et al., 2001), the function and the mechanism 
how mutated myocilin causes POAG is still a secret and suggests a gain of function or a 
dominant-negative effect theory. Even though myocilin is expressed in many organs and 
tissues (reviewed by Tamm, 2002; Ohlmann et al., 2003; Gruber et al., 2006), the only 
pathology that results from MYOC mutations is glaucoma. This suggests an important and 
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specific function for myocilin within the eye in the maintenance of an adequate AH outflow 
resistance. 
 
 
1.4.7.1. Intracellular myocilin 
 
Most data that confer myocilin an intracellular role are derived from in vitro biochemical and 
cell culture experiments. The N-terminal leucine zipper coiled coil motif targets cellular 
recombinant myocilin to intracellular membranes (Stamer et al., 2006). The fact that myocilin 
is found associated with ER (Sohn et al., 2002), the Golgi apparatus, (O´brien et al., 2000) 
and vesicles (Lütjen Drecoll et al., 1998) probably reflects its trafficking between ER and 
Golgi during post-translational modification. The finding that myocilin, vesicles and the 
motor protein kinesin all co-localize within TM cells (Clark et al., 2001), indicates that 
myocilin may be involved in vesicular transport. Myocilin has also been found within 
mitochondria and can, when mutated, disturb normal mitochondrial energy metabolism 
function, affecting cell viability (He et al., 2009).  
 
Another theory gives myocilin a role in the regulation of cytoskeletal architecture, an 
interesting approach, since modulation of the cytoskeleton with various pharmacological 
agents have shown to decrease AH outflow resistancy in living monkey eyes, as well as to 
reduce IOP in human eyes (Tian et al., 2000). A role for myocilin within the actomyosin 
system of TM cells is corroborated by the facts that myocilin interacts with the myosin motor 
protein through its conserved leucine zipper domain, myocilin and myosin co-localize to actin 
stress fibers (Wentz-Hunter et al., 2002) and by the fact that myocilin associates with IFs like 
vimentin and actin (Ueda et al., 2000).  
 
Optineurin is another leucine zipper containing protein found within TM, retina and the CB 
body epithelium, that in its mutated form cause POAG. As myocilin, it can also localize to the 
Golgi apparatus and vesicular structures (reviewed by Chalasani et al., 2008). Over-
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expression of optineurin in TM cells leads to a stabilization of MYOC mRNA with subsequent 
up-regulation of myocilin protein expression (Park et al., 2007).  
  
 
1.4.7.1.1. The olfactomedin domain and secretion  
 
Olfactomedin domain containing proteins are secreted glycoproteins or membrane-bound 
receptors that are involved in neurogenesis, NC formation, dorsal ventral patterning, cell cycle 
regulation, tumorigenesis and cell signalling (Tomarev and Nakaya, 2009). Myocilin shares 
similarities in structure to these proteins regarding the secretory signal peptide, the leucine 
zipper coiled coil region and the C-terminal olfactomedin domain (Nagy et al., 2003). The 
fact that most of the OAG causing mutations reside within the conserved olfactomedin 
domain, indicates that this domain has an important function in OAG pathology. The 
olfactomedin domain of myocilin can form intra- (Nagy et al., 2003) and inter- (Fautsch et al., 
2004) molecular  disulphide bonds by Cys433, an aa that if substituted for Arg can cause 
OAG (de Vasconcellos et al., 2003).  
 
The olfactomedin-domain is responsible for myocilin secretion (Sánchez-Sánchez et al., 
2007). If mutated, folding of myocilin is impaired, leading to accumulation of aggregates of 
misfolded protein within the ER (Liu et al., 2004). This can lead to ER stress and subsequent 
cytotoxicity, affecting the morphology and viability of TM cells (Joe et al., 2003). The theory 
is supported by the facts that only wild-type (WT), but not mutant myocilin, is secreted from 
TM cells in vitro, and that mutated myocilin can not be detected in the AH of OAG patients. 
Mutated myocilin also has a dominant-negative effect in that it can suppress the secretion of 
WT myocilin (Jacobson et al., 2001).  
 
Within the ER, myocilin can be proteolytically spliced at aa position 226 (Aroca-Aguilar et 
al., 2005) (Fig. 1.7) in a Ca
2+
-dependent manner (Sánchez-Sánchez et al., 2007), the cleavage 
is inhibited by some mutations within the olfactomedin domain. The cleavage produces a 20 
kD N-terminal myosin-like domain and a 35 kD C-terminal olfactomedin-domain containing 
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fragment (Aroca-Aguilar et al., 2005). Only the C-terminal part, along with full-length 
myocilin, was shown to be secreted from different cell types (Sánchez-Sánchez et al., 2007), 
whereas the N-terminal fragment has been shown to accumulate within the cell, reduce 
secretion of endogenous myocilin and affect outflow facility (Caballero et al., 2000). This 
may explain why perfusion with the olfactomedin-domain alone through human and porcine 
anterior eyes did not affect outflow facility (Goldwich et al., 2003). 
 
Myocilin and αB-crystallin co-localize and are both up-regulated in the TM of glaucoma 
patients and elderly people (Lütjen-Drecoll et al., 1998). αB-crystallin is a molecular 
chaperone that promotes proper folding of and protects proteins from aggregation during 
stress (Horwitz, 1992). Treatment of TM cells with pharmacological agents that can act as 
chemical chaperones has been shown to restore normal folding and secretion of mutant 
myocilin, as well as to resolve myocilin aggregates. The increased secretion reduced ER stress 
and apoptosis (Yam et al., 2007).  
 
 
1.4.7.2. Extracellular role 
 
The up-regulation of myocilin in dexamethasone-treated perfused cultured human eyes, as 
well as in living monkey eyes, correlates with an increase in IOP in a dose-dependent manner 
(Clark et al., 2001). Immunostaining has shown that myocilin expression is elevated in the 
TM of glaucoma patients (Lütjen-Drecoll et al., 1998). These facts support a theory that an 
elevated amount of myocilin within the TM may lead to glaucoma. Since myocilin is found to 
be associated with ECM material of the TM (Ueda et al., 2000, 2002; Tawara et al., 2000), 
and since myocilin expression is seen to be elevated within the JCT ECM in POAG patients 
(Konz et al., 2009), the role of increased myocilin in causing glaucoma is thought to be 
extracellular. Perfusion of human anterior eye segments with recombinant myocilin increases 
outflow resistance and IOP (Fautsch et al., 2000), but the effect is only seen after complexing 
of myocilin with another unknown protein (Fautsch et al., 2006). Thus, the mechanism by 
which myocilin obstructs the AH outflow pathway is unclear and suggests that myocilin acts 
as a matricellular protein, i.e. a protein that does not itself have a specific function, but that is 
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able to modulate cell-matrix interactions by interacting with various ECM molecules like cell-
surface receptors, cytokines, growth factors, proteases and structural proteins (reviewed by 
Bornstein et al., 2000). 
 
The multi-domain character of myocilin suggests that it is able to form various interactions. In 
fact, myocilin seems to interact with proteins from different categories. Leucine zipper 
domains are known to dimerize into homo- and heterodimers (Hurst et al., 1996). Myocilin 
forms dimers and multimers through its leucine zipper domain in human AH (Fautsch and 
Johnson, 2001). In addition, biochemical in vitro studies have shown that the myocilin leucine 
zipper is capable of binding numerous other proteins (Wentz-Hunter et al., 2002). 
 
In the human eye, myocilin co-localizes with fine fibrils of the sheath material that surround 
elastic fibers of the JCT. Myocilin overlaps with fibronectin, fibrillin-1, microfibril-associated 
glycoprotein, decorin and type VI collagen. In vitro, myocilin interacts physically with 
fibronectin, fibrillin-1, vitronectin, laminin, decorin, and laminins I, III, V and VI (Ueda et al., 
2002). Cell culture experiments have shown that the coiled coil and leucine zipper motifs of 
myocilin are important in forming extracellular interactions that favour adhesion (Gobeil et 
al., 2005). Myocilin binds to the Heparin II domain of fibronectin (Filla et al., 2002). This 
domain mediates cell adhesion, organization of the cytoskeleton, signal transduction and 
phagocytosis (Hynes, 1990). In cell cultures, myocilin impairs fibronectin-mediated adhesion 
and cell spreading (Peters et al., 2005). Experiments using primary cell cultures of human TM 
showed that myocilin inhibits cell-matrix cohesiveness by modulation of cAMP/PKA 
signalling (Shen et al., 2008). cAMP/PKA signalling is known to be involved in cell-matrix 
adhesion and cytoskeletal reorganization, that in turn affect cell migration (reviewed by 
Howe, 2004). Other studies have shown an adhesion promoting effect of myocilin (Goldwich 
et al., 2009).  
  
Via its olfactomedin domain, myocilin can physically interact with the olfactomedin domain 
of optimedin, a secreted candidate glaucoma glycoprotein expressed in the TM and retina 
(Torrado et al., 2002). Hevin is a secretory ECM glycoprotein with anti adhesive activity 
(Girard and Springer, 1996). In cell cultures, myocilin interacts with the C-terminus of hevin. 
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Myocilin co-localize with hevin in the CB epithelium of human eyes, as well as in the ER and 
Golgi apparatus of cultured cells. Myocilin impaired the secretion of hevin, the glaucoma 
causing mutation P370L still augmented the effect (Li et al., 2006). Myocilin has also been 
shown to interact physically with antagonists of the Wnt-pathway, as well as to bind Wnt-
receptors, leading to Wnt-signalling and re-organization of the cytoskeleton in TM cells 
(Kwon et al., 2009).   
  
In summary, myocilin seems to modulate cell adhesion, probably by modulating other cell-
matrix interactions, or/and by changing gene expression of proteins involved in adhesion 
(Paper et al., 2008). This emphasizes its role as a matricellular protein. In addition to 
conferring stability to, the degree of glycosylation of a protein is important for its bioactivity 
(reviewed by Fares, 2006) and adhesive properties (Jones et al., 1986; Kaufmann et al., 2004). 
Thus, the different degree to which myocilin can be glycosylated may regulate its interaction 
with other ECM molecules and the impact it has on cell adhesion.  
         
 
1.4.7.3. Theory for why mutated or an excess of myocilin leads to POAG 
 
The various data of intra- and extracellular roles of myocilin can be summarized in the way 
that when mutated myocilin is retained within the ER (Liu et al., 2004) and thus not secreted, 
it can not fulfil its normal function as a glycosylated matricellular protein within the ECM. As 
a possible modulator of cell-matrix (and matrix-matrix) interactions and adhesion (Peters et 
al., 2005; Goldwich et al., 2009), a decreased amount of extracellular myocilin could impair 
normal interactions within the TM, resulting in morphology changes and alteration of cell 
signalling. In the same way, an excess of myocilin within the ECM would lead to a 
dysregulation of cell-matrix (and matrix-matrix) interactions. Thus, the altered amount of 
myocilin in the ECM could alter the effect it normally has on ECM molecules. This could 
influence normal morphology and resistance of the AH drainage route, resulting in an 
elevated outflow resistance and IOP. Thus, a tight regulation of the amount of extracellular 
myocilin seems to be important. Since glycosylation seems to be important for the function of 
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proteins (reviewed by Fares, 2006; Jones et al., 1986), a tight control of the level of 
glycosylation of myocilin within the Golgi apparatus is important.  
 
The role of myocilin as a modulating matricellular protein may explain the fact that knocking 
out myocilin in mice is without phenotypic effect (Kim et al., 2001). Since matricellular 
proteins do not themselves act as specific structural or ligand-binding proteins, their absence 
may be compensated for by other matricellular proteins (reviewed by Bornstein et al., 2000). 
This possible complex role of myocilin may also explain the genetic complexity of OAG. 
 
 
1.4.8. Inter-species conservation   
 
The sequences of MYOC and myocilin orthologs from different species have been resolved 
and shows that the gene is well conserved both at the nucleotide and protein levels. Human 
myocilin shows a respective homology of 97 and 87 % to monkey (Fingert et al., 2001) and 
cat (Fautsch et al., 2006), a 85 % homology to rat (Taguchi et al., 2000) and rabbit (Shepard et 
al., 2003), a 83 % homology to pig (Obazawa et al., 2004), cow (Taniguchi et al., 2000) and 
mouse (Abderrahim et al., 1998), as well as 82.7 % homology to dog (Ricard et al., 2006) 
myocilins.  
 
All orthologs contain 3 exons. The leucine zipper motif and the olfactomedin domain are well 
preserved, whereas differencies are seen concerning the signal peptide, glycosylation and 
phosphorylation sites as well as cysteine residues. Rat Myoc shares the two both possible start 
ATGs with the human gene (Taguchi et al., 2000) (Fig. 1.7), whereas the MYOC orthologs of 
the other mentioned species only contain the to the human gene corresponding second 
possible start ATG. The C-terminal tripeptide targeting signal for microbodies found within 
MYOC (Adam et al., 1997) (Fig. 1.7) can also be found within the rabbit ortholog (Shepard et 
al., 2003). The majority of the glaucoma causing mutations are conserved (Fautsch et al., 
2006). 
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As the mouse has become the most frequently used animal model in glaucoma research, its 
MYOC ortholog Myoc, has been examined intensively. Myoc resides on chromosome one and 
the locus is surrounded by a genomic landscape that correspond that of the MYOC locus 
(Abderrahim et al., 1998). There is considerable conservation of the proximal 5´-UTR, and 
looking further upstream, there are several conserved putative promoter and enhancer binding 
sites (Fingert et al., 2007). The nucleotide sequence is 83 % identical to that of the human 
gene (Fingert et al., 2007). Exon-intron boundaries are conserved and exons show roughly the 
same size as those of MYOC (Abderrahim et al., 1998). The shorter transcript size of Myoc 
(10 530 bp compared to 17 250 bp for MYOC (Fig. 1.6)) is due to shorter introns. In addition 
to the leucine zipper and olfactomedin domain, the N-terminal signal peptide and many 
possible phosphorylation and glycosylation sites have been conserved in Myoc. Mouse 
myocilin has a length of 490 aa (compared to 504 aa in human) and a molecular weight of 55 
kD.  
 
 
1.4.9 Transcriptional regulation  
 
Analyzes of 5 kb of the 5´-UTR region of MYOC have identified several possible regulatory 
motifs, including hormone response elements for GCs and estrogen, transcription factor 
binding sites for activator proteins (AP-1 and AP-2) and NF-κB (nuclear factor κ light-chain 
enhancer of activated B cells), as well as repeat elements like Alu and MIR (mammalian 
interspersed repetitive) (Nguyen et al., 1998). DNAse I footprinting experiments showed that 
there are many sites of protein binding within the proximal 370 bp MYOC 5´-UTR, some of 
these sites contain a putative NF-κB site, an E-box (enhancer box), a TATA-box, a Sac-box, 
as well as AP-1 and AP-2 like sequences. This proximal promoter confirms basal 
transcription of MYOC in cell cultures. Upstream stimulatory factor (USF) was shown to bind 
the E-box in vitro (Kirstein et al., 2000). It is well known that prolonged, up to 10 d, treatment 
of cultured TM cells with the GC dexamethasone induces the expression of MYOC (Nguyen 
et al., 1998). This, as well as the fact that none of the putative GREs within the analyzed 5´-
UTR of MYOC confer any GC response (Kirstein et al., 2000; Shepard et al., 2001), has led to 
the hypothesis of a delayed secondary GC response for MYOC induction (Shepard et al., 
2001). MYOC expression in cultured TM cells can also be induced by treatment with TGF-ß1, 
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H202 and mechanical stretch (Polansky et al., 1997; Tamm et al., 1999). Fibroblast growth 
factor (FGF) and TGF-ß are able to counteract the induction of MYOC by GCs (Polansky et 
al., 1997). How these factors are linked to myocilin on the molecular level is not clear.   
 
 
1.5. The cornea 
 
The transparent avascular curved cornea transmit and bend incoming light properly to allow 
the likewise transparent and avascular lens to focus the light correctly onto the retina for 
subsequent visual processing. In addition to being responsible for two thirds of the refractive 
power, the cornea protects inner ocular tissues from pathogens and trauma (reviewed by Land 
and Fernald, 1992).   
 
 
1.5.1. Architecture 
 
Of the three corneal layers, the epithelium is the only one that is of ectodermal origin. The 
cornea consists of an outermost 5 – 7 layered stratified non-keratinized epithelium, whose 
undifferentiated dividing BM continously confer new daughter cells that differentiate and 
migrate upwards to replace outermost sloughed off epithelial cells. Barrier function is 
conferred by tight junctions, whereas the corneal reflex or blink reflex is evoked by a dense 
innervation. As an avascular tissue, the corneal epithelium is nourished by the tear film. The 
outermost cells also contribute to a minor outward fluid transport (reviewed by Lu et al., 
2001).  
 
The mesenchymal and/or NC-derived stroma is the thickest corneal layer. The highly ordered 
architecture of stromal keratocytes (differentiated fibroblasts) and ECM material, mainly 
collagens and proteoglycans, is crucial for corneal transparency and refractive power. The 
stroma is, due to the high abundance of proteoglycans, highly hydrated (reviewed by Qasi et 
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by the endothelial BM, the Descemet´s membrane. The well organized architecture of stromal keratocytes and 
ECM confer transparency and refractive power. Proper hydration and nutrition of the avascular stroma is 
conferred by solute transport through the epithelium and endothelium. Adapted image from 
http://www.vetmed.ucdavis.edu/courses/vet_eyes/images/archive/s_4015_a.jpg. 
 
 
1.5.2. Fibrosis 
 
As a protector of inner ocular tissues, a scarred cornea has rapidly to be renewed. Whereas 
corneal epithelium heals by upward migration, division and differentiation of basal cells 
(Krachmer et al., 2005), the stroma shows a fibrotic reaction characterized by keratocyte 
activation into myofibroblasts that recruit inflammatory cells (monocytes and macrophages), 
produce ECM and express α-smooth muscle actin (α-SMA). Fibrotic inflammation, excess 
ECM accumulation and α-SMA mediated contraction reduce corneal transparency and 
function, thus impairing vision (reviewed by Saika et al., 2008). Since corneal endothelial cell 
division in vivo is minimal, the endothelium heals through migration and enlargement of 
neighbouring healthy cells (reviewed by Qasi et al., 2009). 
 
Fibrosis is mediated by growth factors and cytokines, most importantly by TGF-ß. Normally, 
TGF-ß is localized intracellularly within the corneal epithelium. Wounding up-regulates TGF-
ß1 in the stroma, both intra- and extracellularly (reviewed by saika et al., 2008), and it is 
expressed by infiltrating inflammatory cells to be localized to fibrin clots (Stramer et al., 
2003). Thus, TGF-ß1 is the isoform that induces an early fibrotic response, including 
keratocyte activation, myofibroblast transformation and the expression of the major isoform 
TGF-ß2 (Huh et al., 2009). In addition to inducing the expression of TGF-ß2, TGF-ß1 can 
auto-induce its own mRNA expression (Yokozeki et al., 1997), resulting in a positive fibrotic 
feedback loop. TGF-1 and 2 then act in concert with each other, as well as with other 
cytokines and growth factors, to maintain the fibrotic response. TGF-ß signals via the 
Smad2/3 pathway, as can mediators of the mitogen-activated protein kinase (MAPK), c-Jun 
N-terminal kinase (JNK) and p38 kinase pathways. Thus, the attempts to treat fibrosis thus far 
have focused on targeting the Smad2/3 pathway (reviewed by Saika et al., 2006, 2008). 
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2. Scientific objectives 
 
The scientific objectives of the dissertation are various approaches that aim to give 
information that may help to better understand the molecular mechanisms of pathological 
processes in the anterior eye. The main focus was set on POAG, whereby the characterization 
of the myocilin gene, the attempt to create a TM specific promoter element and the creation of 
animal models are described. A part of the dissertation aimed to learn more about the 
molecular signalling mechanisms that are activated during wound healing in the cornea.  
 
 
2.1. Characterization of MYOC 
 
Despite over a decade of investigation about the normal, as well as the pathologic, function of 
myocilin in the eye, there is no definite consensus about how it exerts its pathologic function 
that leads to glaucoma. Most of the data that aim to clear the molecular mechanisms of 
myocilin within the TM come from in vitro studies, but only a few of these studies report the 
analysis of the transcriptional regulation of the myocilin gene. 
 
A better understanding of the transcriptional regulation of myocilin is of clinical interest, 
since a proportion of glaucoma patients show an elevated expression of myocilin within the 
TM (Lütjen-Drecoll et al., 1998; Konz et al., 2009), and since myocilin accumulates within 
TM and elevates AH outflow resistance and IOP in anterior eye segments in vitro (Fautsch et 
al., 2000; 2006). In addition, since myocilin is known to behave as a matricellular protein 
(reviewed by Resch and Fautsch, 2009), regulating molecular interactions within the TM, a 
precise regulation of myocilin protein expression within this tissue is critical for optimal AH 
drainage capacity.  
 
Even though it is known that expression can be regulated by far 5´- and 3´-UTRs, as well as 
by intronic regions (Plaza et al., 1995; Uchikawa et al., 2004; Kleinjan et al., 2006; Aruga et 
Scientific objectives  38 
 
al., 2007), available data from regulation studies only involve the close 5´-UTR of MYOC, 
including the known myocilin basal promoter (Kirstein et al., 2000; Shepard et al., 2001). 
Thus, we wanted to extend earlier regulation studies to encompass also far 5´- and 3´-UTRs, 
as well as intronic regions of MYOC, to find out if these regions contain elements that are 
responsible for up-regulation of myocilin expression over basal transcription level in the TM. 
By inter-species alignment we wanted to search for evolutionarily conserved regions within 
MYOC and to clone these into reporter constructs in front of a reporter gene. We then aimed 
to analyze if the cloned regions contain TM-specific enhancer elements by comparing the 
capacity of these regions to drive reporter gene expression over the MYOC basal promoter 
level in cultured TM cells. 
  
It is known that the expression of myocilin is highly induced by GCs (Polansky et al., 1997; 
Tamm et al., 1999), but no functional GC response elements (GREs) have been found within 
the close 5´-UTR (Kirstein et al., 2000; Shepard et al., 2001). Thus, we also in this context 
wanted to extend available data by searching for TM-specific functional GREs outside the 
close 5´-UTR. We aimed to search for TM-specific functional GREs within our cloned far 5´- 
and 3´-UTRs, as well as within the cloned intronic MYOC regions, by treating transfected 
human TM cells with dexamethasone and by then analyzing and comparing the capacity of 
the cloned regions to drive reporter gene expression in treated vs. untreated cells.  
 
 
2.2. Search for and analysis of an artificial enhancer element for TM directed 
overexpression of protein 
 
To date, there is no data that describe specific targeting of protein expression exclusively to 
the TM. Available in vivo glaucoma animal models are restricted to overexpression models 
that make use of either the endogenous myocilin or lens-derived promoters (e.g. Gould et al., 
2004; Zillig et al., 2005), targeting expression not only to the TM. In addition to being 
important for basic research, specific TM-directed expression would enable clinically relevant 
gene targeting approaches. 
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Thus, we wanted to create an artificial enhancer element that in combination with the MYOC 
basal promoter would target an overexpression specifically to the TM in vivo. We first wanted 
to analyze the capacity and specificity of cloned enhancer elements to drive reporter gene 
expression over MYOC basal promoter level in TM cells in vitro. Later, we aimed to prove the 
capacity and specificity of candidate elements to drive visible reporter gene expression in vivo 
in a mouse model. The dissertation describes the in vitro analysis of candidate elements, the 
cloning of a candidate enhancer element-driven ß-galactosidase overexpression construct, as 
well as the creation and analysis of an in vivo mouse model.   
 
 
2.3. Creation of an animal model that would allow a TM directed conditional knock-out 
   
The majority of available animal models relevant for POAG involve myocilin and are 
restricted to lines that either overexpress (e.g. Zillig et al., 2005), are stably deficient in (e.g. 
Kim et al., 2001), or show a mutation in one or both of the allelles (e.g. Gould et al., 2006). A 
conditional knock-out shows many advantages over a stable knock-out. It makes it 
unnecessary to create a new stable knock-out line for every gene of interest, and it makes it 
possible to study the effect of a deletion of a gene, that normally would be embryonic lethal, 
in the adult.  
 
We wanted to create a mouse line that would allow a conditional knock-out in the TM by the 
Cre/loxP system (reviewed by Sauer, 1998) by homologous recombination. We wanted to 
design and clone a knock-in construct that would target the endogenous myocilin locus and 
which would allow the Cre recombinase (Cre) to be driven by the endogenous Myoc promoter 
in mouse embryonic stem cells (ESCs). Screening for correct targeting by Southern blot and 
injection of respective positive clone into blastocysts would then allow the screening for 
founder animals with a germ line knock-in and the establishment of a mouse line with 
endogenous Myoc promoter-directed expression of Cre. Analyses of spatial and temporal 
patterns of expression of Cre would then confirm the usefulness of the knock-in mouse line as 
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a tool for a myocilin expression pattern-like knock-out of any loxP-flanked gene of interest. 
The dissertation describes the design and cloning of the knock-in construct, as well as the 
screening of mouse ESCs for homologous recombination.   
 
 
2.4. Analysis of gene expression during corneal fibrosis 
 
Wounding and subsequent fibrosis (scar formation) of the cornea due to trauma, infection or 
complications during surgery may severely affect corneal transparency and vision. To date, 
there is no effective way to treat early wound healing in order to minimize scar formation.  
The main area of investigation has been early molecular and signalling events that evoke a 
fibrotic response. Experiments indicate that targeting the TGF-ß signalling pathway may be a 
solution to avert scar formation in the cornea (reviewed by Saika 2006; Saika et al., 2008). 
Against these facts we wanted to analyze which genes downstream of the TGF-ß signalling 
pathway are differentially regulated during fibrosis and that may be crucial regulators of 
corneal transparency.  
 
Our lab earlier generated a transgenic mouse line that due to an overexpression of TGF-ß1 in 
the lens show a corneal phenotype that in many aspects resemble fibrosis (Flügel-Koch et al., 
2002). By microarray analysis we earlier showed that the fibrotic corneas from transgenic 
animals have hundreds of differentially expressed genes when compared to normal WT 
corneas (not yet published). We now wanted to validate earlier microarray data for selected 
interesting genes by RT-real-time PCR. The dissertation describes the criteria for the selection 
of genes of interest, as well as the validation of these genes as downstream effector genes of 
TGF-ß1 in leading to the observed opaque fibrotic-like cornea in transgenic mice. Finding and 
validating downstream TGF-ß signalling targets are important in trying to understand how 
and through which signalling mechanisms TGF-ß1 evokes an early fibrotic response in the 
cornea, as well as in finding candidate genes that are responsible for corneal transparency. 
Studies like this are fundamental for future therapeutic targeting strategies in reducing corneal 
scar formation. 
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3. Materials and methods 
 
Recipes for buffers, solutions and media, as well as used laboratory supplies are listed in 
Chapter 9: Appendix. 
 
3.1. Molecular biology techniques 
 
3.1.1. General cloning techniques 
 
3.1.1.1. Polymerase chain reaction (PCR) 
 
In vitro amplification of DNA was carried out by the PCR technology by using the GoTaq
®
 
Green Master Mix (MM) 2 X-Kit. The 2 X MM is an optimized mix containing Taq (from 
Thermus aquaticus) polymerase, 400 µM of each dNTP, 3 mM MgCl2 and buffer. A 25 µl 
reaction volume was set up as follows (Table 3.1.): 
 
 
2 X GoTaq
®
 Green MM 12.5 µl 
Primer: forward (fw) 0.4 µM 
Primer: reverse (rev.) 0.4 µM 
Template (plasmid/genomic DNA) 1 - 10 ng 
H20 ad 25 µl 
 
 
 
For colony PCR, a bacterial clone was picked with a sterile pipette tip and inserted into the 25 
µl reaction mix. The following PCR program (Table 3.2) was modified to be optimal for each 
type of template, primer pair and amplicon: 
Table 3.1: PCR reaction setup using the 
GoTaq
®
 Green MM from Promega.   
Materials and methods     42 
 
Step: Temperature: Time: 
Initial denaturation  95 °C  2 min 
Denaturation 95 ° C 30 s - 1 min 
Primer annealing 55 °C – 65.9 °C 30 s - 45 s 
Elongation 72 °C  1 min/kb 
Final elongation 72 °C 5 - 7 min 
 
 
30 - 35 cycles of denaturation, primer annealing and denaturation were carried out. 
 
 
3.1.1.2. Agarose gel electrophoresis 
 
For analysis and purification of DNA, fragments of different size were separated by agarose 
gel electrophoresis. Depending on expected fragment size, 0.7 – 2.0 % (w/v) agarose was 
dissolved in 100 - 150 ml of 1 X TBE or 1 X TAE by boiling. The solution was cooled down 
to ~ 60 °C and EtBr was added at a concentration of 0.1 µg/ml. The mix was poured into a gel 
rack for polymerization. The DNA samples were mixed with 6 X loading buffer, loaded into 
the wells of the gel and run for 15 min – 2 h in an electrical field of 120 - 140 V towards the 
cathode. For the evaluation of fragment size, 0.5 µg of an appropriate molecular weight 
marker was run in parallel. For the analysis of RNA, the gel chamber equipment was rinsed 
with 0.5 M NaOH before use to reduce the risk of RNAse contamination. The nucleic acids 
were visualized by UV-irradiation and subsequent fluorescence of the between the base pairs 
intercalated EtBr. 
 
 
 
 
 
Table 3.2: For amplifications by 
GoTaq
®
 Green MM, variations of 
the following PCR program were 
run to be optimal for each type of 
template, primer pair and amplicon. 
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3.1.1.3. Extraction of DNA fragments from agarose gel 
 
The extraction of DNA fragments from agarose gel for further cloning applications was 
achieved by cutting out the DNA fragment of interest with a scalpel under UV-light at low 
irradiation intensity. The gel slice was put into an Eppendorf tube and the DNA fragment was 
purified using the NucleoSpin
®
 Extract II kit by following the instructions provided by the 
manufacturer. 
 
 
3.1.1.4. Dephosphorylation of 5´-ends 
 
To remove 5´-phosphoryl groups from linearised plasmids bearing equal restriction 
overhangs, the plasmid was dephosphorylated by treating it with 5 U of antarctic phosphatase 
per 1 mg of DNA and by adding 1/10 vol. of 10 X antarctic phosphatase reaction buffer. For 
5´-extensions and blunt ends, the reaction was allowed to proceed at 37 °C for 15 min, 
whereas for 3´-extensions the reaction was run for 60 min. Antarctic phosphatase was 
inactivated for 5 min at 65 °C.  
 
 
3.1.1.5. Ligation 
 
Subcloning of amplified inserts bearing A-overhangs was carried out by ligation into the 
pDrive
®
-cloning vector (Fig. 3.1) by the QIAGEN PCR Cloning kit and the reaction setup in 
Table 3.3. For a clean PCR reaction, maximally 2 µl of PCR reaction was directly mixed into 
the ligation. In case of unspecific amplicons, the wanted PCR product was purified via 
agarose gel electrophoresis and then mixed with the ligation reaction at a volume of 1 - 4 µl. 
The reaction was allowed to proceed O/N at 4 - 16 °C. 
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Figure 3.1: Amplified PCR products bearing A-overhangs were subcloned by ligation between the U´-
overhangs in the multiple cloning site (MCS) of the pDrive
®
 cloning vector. Positive colonies were selected by 
blue/white screening and by test cutting the isolated plasmids by one of the restriction enzymes that recognize a 
restriction site in the MCS. Positive clones were sequenced by using the primers M13 fw (-20) and M13 rev. 
(source: Qiagen).  
 
 
 
pDrive
®
-vector 1 µl (= 50 ng) 
PCR product 1 - 4 µl 
2 X Ligation MM 5 µl 
H20 ad 10 µl 
 
 
 
The ligation of inserts bearing restriction overhangs was performed by adding an excess of 
insert compared to vector (equimolar insert:vector ratios ranging from 2:1 - 5:1) in the 
ligation reaction (Table 3.4). In parallell, a re-ligation control without insert was setup. The 
ligation was allowed to proceed at RT O/N. The recombinant plasmid, as well as the re-
Table 3.3: Ligation setup for subcloning of 
A-overhanged PCR products into pDrive
®
-
cloning vector.  
Materials and methods     45 
 
ligation control, were directly transformed into competent E. coli, or stored at – 20 °C until 
use. 
 
 
Insert 2:1 – 5:1 to ng vector 
Vector 1:2 – 1:5 to ng insert 
10 X T4-ligase buffer 2 µl 
T4-ligase 1 µl (= 1 U) 
H20 ad 20 µl 
 
 
 
3.1.1.6. Transformation of E. coli  
 
For the propagation of a recombinant plasmid it was transformed by a heat-chock into 
chemically competent one shot
®
TOP10 E.coli cells by following the instructions provided by 
the manufacturer. 20 - 300 µl of the propagated bacteria were plated onto agar plates 
containing the antibiotics to be selected for. For blue/white screening the bacteria were plated 
onto agar plates containing IPTG, X-gal and the antibiotic to be selected for. The plates were 
incubated upside down at 37 °C for 16 - 20 h.  
 
 
3.1.1.7. Preparing and inoculating of bacterial glycerol stock 
 
For long-term storage of a transformed bacterial culture, 850 µl of an O/N propagated culture 
was properly mixed with 150 µl sterile 100 % glycerol. The mix was snap-frozen in liquid 
nitrogen and stored at – 80 °C. If required, a scrape of a glycerol-stock was inoculated for 
propagation and plasmid isolation.    
 
Table 3.4: Ligation setup for inserts bearing 
restriction enzyme overhangs. In most cases the 
liagtion was performed in a reaction volume of 
20 µl. 
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3.1.1.8. Preparation of plasmid DNA 
 
To isolate and purify a plasmid, a bacterial colony was picked and inoculated to grow O/N in 
LB-medium containing ampicillin or kanamycin (dependent on plasmid resistance). For mini-
preparation of plasmid DNA a volume of 2.5 - 5 ml of bacterial culture was propagated, 
whereas for midi- and maxi-preparations the volumes were 500 ml and 1 l, respectively. Mini- 
and midi-preparation of plasmid DNA was carried out by using the NucleoSpin
®
 Plasmid-kit 
and PureYield
™ 
Plasmid Midiprep System, respectively, by following the instructions 
provided by the manufacturer. Maxi-preparation of plasmid DNA was carried out by using the 
QIAfilter Plasmid Maxi Kit, or in the case of endotoxin-free preparations, the EndoFree 
Plasmid Maxi Kit by following the instructions provided by the manufacturer. For mini-
preparations, the DNA was eluted in 50 - 100 µl of nuclease-free H20. For midi- and maxi-
preparations the DNA was, depending on pellet size, dissolved in 500 µl – 2 ml of (endo) 
nuclease-free H20. 
 
 
3.1.1.9. Quantification of nucleic acids 
 
Spectrophotometric analysis of DNA and RNA was carried out by measuring the absorptions 
of UV-light at a wavelength of 260 nm by appropriate sample dilutions. The absorbance of a 
sample at a given wavelength is proportional to its optical density, and the concentration can 
be calculated by the formula: 
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c (µg/ml) = OD x V x Fm, where 
 
OD  = optical density 
c = concentration 
V  = dilution factor 
Fm  = factor of multiplicity (= 50 for double-stranded (ds)DNA, 40 for RNA) 
 
 
The purity of nucleic acids was measured by calculating the ratio of absorbance of nucleic 
acid at 260 nm to the absorbance of protein at 280 nm. For a pure DNA/RNA preparation this 
ratio is 1.8 - 2.0. 
 
 
3.1.1.10. Restriction digestion 
 
Depending on approach, 0.5 - 2 µg of plasmid DNA was digested in a volume of 10 - 50 µl by 
the restriction setup in Table 3.5. For double digests, equal amounts of U of enzyme were 
added. 
 
 
DNA 0.5 – 2 µg 
For the enzyme appropriate 10 X restriction buffer 1/10 vol.  
10 X BSA (if required for the restriction enzyme) 1/10 vol. 
Restriction enzyme 1 – 10 U/1 µg DNA 
H20 Ad to appropriate reaction volume 
 
Table 3.5: Restriction setup for plasmid DNA. Depending on approach (test-cut or preparative cut), 0.5 – 2 µg 
of DNA was digested.  
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The reaction was allowed to proceed at 37 °C for 1 - 2 h. For direct use of a linearized 
plasmid in downstream cloning applications, the enzyme(s) were heat inactivated at their 
respective temperature for heat inactivation. In the case of equal restriction overhangs, the 
linearized plasmid was dephosphorylated to avoid re-ligation. The plasmid was purified with 
the NucleoSpin
®
 Extract II kit by following the manufacturer´s instructions. To recover a 
released insert, the restriction reaction was resolved on an agarose gel and the insert was 
purified as described in section 3.1.1.3.  
          
 
3.1.1.11. Sequencing of DNA 
 
Plasmid DNA containing an insert to be sequenced was mixed at a concentration of 150 - 300 
ng with 1.25 µM of primer and H2O in a final volume of 8 µl and sent to GENEART AG. The 
sequences were analyzed by using the Vector NTI
® 
Software from Invitrogen.  
 
 
3.1.2. Molecular biology techniques specific for the creation of a ß-galactosidase 
overexpression mouse line  
 
3.1.2.1. Cloning of ß-galactosidase overexpression construct 
 
As backbone plasmid for cloning of a ß-galactosidase overexpression construct we used 
psDLacZ-pA, a gift from Prof. Wegner (Institute of Biochemistry, University of Erlangen-
Nürnberg). psDLacZ-pA already contained the gene for ß-galactosidase, LacZ, as well as an 
SV late polyA signal (fig. 3.2). The function of the polyA signal is to confer stability to, and 
to assist in termination, export and translation of the mRNA (reviewed by Bernstein and Ross, 
1989; reviewed by Sachs, 1990).  
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MYOC basal promoter p313
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(Fig. 3.3). 
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imported into the nucleus, a repetitive NLS, 3 X NLS, was cloned in frame with the LacZ 
open reading frame (ORF), just behind the codon for the start ATG between the restriction 
enzyme overhangs NcoI and NruI (Fig. 4.10). We created the ds3 X NLS by phosphorylating 
and annealing two long complementary oligonucleotides coding for this sequence. The oligos 
had been designed to create correct restriction enzyme half-sites for cloning at each end of the 
annealed duplex, as well as not to cause a frame-shift of the LacZ ORF after insertion (Fig 
3.4). 
 
 
 
NLS1:  5´ CATGGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGCTCG 3´ 
 
                                           + 
 
NLS2:  5´ CGAGCTACCTTTCTCTTCTTTTTTGGATCTACCTTTCTCTTCTTTTTTGGATCTACCTTTCTCTTCTTTTTTGGAT 3´ 
 
 
 
 
                                            
 
 
 
 
                                                                                                                                      
  
  5´ CATGGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGCTCG 3´ 
      3´  TAGGTTTTTTCTTCTCTTTCCATCTAGGTTTTTTCTTCTCTTTCCATCTAGGTTTTTTCTTCTCTTTCCATCGAGC 5´ 
 
      
 
Figure 3.4: Complementary single-stranded long oligos NLS1 and NLS2 were phosphorylated and annealed to 
create a 72 bp 3 X NLS duplex that aimed to direct ß-galactosidase overexpression into the nucleus. The oligos 
had been designed to create correct restriction enzyme recognition half-sites for cloning at each end of the 
annealed duplex, as well as not to cause a frame-shift of the LacZ ORF after insertion. 3 X NLS is depicted in 
red, where the recurring NLS motif is marked with horizontal large curly brackets. Start ATG of LacZ is 
depicted in green and restriction enzyme recognition half-sites for NcoI and NruI are underlined. After 
annealing, the phosphorylated duplex was immediately cloned into psD-LacZ-pA between the restriction enzyme 
recognition sites NcoI and NruI (Fig. 4.10).   
 
NruI NcoI 
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The phosphorylated 3 X NLS duplex was cloned into psDLacZ-pA between the restriction 
enzyme overhangs NcoI and NruI in-frame with the LacZ ORF (Fig. 4.10). To be sure that the 
long oligos creating the 3 X NLS had annealed properly, the overexpression construct was 
sequenced over this region by the primer LacZ rev. 3. The construct was propagated in 
bacteria and extracted as an endonuclease-free maxi-preparation (section 3.1.1.8). 
 
 
3.1.2.1.1. Phosphorylation of DNA 5´-OH ends 
 
The phosphorylation of single-stranded (ss) DNA oligonucleotides at their 5´-OH overhangs 
was carried out by mixing 8 µl of substrate with 1 µl (= 10 U) of T4 polynucleotide kinase 
(PNK) and 1 µl of 10 X T4 ligase buffer containing ATP. The reaction was incubated at 37 °C 
for 30 min, followed by incubation at 65 °C for 20 min. The phosphorylated oligonucleotides 
were stored at + 4 °C until use, or directly used for annealing as described below. 
  
 
3.1.2.1.2. Annealing of oligonucleotides 
 
The annealing of phosphorylated DNA oligonucleotides to create an insert for ligation into a 
vector was carried out by mixing 8 µl of one PNK-reaction with 10 µl of the other PNK-
reaction (described above). 2 µl of 10 X annealing buffer was added and the mixture was 
vortexed. The annealing reaction was allowed to proceed in a heat block at 95 °C for 3 min, 
after which it was slowly let to cool down to RT. The mixture was vortexed and subsequently 
ligated into an appropriate dephosphorylated vector. 
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3.1.2.2. Purification of DNA for pronuclear injection 
 
To get a highly pure transgene for injection into a male pronucleus of a fertilized mouse 
oocyte, the transgene was cut out O/N from 50 µg endotoxin-free plasmid construct in a 
reaction volume of 400 µl. An aliquote of the reaction was proved for digestion by agarose 
gel electrophoresis. The reaction was dissolved by agarose gel electrophoresis on a 0.7 % 
agarose gel using a clean gel apparatus and sterile filtrated 1 X TAE buffer. No DNA 
standards were used because of the risk of contamination. The sample was run until the 
transgene had completely separated from the vector backbone. The transgene was cut out 
from the gel under UV-light of low intensity (320 nm wave length) and transferred into a 
dialysis bag. The bag was filled with fresh running buffer and closed with clamps. The 
dialysis bag was fixed across the electrical field in the running chamber and the transgene was 
electroeluted out from the gel into the buffer of the bag for ~ 1 h at 80 V. To force the 
transgene back from the dialysis bag wall into the solution, the polarity of the electrophoresis 
was changed by changing the orientation of the dialysis bag by 180 ° and by continuing the 
run for another 30 s at 80 V. The electroelution was controlled under UV-light of low 
intensity. The solution containing the transgene was transferred into a sterile Falcon tube with 
a syringe needle plunged through the wall of the dialysis bag. The DNA-solution was diluted 
1:2 with sterile filtrated low-salt buffer. The mixture was slowly pressed through an 
equilibrated (equilibration was carried out as described by the manufacturer) elutip-D
®
 
column with a flow rate of 0.5 - 1.0 ml/min to adsorb the DNA to the column matrix. The 
column was washed twice with 5.0 ml of low-salt buffer. The transgene was eluted into an 
eppendorf tube with 400 µl of sterile filtrated high-salt buffer. 1.0 ml of EtOH abs. was added 
and the mixture was put into – 20 °C O/N to enhance the yield of precipitation. The transgene 
was precipitated by centrifugation at 12 300 rpm for 30 min at + 4 °C and washed three times 
with ice cold 70 % EtOH abs. The pellet was air-dried and dissolved into an appropriate 
volume of sterile filtrated injection buffer to give an endconcentration of 100 ng/µl. The 
purity and the spectrophotometrically measured concentration were verified by loading 
different concentrations of the transgene on an agarose gel and by comparing the band 
intensities with those of a reference DNA of known concentration.  
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3.1.3. Molecular biology techniques specific for the creation of a myoc knock-in mouse    
line 
 
3.1.3.1. Cloning of myoc knock-in construct 
 
A myocilin knock-in construct, which would allow the expression of Cre under the control of 
the endogenous myoc promoter, was designed in the way that aimed the construct to be 
integrated at the published mouse myoc translational start ATG (Tomarev et al., 1998) by 
homologous recombination (Tymms and Kola, 2001; Ch. 3). Published information about the 
transcriptional regulation of myoc is restricted to the 5´-UTR of the gene (Kirstein et al., 
2000; Shepard et al., 2001). Our promoter studies corroborate a theory that some intragenic 
regions of myoc are able to drive expression above basal promoter level (Fig. 4.3). 
Consequently, the knock-in construct was designed in a way that would allow a homologous 
recombination without deletion of any intragenic regions (Fig. 4.22). As construct backbone 
vector, we chose pTV-0 (Fig. 3.5), a kind gift from Prof. Michael Wegner. pTV-0 contains 
two MCSs that were of advantage in the introduction of the two homologous flanks. The 
backbone carries genes for neomycine resistance (Neo), as well as for thymidine kinase (TK), 
which are required for positive and negative selection, respectively, of electroporated ESCs 
(Tymms and Kola, 2001; Ch. 3). 
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Because the exact nucleotide sequence of the gift plasmid was unknown, and because we 
wanted to avoid any cloning problems arising from unknown restriction enzyme recognition 
sites within this construction, we first sequenced the plasmid through. We started the 
sequencing with primers that bind the backbone plasmid at the 5´- and 3´- ends of NLS-Cre-
IRES-eGFP-intron-polyA (Cre fw 1 and Cre rev. 1, respectively). Based on these sequences, 
we designed the next primers (Cre fw 2 and Cre rev. 2) that allowed further inward 
sequencing of the construction. In this way, we sequentially sequenced a 4232 bp region of 
the plasmid beginning from the 5´- and 3´-end. By assembling the sequences by the Vector 
NTI
® 
Software we got the whole 5´-NLS-Cre-IRES-eGFP-intron-polyA-3´ sequence (Fig. 
3.6). 
  
 
 
 
 
Fig. 3.6: Based on overlapping sequence data, the exact nucleotide sequence of NLS-Cre-IRES-eGFP with its ß-
globin intron polyA-tail was reconstituted. Based on the data we made up a cloning strategy for the myoc knock-
in construct. We aimed to release NLS-Cre-IRES-eGFP with its polyA-tail from the backbone by restriction with 
XhoI and ligate the 3416 bp fragment into pTV-0-5´-flank-3´-flank, just downstream of the 5´-flank.  
 
 
Based on the sequence data we made up a cloning strategy that first aimed to introduce the 
homologous flanks into the pTV-0 backbone vector by the restriction enzyme overhangs 
NotI/XhoI for the 5´-flank, and NheI/SalI for the 3´-flank. After that we aimed to release NLS-
Cre-IRES-eGFP-intron-polyA from pSL1180 by restriction with XhoI and to clone the 3416 
bp fragment in correct orientation downstream of the 5´-homologous flank (Fig. 4.22).    
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3.1.3.1.2. Amplification of the 5´-homologous flank 
 
The 5´-flank is homologous to 3072 bp of the 5´-UTR of myoc and ends at the described start 
ATG of the mouse gene (Tomarev et al., 1998). It was amplified for 35 cycles from mouse 
ESC DNA by the primer pair NotI-5´-flank fw and XhoI-5´-flank rev. by the following 
reaction conditions (Table 3.6): 
 
 
 
Step: Temperature: Time: 
Initial denaturation 95 °C 2 min 
Denaturation  95 °C 1 min 
Primer annealing 65.9 °C 30 s 
Elongation 72 °C 4 min 
Final elongation 72 °C  7 min 
 
 
 
The amplified 5´-flank was purified via agarose gel electrophoresis and subcloned into the 
pDrive
®
-cloning vector for sequencing.  
 
 
3.1.3.1.3. Amplification of the 3´-homologous flank 
 
The 3´-homologous flank is homologous to a 2268 bp stretch of exon 1 and intron 1 of mouse 
myoc. It was amplified for 35 cycles from mouse ESC DNA by the primer pairs NheI-3´-flank 
fw and SalI–3´-flank rev. by the following reaction conditions (Table 3.7): 
 
Table 3.6: Reaction conditions for amplification 
of the 5´-homologous flank from mouse ESC 
DNA. 35 cycles of denaturation, primer annealing 
and elongation were performed. 
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Step: Temperature: Time: 
Initial denaturation 95 °C 2 min 
Denaturation  95 °C 1 min 
Primer annealing 59°C 45 s 
Elongation 72 °C 2 min 
Final elongation 72 °C 5 min 
 
 
 
The amplified 3´-flank was purified via agarose gel electrophoresis and subcloned into the 
pDrive
®
-cloning vector for sequencing.  
 
 
3.1.3.2. Purification of DNA for electroporation into mouse ESCs 
 
To get highly pure DNA for the electroporation into mouse ESCs, 150 µg of endonuclease-
free plasmid construct was linearized in a reaction volume of 500 µl O/N. The linearization 
was proved by running a small aliquote of the reaction on an agarose gel. 1 vol. of 
phenol/chloroform/isoamylalcohol (in the proportions 24:24:1, respectively) was added to the 
linearized plasmid, the mix was vortexed, and transferred to a pelleted Phase Lock Gel
™
 
(preparation of the Phase Lock Gel
™
 tube was carried out as described by the manufacturer) 
tube. The sample was centrifuged at 12 000 g for 20 min at + 4 °C, whereby the organic phase 
and interface became trapped below the phase lock gel barrier and the aqueous phase 
containing the DNA was found above the gel. 500 µl phenol/chloroform (1:1) was added to 
the aqueous phase, the mixture was vortexed and centrifuged at 12 000g for 20 min at + 4 °C. 
The upper phase was transferred into a fresh eppendorf tube, followed by the addition of 1/10 
vol. of sterile 1 M natrium acetate (pH 5.5) and 2.5 vol. of 95 % EtOH abs. The mix was 
vortexed and held on ice for 10 min. DNA was precipitated by centrifugation at 13 200 rpm 
for 10 min at + 4 °C. The pellet was washed with 500 µl 80 % EtOH abs. by mixing and 
centrifugation at 13 200 rpm for 5 min at + 4 °C. The pellet was air-dried and dissolved into 
an appropriate volume of sterile nuclease-free H20 to give an endconcentration of 1 µg/µl. 
Table 3.7: Reaction conditions for 
amplification of the 3´-homologous flank from 
mouse ESC DNA. 35 cycles of denaturation, 
primer annealing and elongation were 
performed. 
Materials and methods     59 
 
3.1.3.3. Screening of ESC clones for homologous recombination 
 
3.1.3.3.1. Amplification and cloning of 5´-flank and 3´-flank probes 
 
DNA templates for radioactive probes for Southern blot were amplified from mouse ESC-
DNA by the primer pair 5´-probe fw and 5´-probe rev. for the 5´-flank probe, and 3´-probe fw 
and 3´-probe rev. for the 3´-flank probe. The probes were designed to bind outside of the 
recombinated construct, but within the resulting restriction fragments (Fig. 4.23). The PCR-
programs for the amplifications were as follows (Tables 3.8 and 3.9): 
 
 
5´-flank probe (360 bp):  
 
Step: Temperature: Time: 
Initial denaturation 95 °C 2 min 
Denaturation  95 °C 1 min 
Primer annealing 61 °C 30 s 
Elongation 72 °C 30 s 
Final elongation 72 °C 5 min 
 
 
 
3´-flank probe (729 bp): 
 
Step: Temperature: Time: 
Initial denaturation 95 °C 2 min 
Denaturation  95 °C 1 min 
Primer annealing 65.7 °C 30 s 
Elongation 72 °C 1 min 
Final elongation 72 °C 5 min 
Table 3.8: Reaction conditions for the 
amplification of the 360 bp template for the 
radioactive 5´-flank probe. 35 cycles of 
denaturation, primer annealing and 
elongation were performed. 
Table 3.9: Reaction conditions for the 
amplification of the 729 bp template for the 
radioactive 3´-flank probe. 35 cycles of 
denaturation, primer annealing and 
elongation were performed. 
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The amplified probes were cloned into the pDrive
®
-cloning vector and propagated for 
midipreparation of plasmid DNA. The pDrive-probe plasmids were stored at – 20 °C. For 
Southern blot, linear probe templates were amplified from the midipreps, purified from the 
agarose gel and used as templates for radioactive labelling. Purified linear probe templates 
were stored at – 20 °C.    
 
 
3.1.3.3.2. Radioactive labelling of DNA probes 
 
The radioactive labelling of DNA probes to be used in Southern blot was carried out by using 
the Random Primers DNA Labeling System by following the instructions provided by the 
manufacturer. The labelling system takes advantage of the Klenow fragment, the large protein 
subunit produced by the cleavage of E. coli DNA polymerase I (Klenow and Henningsen, 
1970). The Klenow fragment possesses a 5´ → 3´ polymerase activity and thus fills up the 
gaps produced by bound hexamer random primers with labelled and unlabelled 
deoxynucleotides. 
 
50 - 100 ng of linear dsDNA probe template was diluted in 23 µl of H20. To separate the 
DNA double helix, the sample was boiled at 95 °C for 5 min and immediately put onto ice to 
avoid reannealing. 2 µl each of dATP, dGTP and dTTP, and 15 µl of Random Primers Buffer 
Mixture were added and the sample was mixed. The following steps were performed in an 
isotope laboratory: 5 µl of [α-
32
P]-labeled dCTP (= 50 µCi) and 1 µl (3 U) of Klenow 
fragment were added and the total 50 µl reaction volume was mixed. The reaction was 
allowed to proceed for 1 h at RT. Mini Quick Spin
™
 Columns for the elimination of 
unincorporated nucleotides were prepared and the probe was purified according to the 
instructions provided by the manufacturer. The double-stranded labelled probe was denatured 
at 95 °C for 3 min and immediately put onto ice to avoid reannealing. Subsequently, the 
whole reaction volume (50 µl) was added to the hybridization solution (21.2 ml).     
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3.1.3.3.3. Southern blot        
 
Electroporated ESC clones were screened for homologous recombination by Southern Blot 
(Southern, 1975). For each clone, the following restriction reaction was setup (Table 3.10) 
and allowed to proceed at 37 °C O/N. 
 
 
Genomic DNA 41.5 µl 
Restriction enzyme (20 U/µl) 2 µl 
Appropriate 10 X restriction buffer 5 µl 
RNAseA (10 µg/µl) 1 µl 
100 X BSA 0.5 µl 
Total volume 50 µl 
 
 
The reaction was resolved on a 0.7 % agarose gel in 1 X TAE for 2 h at 120 V. To prove for 
complete digestion, the resolved DNA was visualized under UV-light at low intensity and 
photographed. The DNA was prepared for membrane transfer by treating the gel as follows 
(Table 3.11). 
 
 
 
Treatment: Solution: Time: 
Depurination 0.25 M HCl  15 min  
Rinsing of gel H20 15 min 
Denaturation Denaturation solution 2 X 15 min 
Neutralization Neutralization solution 2 X 15 min 
Equillibration of gel 20 X SSC 10 min 
 
 
 
Table 3.10: Restriction setup for each 
ESC clone to be screened for homologous 
recombination by Southern blot. 
Table 3.11: The following steps of gel 
treatments were performed to prepare 
the high molecular weight dsDNA for 
transfer to the blotting membrane. All 
incubations were carried out by gentle 
rocking.  
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The DNA was transferred to a positively charged nylon membrane by building up a capillary 
transfer assembly in a tray filled with 20 X SSC. Beginning from the bottom, the assembly 
was composed of saturated blotting filter papers, the gel, an equilibrated nitrocellulose 
membrane, saturated blotting filter papers and paper towels. A weight of 250 g was placed on 
top of the assembly and the DNA was let to transfer upwards O/N with the capillary force 
from the gel into the membrane. The membrane was air-dried and the DNA was cross-linked 
to the membrane in a UV-transilluminator by exposing it to 0.160 J of UV-light. The 
membrane was put into a hybridization vial filled with 20 ml of pre-hybridization solution. To 
prevent the probe from unspecific hybridization, the memrane was pre-hybridized in a 
hybridization oven at 42 °C for 1 h. The hybridization of radioactive probe to its 
complementary DNA fragment was carried out in an isotope laboratory. Dextransulphate and 
denatured [α-
32
P]-labeled probe were added to the pre-hybridization solution. The 
hybridization was let to proceed in a hybridization oven at 42 °C O/N. The following steps of 
washing the membrane were performed (Table 3.12): 
 
 
 
Step: Solution: Duration: Temperature: 
1. 2 X SSC + 0.5 % SDS 5 min RT 
2. 2 X SSC + 0.1 % SDS 15 min RT 
3. 0.1 X SSC + 0.1 % SDS 30 min 65 °C 
 
 
 
The radioactive membrane was wrapped in thin plastic wrap and exposed to a phosphoimager 
screen in a dark cassette for 24 h. The hybridized [α-
32
P]-labeled probes were visualized by 
reading the screen in a phosphoimager. The obtained data were analyzed by using the Aida 
Image Analyzer V.3.28 software. 
 
 
Table 3.12: Steps for 
washing the radioactively 
labeled membrane. 
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3.1.4. Molecular biology techniques specific for the analysis of corneal gene expression in 
TGF-ß1 overexpression mice   
 
3.1.4.1. Preparation of mouse corneas 
 
Newborn WT and transgenic (TG) mice were sacrified for gene expression analysis by 
quickly cutting off their heads. The preparation of the corneas was carried out under a 
binocular by freeing the eye from overlying skin with scissors. The cornea was prepared in 
situ by making an incision through the cornea into the anterior chamber and by extending this 
incision along the corneal-conjunctival border. The cornea could then easily be lifted up by 
mini-forceps. The corneas from both eyes were put into a cooled eppendorf tube, immediately 
snap-freezed in liquid nitrogen and stored at – 80 °C until use. 
 
 
3.1.4.2. RNA isolation 
 
Stored corneas were thawed on ice. RNA was isolated by adding 500 µl of TRI reagent
®
 and 
by incubating the sample for 5 min at RT. The tissues were homogenized with a tissue 
shredder and centrifuged at 12 000 for 10 min at + 4 °C to pellet cell debris and contaminants. 
The supernatant was transferred into a fresh eppendorf tube and 1/5 vol. of chloroform was 
added. The sample was mixed for 15 s, incubated for 2 - 3 min at RT and centrifuged at 12 
000 g for 15 min at + 4 °C. The aqueous phase was carefully transferred into a fresh 
eppendorf tube and 350 µl isopropanol was added. The sample was vortexed and put into – 20 
°C O/N to enhance the yield of precipitation. RNA was precipitated by centrifugation at 12 
000 g for 10 min at + 4 °C. The pellet was washed twice by adding 700 µl of 75 % EtOH abs., 
by vortexing the mix, and by centrifugation at 7 500 g for 5 min at + 4 °C. The pellet was air-
dried and dissolved in 20 µl of sterile nuclease-free H20. The quantity and purity of RNA was 
analyzed spectrophotometrically in a dilution volume of 1:20. The integrity of RNA was 
analyzed by running 2 µl of RNA on an agarose gel. If the RNA is not degraded, most of the 
Materials and methods     64 
 
sample should be visualized as two bands corresponding to the 28S and 18S spliced ribosomal 
RNA subunits (Farrell, 1993). RNA of good quality was stored at – 80 °C. 
 
 
3.1.4.3. Preparation of cDNA (= complementary DNA) 
 
RNA that had been stored at – 80 °C were transcribed into cDNA by using the iScript™ 
cDNA Synthesis Kit. The kit takes advantage of an RNAse inhibited RNAse H+ reverse 
transcriptase (RT), as well as a blend of oligo (dT) and random hexamer primers to initiate the 
transcription of mainly polyA-tailed mRNA. Per sample, 448.5 ng of RNA was transcribed 
into cDNA by adding 4 µl of 5 X iScript reaction mix, 1 µl of iScript RT and nuclease-free 
H20 to fill up the volume to 20 µl. To prove the sample for any DNA contaminants, a control 
sample without RT (referred to as the - RT-reaction) was mixed in parallel. The reaction was 
allowed to proceed in a mastercycler by using the following steps of reaction conditions 
(Table 3.13): 
  
 
Step: Temperature: Time: 
1. Primer annealing 25 °C 5 min 
2. Reverse transcription 42 °C 30 min 
3. Inactivation of RT 85 °C 5 min 
4. Cooling down reaction 4 °C ∞ 
  
 
The cDNA was stored at – 20 °C until use. 
 
 
 
 
Table 3.13: Reaction steps for 
preparation of cDNA by the iScript™ 
cDNA Synthesis Kit.  
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3.1.4.4. Primer design 
 
Primer pairs for quantitative RT-PCR that spanned intron boundaries of the mouse genome 
were designed by the Universal ProbeLibrary System from Roche (https://www.roche-
applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000) for genes selected according to the 
criteria described in Results 4.5.1. Target gene names, primer sequences, positions of primer 
binding sites within mouse genome and product sizes are listed in Table 3.14. 
 
 
Target 
gene: 
Primer sequence: Position in mouse 
genome: 
Product 
size: 
Egr2 fw: 5´-ctacccggtggaagacctc-3´ 
rev.: 5´-aatgttgatcatgccatctcc-3´ 
317 - 335  
408 - 428  
112 bp 
Fst fw: 5´-aagcattctggatcttgcaact-3´ 
rev.: 5´-gataggaaagctgtagtcctggtc-3´ 
928 - 949  
988 - 1011 
84 bp 
Gjb2 fw: 5´-acccatttcggaccaacc-3´ 
rev.: 5´-aatccatcttgtcctctggatg-3´ 
94 - 111  
217 - 238  
145 bp 
Krt14 
 
fw: 5´-tcccaattctcctcatcctc-3´ 
rev.: 5´-atgaccttggtgcggatct-3´ 
1358 - 1377  
1431 - 1449 
92 bp 
Lamb3 
 
fw: 5´-agccagcaggcaatgaat-3´ 
rev.: 5´-gccggtccttcaactctgt-3 
3338 - 3355  
3392 - 3410  
73 bp 
Lama3 fw: 5´-ccaggagctgctgaaacc-3´ 
rev.: 5´-tggtgcctgtgtgaaacact-3´ 
8997 - 9014  
9063 - 9082  
86 bp 
Mmp13 
 
fw: 5´-cagtctccgaggagaaactatga-3´ 
rev.: 5´-ggactttgtcaaaaagagctcag-3´ 
895 - 917  
966 - 988  
94 bp 
Igfbp6 
 
fw: 5´-agagaccggcagaagaatcc-3´ 
rev.: 5´-gctgcagtactgaatccaagtg-3´ 
586 - 605  
673 - 694  
109 bp 
Oca2 
 
fw: 5´-gagcctagtgagatcgtcgaa-3´ 
rev.: 5´-gcaagcactttctccagca-3´ 
1733 - 1753  
1839 - 1857  
125 bp 
Trpm1 
 
fw: 5´-cctcatggcctgttatctcc-3´ 
rev.: 5´-acttgacttcaaagaaggtattgttg-3´ 
749 - 768  
812 - 837  
89 bp 
Dkk2 
 
fw: 5´-ctggtacccgctgcaataat-3´ 
rev.: 5´-catggttgcgatctctatgc-3´ 
1085 - 1104  
1170 - 1189  
105 bp 
Ptgds 
 
fw: 5´-ggctcctggacactacacct-3´ 
rev.: 5´-atagttggcctccaccactg-3´ 
360 - 379  
416 - 435  
76 bp 
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Table 3.14: Primer pairs for quantitative RT-PCR were designed for selected genes by the Universal 
ProbeLibrary System (Roche). The list summarizes target gene names, primer sequences, positions of primer 
binding sites within mouse genome and product sizes.   
 
 
3.1.4.5. Quantitative real-time PCR 
 
To analyze the differences in corneal gene expression between WT and TG mice, a 
quantitative real-time PCR was performed by using cDNA as a template. In an optimal RT-
reaction the amount of a given transcribed cDNA corresponds to the amount of copies of its 
mRNA in the original RNA sample. Thus, the rate of amplification for a given gene from the 
cDNA template mix can be used to calculate the number of copies of its mRNA in the 
original sample. In practice, the PCR was carried out by using a combination of the 
multicolour iQ
™
5 RT-PCR Detection System and an iCycler
®
 thermal cycler. The system 
takes advantage of SYBR-Green I, a fluorescent dye that binds non-specifically to dsDNA 
(Witzthum et al., 1999). As the amplification reaction proceeds into its exponential phase, the 
intensity of the fluorescence exceeds a background level. This time-point is called the cycle-
threshold, CT, for that gene. The more cDNA for a given gene in the template the less cycles 
the reaction has to proceed until it reaches its CT. To get a relative quantification of the 
expression levels of tested genes, their CT-values were compared with those of selected 
reference genes. Reference genes are referred to as genes that function as “house-keeping” 
genes in the investigated tissue and that, independent of treatment, show no transcriptional 
regulation between samples. Because of variance in composition, each amplicon has its 
individual melting temperature, resulting in an individual sharp melting curve. To avoid any 
false positive results caused by primer dimers or mis-priming, the melting curves for each 
sample product were analyzed for their purity. 
 
To get reliable data, duplicates or triplicates of each sample were investigated. For each 
investigated gene, one – RT-reaction and one NTC (no template control) were run in parallel. 
Because of the huge amount of samples, two different master mixes for the reagents were 
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mixed. The 2 X MM was mixed first and was a part of the SYBR-Green I (Sg) MM (Tables 
3.15 A and B). 
 
 
A) 2 X MM:                                         B) SgMM (for one reaction):  
 
 
 
 
 
 
 
 
 
Table 3.15: Master mix for 2 X MM (A) and one Sg (SYBR-Green I) MM (B). The 2 X MM was made up first 
and was then used as a component in the SgMM. The 2 X MM can be stored at - 20 ° for later use.
 
In the next step, master mixes for primers, cDNAs, RT-reactions and NTCs were setup 
(Tables 3.16 A, B and C). 
 
 
 
 
 
 
 
2 X  MM 7.24 µl 
Taq Polymerase (5 U/µl)  0.06 µl  
SYBR-Green I (7.4 % (w/v) in DMSO) 0.19 µl 
Fluorescein (1:100 in H20) 0.015 µl 
 
10 X buffer 300 µl 
MgCl2 (25 mM) 120 µl 
dNTPs (25 mM each) 24 µl 
H20 1006.5 µl 
Total volume 1450.5 µl 
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A) cDNA/-RT mix (10 µl):              B) NTC-mix (10 µl):          C) Primer mix (5 µl):  
 
 
 
 
 
Table 3.16: A) The cDNA/-RT-reaction mix (10 µl) for one reaction. The amount cDNA/-RT-reaction was 
taken directly from the RT/-RT-reaction volume of 20 µl. B) The NTC mix (10 µl) for one reaction. C) The 
primer mix (5 µl) for one reaction. 
 
 
Finally, the cDNA/-RT-reaction/NTC-mix of 10 µl was added together with the 5 µl primer 
mix in a reaction well of a 96-well PCR plate to give a total reaction volume of 15 µl. The 
PCR-plate was covered with a sealing film and the samples were shortly centrifuged. The 
reactions were run by the following steps of reaction conditions (amplification + melting 
curve) (Table 3.17): 
SgMM  7.5 µl 
H20 2.5 µl 
Total volume 10 µl 
 
Primer fw (100 µM) 0.08 µl  
Primer rev. (100 µM) 0.08 µl 
H20 ad 5 µl 
 
SgMM  7.5 µl 
cDNA/-RT-reaction 0.7 µl  
H20 ad 10 µl 
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Step: Temperature: Time: 
1. Taq polymerase activation 95 °C 15 min 
2. Amplification 40 cycles 95 °C ↔ 60 °C 10 s ↔ 40 s 
3. Final elongation 95 °C 1 min 
4. Transit to melting cycles 55 °C 1 min 
5. 81 cycles for melting curve 55 °C + 0.5 °C/cycle 6 s 
 
 
Table 3.17: The quantitative real-time PCR by the iQ™5 RT-PCR Detection System and iCycler
®
 thermal 
cycler was run by the following steps of reaction conditions. The program combines the amplification with the 
melting curve calculation.  
 
 
The data were calculated and evaluated by using the iQ Optical System Software version 2.0 
to give the relative expression values for each sample. The relative expression values are 
calculated by the comparative CT- method, ∆∆CT, according to the formula 
 
 
∆∆CT = ∆CT (sample) -  ∆CT (reference gene) (Livak et al., 2001) 
 
 
The relative expressions were graphically presented by transferring the obtained expression 
data into Microsoft
® 
Excel. The statistical significance was calculated according to the 
student´s t-test by assessing a p-value of p < 0.05 as significant, and a p-value of p < 0.02 as 
highly significant. 
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3.2. Cell culture techniques 
 
3.2.1. Description of cell lines 
 
1. HTM-N (immortalized human trabecular meshwork cells)  
 
HTM-N cells are adherent cells that grow as a monolayer culture. The cells are derived from 
the TM of a glaucoma patient. The cell line has been immortalized by transforming it with an 
origin defective mutant of SV40, which significantly increases its growth rate, whereas its 
cellular and extracellular composition, as well as its signalling mechanisms, correspond to 
those of non-transformed cells (Pang et al., 1994). 
 
2. HEK (human embryonic kidney)-293 cells   
 
HEK-293 cells are adherent cells that grow as a monolayer culture. The cells are derived from 
human embryonic kidney cells of a healthy aborted fetus. The cell line has been immortalized 
by transforming it with adenovirus type 5 DNA (Graham et al., 1977). 
 
 
3.2.2. Storage and culturing 
 
For long-term storage, cells were suspended in appropriate culture medium containing 10 % 
DMSO, and stored in a cryovial in liquid nitrogen. For culturing, a cryovial of cells were 
thawed in a water-bath. The cell suspension was transferred into 1 vol. of appropriate culture 
medium and the cells were pelleted by centrifugation at 1000 rpm for 5 min. The pellet was 
resuspended in 2 ml of culture medium and the suspension was transferred into a 75 cm
2
 
culture flask containing 11 ml of medium. The cells were grown in a cell culture incubator at 
Materials and methods     71 
 
37 ° C with a CO2-content of 7 %. At confluence, the cells were passaged by washing them 
twice in 2 ml of 1 X PBS, and by trypsinizing them in 2 ml of 0.05 % trypsin dissolved in 
EDTA. After detaching, the cells were transferred into a Falcon tube containing 2 vol. of 
culture medium. The cells were pelleted by centrifugation at 1000 rpm for 5 min and the 
pellet was resuspended in 1 - 5 ml of culture medium. An aliquote of the suspension was 
transferred into a new culture flask containing 12 ml culture medium.  
 
 
3.2.3. Transient transfection 
 
Transient transfection of cultured cells was carried out by lipofection. The technique takes 
advantage of cationic lipids that form a complex with the foreign DNA, and which then fuse 
with the plasma membrane to enter the cell (Felgner et al., 1987). The day before transfection 
cells were counted by using the Casy
®
 Cell Counter system according to the instructions 
provided by the manufacturer. The cells were plated out at a density of 2 X 10
5
 cells/well in a 
24-well culture plate. On the day of transfection the cells had reached a confluence of 80 - 95 
%. For transfection, 25 µl of culture medium without additives, 4 µl of Plus™ Reagent and 
100 – 500 ng of plasmid were mixed and let to pre-complex for 15 min at RT. In case of co-
transfection, 5 ng of plasmid expressing Renilla Luciferase was added to the pre-complexing 
mix. 1 µl Lipofectamine™ 2000 was diluted in 25 µl of culture medium without additives and 
the dilution was mixed with the pre-complexing mix. The complexing of DNA and 
lipofectamine was allowed to proceed for 20 min at RT. The cells were washed twice with 1 
ml of culture medium without additives. 200 µl of culture medium without additives was 
added to the cells, after which the lipofectamine-DNA complexes were added. The plate was 
gently agitated to blend the complexes throughout the medium. The transfection was allowed 
to proceed at 37 °C, 7 % CO2, for 6 h. The medium was changed to 1 ml culture medium with 
additives. 24 h after transfection the medium was changed once more, and the protein 
expression was allowed to proceed for an additional 48 h. 
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3.2.4. Dexamethasone treatment 
 
Dexamethasone treatment of transfected cells was carried out 6 h or 24 h after transfection, 
concomitantly to culture medium exchange. Dexamethasone at a concentration of 10
-5
 M 
dissolved in EtOH was added to the fresh culture medium to give an endconcentration of 10
-7
 
M. The treatment was continued until the cells were harvested. 
 
 
3.2.5. Dual-Luciferase
®
 Reporter assay 
 
Promoter activity was analyzed by measuring the relative activities of the reporter genes 
firefly luciferase (Photinus pyrialis) (experimental reporter) to Renilla luciferase (Renilla 
reniformis) (control reporter) from the same sample by applying the Dual-Luciferase
®
 
Reporter Assay System according to the instructions provided by the manufacturer. The 
normalization of the activity of the experimental reporter to the activity of the control reporter 
minimizes experimental variability caused by differences in cell density, transfection 
efficiency or assay efficiency. Co-transfected cells were harvested 72 h after transfection by 
washing them with 1 X PBS and by rocking the plate in 150 µl/well 1 X PLB (passive lysis 
buffer) for 20 min at RT. The cell lysate was transferred to an Eppendorf tube and cell debris 
was pelleted by centrifugation for 5 min at 13 200 rpm. 20 µl of lysate was transferred to a 
luminometer vial and the activities of firefly luciferase and Renilla luciferase were 
subsequently measured in an AutoLumat LB953 luminometer according to the instructions 
provided by the manufacturer. 5 readings for 10 s were performed for each reporter gene. 
First, the activity of firefly luciferase was measured by injecting 100 µl Luciferase Assay 
Substrate II to the vial. In this reaction firefly luciferase converts beetle luciferin to 
oxyluciferin, which emits light (Lottspeich and Zorbas, 1998). Secondly, the activity of 
Renilla luciferase was measured by injecting 100 µl of Stop & Glo
®
 buffer, which quenches 
the firefly luminescence and subsequently activates Renilla to convert coelenterazine to 
coelenteramide by the emission of light (Matthews et al., 1977). The activities of 5 readings 
were summarized, and the activity of firefly luciferase was divided by that of Renilla 
luciferase. The results were graphically presented by using the Microsoft
® 
Excel software. 
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Because of ease in handling, we later went over to a more sophisticated luminometer system, 
the Centro XS
3
 LB 960 microplate luminometer. In this system 10 µl of cell lysate was 
pipetted into the wells of a 96-well luminometer plate and the Dual-Luciferase
®
 Reporter 
Assay was performed by injection of 50 µl LAR II, followed by injection of 50 µl Stop & 
Glo
®
 buffer. The measurement and normalization of the values were performed as above by 
using the MicroWin 2000 software and the data were further exported to Microsoft
® 
Excel for 
graphical presentation. 
 
 
3.3. Mice  
 
TG mice were generated in an inbred defined FVB/N genetic background. This mouse strain 
is characterized by a vigorous reproductive performance, large litters and pronuclei that are 
large and easy to microinject (Taketo et al., 1991). Two of the many characterized genetic 
markers described for this strain are the classical albino mutation (c) and the Pdeb
rd1
 retinal 
degeneration mutation (Gimenez and Montoliu, 2001). 
 
 
3.3.1. Breeding of mice 
 
Breeding of mice was carried out at the age of 5 - 6 weeks by crossing a TG mouse with a 
WT mouse of the same FVB/N genetic background. The offspring were separated from the 
parent animals at the age of 3 weeks, or as soon as a new litter was born. The litter was kept 
together until an age of 4 weeks, after which it was separated into females and males, and 
genotyped.  
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3.3.2. Isolation of genomic DNA from mouse tail biopsies 
For genotyping of mice at the age of 4 weeks, the animals were etherized, pierced with an 
earmark and cut for a 0.5 cm tail biopsy. The fresh biopsy was lysed by adding 200 µl of 
Proteinase K lysis buffer and by shaking the sample at 55 °C at 1200 rpm O/N. Proteinase K 
was inactivated by incubation for 15 min at 95 °C. Cell debris was pelleted by centrifugation 
at 13 200 rpm for 10 min. The supernatant was spectrophotometrically measured for DNA 
concentration and purity, and the sample was diluted in H20 to give an endconcentration of ~ 
25 ng/µl. The mouse tail DNA was stored at + 4 °C. 
 
 
3.3.3. Genotyping of transgenic mice 
 
Screening of possible founder animals was carried out by PCR of genomic DNA isolated 
from tail biopsies. A primer pair was designed (LacZ fw and LacZ rev.) that binds within 
LacZ of the transgene, and which amplifies a sequence of 524 bp length (Fig. 4.10). For 
genotyping, the following reaction setup was mixed (Table 3.18). 
  
 
 
Template 2 µl (~ 50 ng) 
Primer fw 0.6 µl 
Primer rev. 0.6 µl 
2 X GoTaq
®
 Green MM 7.5 µl 
H20 4.3 µl 
Total volume 15 µl 
 
 
The PCR was carried out for 34 cycles by the following reaction conditions (Table 3.19). 
 
Table 3.18: The reaction setup for 
genotyping of TG mice by PCR. 
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Step: Temperature: Time: 
Initial denaturation 95 °C 2 min 
Denaturation 95 °C 30 s 
Primer annealing 55 °C 30 s 
Elongation 72 °C 30 s 
Final elongation 72 °C 5 min 
  
 
 
For routine genotyping during breeding of the lines, a new primer pair was designed, NLS fw 
and LacZ rev. 2, which binds within the sequence of 3 X NLS and LacZ, respectively, and 
which amplifies a sequence of 220 bp length (Fig. 4.10). Reaction setup and PCR conditions 
were as above (Tables 3.18 and 3.19), with the exception that the PCR was carried out for 
only 32 cycles. 
 
 
3.4. Histological techniques          
 
3.4.1.  LacZ-staining of transfected cells  
 
HTM-N cells were plated out at a density of 2 X 10
5
 cells on a 1.8 cm
2
 chamber slide and 
transiently transfected with cloned ß-galactosidase overexpression construct by lipofection as 
described in chapter 3.2.3. For staining, the cells were washed once with 0.1 M NaPO4 buffer 
and fixed for 5 min at RT in LacZ-fixation buffer. The cells were washed 3 times for 5 min in 
LacZ-wash buffer and stained in LacZ-staining solution in a moist chamber at 37 °C for 1 - 3 
d, or until blue colour was visible. The cells were washed 3 times for 5 min in LacZ-wash 
buffer, after which the object slide was released from the chamber rim. The slide was 
dehydrated by incubating it in a series of increasing ethanol concentrations and xylol (Table 
3.20): 
 
Table 3.19: PCR reaction 
conditions for genotyping of TG 
mice. 32 cycles of denaturation, 
primer annealing and elongation 
were carried out. 
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Step: Solution: Duration: 
1. 70 % isopropanol 5 min. 
2. 80 % isopropanol 5 min. 
3. 96 % isopropanol 2 X 5 min. 
4.  100 % isopropanol 2 X 5 min. 
5.  xylol 2 X 10 min. 
 
 
The slides were mounted by coverslips with a few drops of Depex mounting medium and 
stored in dark at + 4 °C. 
 
 
 
3.4.2. Fixation and LacZ-staining of adult mouse organs  
 
Eyes, heart and sciatic nerves from adult TG mice were prepared for LacZ-staining as follows. 
The mouse was etherized and killed by cervical dislocation and the organs were removed by 
using scissors and forceps. The organs, whereby the heart was halved, were shortly washed in 
0.1 M NaPO4 buffer and fixed in 0.1 M NaPO4 buffer with added 4 % PFA for 6 h at + 4 °C. 
The organs were washed twice in 0.1 M NaPO4 buffer for 30 min and left in 0.1 M NaPO4 
with 0.02 % (w/v) added NaN3 in dark at + 4 °C until cryoprotection and embedding in 
Tissue-Tek
®
 (section 3.4.4). Alternatively, mouse adult organs were fixed, cryoprotected and 
embedded in Tissue-Tek
®
 before LacZ-staining. Stored cryosections of organs were stained 
for LacZ as described in section 3.4.1 and, if required for a better recognition of fine 
structures, counterstained by haematoxylin-eosin staining by standard protocols before 
dehydration and mounting.   
 
 
3.4.3. Fixation and LacZ-staining of embryos 
 
For mouse embryo preparation at E12.5, TG and control females were superovulated by 
standard protocols (Nagy et al., 2003). On the morning after mating, the females were 
Table 3.20: Dehydration of LacZ-stained 
object slides was carried out by 
incubating them in a series of increasing 
ethanol concentrations and xylol.  
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checked for a copulation plug. The visible plug was considered as E0.5. The pregnant female 
was etherized and killed by cervical dislocation at E12.5. The embryos were recovered from 
the uterus and immediately washed in 0.1 M NaPO4 buffer. Each embryo was separately 
prepared under a binocular. The embryo was freed from the amnion and a tail biopsy was 
taken for genotyping. To enable proper penetration of the fixation solution, an incision was 
made in the abdomen. The embryos were fixed in LacZ-fixation buffer for 30 min, washed 3 
times for 15 min in LacZ-wash buffer and stained in LacZ-staining solution in dark at 37 °C 
for 1 - 2 d. After staining, the embryos were washed 3 times for 15 min in LacZ-wash buffer 
and once for 10 min in 0.1 M NaPO4 buffer. The embryos were stored in 0.1 M NaPO4 with 
0.02 % (w/v) added NaN3 in dark at + 4 °C until cryoprotection and embedding as described 
in section 3.4.4. 
 
  
3.4.4. Cryoprotection and embedding of adult mouse organs and embryos 
 
In order to protect organs and embryos from structural damage during freezing, they were 
cryoprotected by infiltrating them successively for 4 – 24 h in each 10 %, 20 % and 30 % 
sucrose in 0.1 M NaPO4 buffer. The organs were embedded in Tissue-Tek
®
, snap-freezed in 
liquid nitrogen and stored at – 20 ° C until sectioning 
 
 
3.4.5. Cryosectioning of embedded mouse organs and embryos 
 
Embedded mouse organs and embryos were sectioned by cutting sagittal or transverse 
cryosections of 12 µm thickness in a Microcom HM 500 OM cryostat. For storing, the 
sections were placed on SuperFrost
®
Plus object-plates, wrapped in aluminium foil, and stored 
at - 20 °C until mounting and analysis by phase contrast microscopy. Sections of unstained 
adult organs were stored at - 20 °C until staining, dehydration and mounting as described in 
section 3.4.1.  
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3.4.6. Phase contrast microscopy  
 
Active ß-galactosidase cleaves X-gal into a blue substrate (Pearson et al., 1963), which can be 
visualized by normal phase contrast microscopy. LacZ-stained adult organs and embryos were 
analyzed by a Zeiss Axioskop 40 microscope and observed blue staining was documented by 
making images by an Axio Imager Z1 microscope in a Carl Zeiss AxioVision format (.zvi) at 
different magnifications (5 X - 40 X). The data were converted into .tif-format and further 
edited by using the Adobe
®
 Photoshop
®
 CS3 Extended software. 
 
 
3.4.7. Immunohistochemistry 
 
The vascular system of the brain of a 6 week old rat of the strain Wistar was perfused with 4 
% PFA by standard protocols to remove erythrocytes and thus to eliminate possible 
background labelling. The brain was fixed in 0.1 M NaPO4 buffer with added 4 % PFA for 5 - 
6 h, washed 3 times for 15 min in 0.1 M NaPO4 buffer and left in this buffer O/N. The brain 
was sectioned, dehydrated and embedded in paraffin by standard protocols, or cryoprotected 
and embedded in Tissue-Tek
®
 as described in section 3.4.4. Paraffin embedded brain was cut 
coronal by a microtome in 6 µm thin sections, put onto object slides and dried O/N in 37 °C. 
Slides were de-paraffinized and hydrated by standard protocols and incubated in 0.1 M 
boiling citrate buffer, which was then let to cool down to RT. Slides were incubated in H20 
for 5 min, in 0.1 M NaPO4 buffer containing 0.05 % Tween-20 for 5 min, and blocked with 
0.5 % BSA diluted in 0.1 M NaPO4 buffer for 45 min. For detection of myocilin expression, 
slides were incubated with a rabbit-derived anti-myocilin antibody diluted 1:50 in 0.1 M 
NaPO4 buffer containing 0.5 % BSA O/N in a moist chamber at + 4 °C. Control slides were 
incubated with 0.1 M NaPO4 containing 0.5 % BSA alone. Slides were washed three times for 
5 min in 0.1 M NaPO4 and incubated with a green fluorescing goat-derived anti-rabbit 
secondary antibody diluted 1:1000 in 0.1 M NaPO4 containing 0.5 % BSA in dark for 1 h at 
RT. Slides were washed 3 times for 5 min in 0.1 M NaPO4 buffer and mounted by coverslips 
with a few drops of 1:10 DAPI (4'-6-diamidine-2-phenyl indole) mounting medium. The 
slides were stored in dark at + 4. 
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3.4.8. Fluorescence microscopy  
 
DAPI stained nuclei and GFP-labelled myocilin were analyzed by UV-light and appropriate 
filter systems in an Axio Imager Z1 fluorescence microscope. Images were documented in a 
Carl Zeiss AxioVision format (.zvi) at 20 and 40 X magnifications. The data were converted 
into .tif-format and further edited by using the Corel PHOTO-PAINT
®
 software. 
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4. Results 
 
4.1. Characterization of MYOC  
 
4.1.1. Search and analysis of conserved genomic regions 
 
4.1.1.1. Functional analysis of conserved intronic and 3´-UTR regions 
 
Since only the basal MYOC promoter has been characterized (Kirstein et al., 2000), and since 
a better understanding of the regulation of MYOC would be of importance to better 
understand the role of myocilin in glaucoma, we analyzed the capacity of different regions of 
human MYOC to drive reporter gene expression. It is known that non-coding (nc) parts of a 
gene like introns, or even more distal regions lying tens of kb up- or downstream of the 
translated part, can contain important transcriptional enhancers (Plaza et al., 1995; Uchikawa 
et al., 2004; Kleinjan et al., 2006; Aruga et al., 2007). A search for evolutionary conserved 
regions by inter-species comparison of orthologous sequences can reveal distal enhancers 
even within gene-sparse regions, so called gene deserts (Nobrega et al., 2003). VISTA is a 
computational tool for comparative genomics aimed to identify functional elements (Frazer et 
al., 2004). To find regions within MYOC that have been conserved between species 
throughout evolution, and that may serve a regulatory role in the transcription process, we 
used the VISTA Browser 2.0 software (http://pipeline.lbl.gov/cgi-bin/gateway2) that is based 
on pre-computed alignments, and that offers a graphical view of conserved areas. By 
comparing the human and mouse MYOC/myoc locus, we identified several intronic conserved 
regions, as well as a 3´-UTR, which peaked in a homology of over 70 %. The possible 
intronic distal control regions (DCRis) were named DCRi2a, DCRi2b3´, DCRi2b5´ and 
DCRi2c (Fig. 4.1). 
 
 
Results 
 
Fig. 4.1: Comparison of human 
software for inter-species alignme
heights of the peaks illustrate the
UTRs are shown in blue and turq
of at least 70 % for a length of 
regions, possible distal control r
homologous 3´-UTR from human
(p313+67) (Fig. 4.2) for Luciferas
 
 
The human MYOC basal pro
frame transcriptional start 
Luciferase-reporter construct
the 377 bp MYOC basal pro
mouse myocilin genes, whe
aligned to match the second 
authors showed that p313+6
cultures of human TM, as w
cell line MUTM-NEI/1 (Tam
above conserved MYOC regi
over the level than p313+67
functional role in the regula
DCRi2a, DCRi2b3´, DCRi
 
and mouse myocilin genes by using the VISTA Br
nt. Mouse myoc is depicted from the right to the left o
 degree of homology to human MYOC at that nucleo
uoise, respectively. Conserved nc sequences that sho
at least 100 bp are shown in pink. We amplified 
egions (DCRs), named DCRi2a, DCRi2b5´, DCRi2
 genomic DNA and cloned these in front of the huma
e-reporter assays. 
moter (p313+67), which extends until the p
ATG (Nguyen et al., 1998), had alread
s by Kirstein et al. (2000) (Fig. 4.2). The des
moter was deduced from the alignment betw
re the start ATG of mouse myoc (Tomare
possible start ATG of the human gene (Kirst
7 effectively enhanced reporter gene expres
ell as in the clonal, immortalized and diffe
m et al., 1999), when compared to a contro
ons (Fig. 4.1) for their capacity to drive repo
 does, and consequently to find out if the 
tion of MYOC, we cloned the four homolog
2b5´, DCRi2c, as well the homologous 
81 
 
owser 2.0 bioinformatic 
n chromosome one. The 
tide position. Exons and 
w a consensus homology 
four intronic homologous 
b3´, DCRi2c, as well a 
n MYOC basal promoter 
ublished second in-
y been cloned into 
ignation p313+67 of 
een the human and 
v et al., 1998) was 
ein et al, 2000). The 
sion in primary cell 
rentiated mouse TM 
l vector. To test the 
rter gene expression 
conservation plays a 
ous intronic regions 
3´-UTR, in front of 
Results 
 
p313+67 between the restric
homologous regions, their le
 
 
Name o
DCRi2a
DCRi2b
DCRi2b
DCRi2c
3´-UTR
Table 4.1: List of conserved, po
Luciferase-reporter constructs. Th
The positions refer to the nucleo
1998).  
 
 
 
 
 
tion enzyme recognition sites KpnI and Xh
ngths and positions within MYOC are listed i
f region: Length (bp): Position in hmyoc
 548 +2207 - (+)2755 
3´ 1311 +4502 - (+)5813 
5´ 1690 +5715 - (+)7405 
 609 +7459 - (+)8068 
 1537 +16896 - (+)18433 
 
ssible regulatory MYOC regions that were cloned i
e lengths of the regions, as well as their positions w
tide positions after the published second possible st
82 
oI (Fig. 4.2). Cloned 
n Table 4.1. 
: 
n front of p313+67 into 
ithin MYOC, are shown. 
art ATG (Nguyen et al., 
 
Results  83 
 
Figure 4.2: Luciferase-reporter construct, where the human MYOC basal promoter (p313+67) had been 
introduced into the MCS between the restriction enzyme overhangs XhoI and HindIII to drive firefly Luciferase 
expression, had already been cloned by Kirstein et al. (2000) by using the pGL3-Basic vector from Promega as a 
backbone. We cloned the conserved MYOC regions listed in Table 4.1, as well as the artificial enhancer elements 
PITX3, FOX, PITX3/FOX and RAREß/PITX3/FOX listed in Table 4.3, in front of p313+67 between the 
restriction enzyme overhangs KpnI and XhoI. The conserved MYOC regions listed in Table 4.2, as well as the 
human MYOC E-box listed in Table 4.3, were cloned in front of p313+67 between the restriction enzyme 
overhangs NheI and XhoI.  
 
 
The above cloned reporter constructs were transiently transfected into HTM-N cells and the 
relative light units (RLUs) produced by expressed reporter were measured by Dual-
Luciferase
®
 Reporter assays as described in Materials and methods 3.2.5. Repeated assays 
revealed that DCRi2b5´ and DCRi2c did enhance the expression up to 3.7- and 2.2-fold, 
respectively, over the basal promoter level. In both cases the capacity to drive reporter 
expression in comparison to the basal promoter was highly significant (p = 0.014 and p = 
0.001 for DCRi2b5´ and DCRi2c, respectively). The two other conserved intronic regions 
DCRi2a and DCRi2b3´ did not have any positive effect on gene expression, the effect was 
rather negative (Fig. 4.3). Also the region 3´-UTR showed rather a negative than a positive 
effect on gene regulation in these cells (data not shown). 
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4.1.1.2. Deletion study of conserved intronic and 3´-UTR regions 
 
In order to exactly find out which parts of the conserved intronic and 3´-UTR regions of 
MYOC are responsible for the positive/negative regulation of reporter gene expression in 
comparison to p313+67, we deleted the outermost parts of above regions to comprise only the 
highest sharp peaks of homology. By aligning human and mouse DCRia, DCRi2b5´, DCRi2c 
and 3´-UTR regions by VISTA Browser 2.0, we reduced the lengths of these regions to span 
only the most conserved parts, to regions that show a homology of 69.2 to 75.8 % throughout 
their sequence. These shorter new regions of homology range from 87 to 275 bp and were 
called H3, H4, H5-6 and H7 (H stands for Homology). In fact, H5-6 consists of two sharp 
homologous peaks residing only 28 bp apart, but because of difficulties in finding appropriate 
primer pairs for the amplification of H5 and H6 separately, we decided to amplify H5 and H6 
in one stretch (Fig. 4.4).  
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H3, H4, H5-6 and H7 were cloned in front of p313+67 into Luciferase-reporter constructs 
between the restriction enzyme overhangs NheI and XhoI (Fig. 4.2). Because of problems in 
finding appropriate primer pairs for amplification, the cloned amplicons are a bit longer than 
the conserved regions themselves. The exact lengths and %-homologies between human and 
mouse regions H3, H4, H5-6 and H7, as well as their positions within MYOC are listed in 
Table 4.2. The list also summarizes lengths and positions of respective amplicons. 
 
 
Name of 
region: 
Length (bp) with % 
homology to hmyoc: 
Position within 
hmyoc: 
Length of 
Amplicon: 
Amplicon position 
within hmyoc: 
H1 94 (70.0) +24249 - (+)24343 256 +24190 - (+)24446 
H2 102 (70.9) +22843 - (+)22945 220 +22815 - (+)23035 
H1-2 102+94 +22843 - (+)22945; 
+24249 - (+)24343 
1631 +22815 - (+)24446 
H3 86 (75.8) +17104 - (+)17190 281 +17012 - (+)17293 
H4 181 (69.5) +7591 - (+)7772 267 +7562 - (+)7829 
H5 133 (72.9) +6324 - (+)6457 413 6152 - (+)6565 
H6 123 (69.2) +6173 - (+)6296 413 6152 - (+)6565 
H7 101 (70.5) 2470 - (+)2571 294 2374 - (+)2668 
H8 107 (73.8) -4961 - (-)4854 288 -5042 - (-)4754 
H9 514 (72.0) -11122 - (-)10608 514 -11122 - (-)10608 
H10 1044 (85.0) -31826 - (-)30782 1178 -31869 - (-)30691 
 
Table 4.2: List of highly conserved, possible regulatory MYOC regions, that were cloned in front of p313+67 
into Luciferase-reporter constructs. The list summarizes regions analyzed in the deletion study (H3 - H7), as well 
as tested possible long-range regulatory elements (H1 - 2 and H8 - 10). The lengths of the conserved regions 
with their %-homology between human and mouse, as well as their positions within MYOC, are depicted. The 
list also summarizes lengths and positions of respective amplicons. The positions refer to the nucleotide 
positions after the published second possible start ATG of MYOC (Nguyen et al., 1998).  
 
 
To test for the transcriptional enhancer capacity of H3, H4, H5-6 and H7 in comparison to 
p313+67, and in order to look at which effect a deletion of parts of DCRia, DCRi2b5´, 
DCRi2c and 3´-UTR has on transcriptional gene regulation, we transiently transfeceted the 
deletion constructs into HTM-N cells and measured reporter gene expression in comparison to 
reporter expression in lysates that had been transfected with p313+67 alone. Repeated Dual-
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Luciferase
®
 assays as described Materials and methods 3.2.5. showed that the intronic regions 
H4 and H5-6 had slight, but not statistically significant, positive effects on gene regulation in 
comparison to p313+67. The effect of H7 on transcriptional gene regulation was also small, 
though statistically significant (p = 0.028). The effect of H3 was slight negative, but without 
significance (Fig. 4.5). In conclusion, the deletion analysis showed us that the capacity of 
DCRi2b5´ and DCRi2c to drive reporter gene expression statistically highly significant above 
the level than the basal promoter does (Fig. 4.3), went down drastically, when parts of these 
regions were deleted (Fig. 4.5). In contrast, the rather negative effect on reporter gene 
expression of the intronic region DCRi2a compared to the effect of p313+67 (Fig. 4.3) turned 
out into a slight positive effect when parts of it were deleted (Fig. 4.5). 
 
 
 
 
Figure 4.5: Deletion analysis of conserved intronic and 3´-UTR MYOC regions by Dual-Luciferase
®
 Reporter 
assay to analyze their capacity to regulate reporter gene expression in comparison to the MYOC basal promoter 
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(p313+67) in cultured HTM-N cells. H3, H4, H5-6 and H7 are shortened versions of the human intronic regions 
3´-UTR, DCRi2c, DCRi2b5´ and DCRi2a, respectively. Reporter constructs bearing the human regions H3, H4, 
H5-6 and H7 in front of p313+67 were transiently transfected into HTM-N cells and a Dual-Luciferase
®
 
Reporter assay was carried out after 72 h of expression. pGL3-Basic contains no eukaryotic promoter or 
enhancer sequences and was used as a background control. Reporter gene expression was measured as relative 
light units (RLUs) of the experimental reporter to the control reporter. Repeated assays showed that all intronic 
regions slightly increased reporter gene expression over basal promoter level, H7 even statistically significant (p 
= 0.028). However, the experiment showed us that a deletion of parts of DCRi2b5´ and DCRi2c results in a 
dramatic loss of enhancer capacity. In contrast, a deletion of parts of DCRi2a slightly elevated its capacity to 
drive reporter gene expression over basal promoter level. The graph shows an individual experiment, where 
duplicate samples were analyzed. Mean standard deviation (± SD) between duplicates are shown. Asterisks mark 
statistically significant differences of reporter gene activity between p313+67 and H (*p < 0.05).   
   
 
4.1.1.3. Search and analysis of long-range regulatory regions within MYOC 
 
We still extended our inter-species comparison between human and mouse myocilin genes to 
a long-range search for conserved elements far beyond the translated part of MYOC. We 
found three distal 5´-upstream homologous regions (H8 - H10) and two distal 3´-downstream 
homologous regions (H1 and H2), where the whole sequence showed a homology ranging 
from 70 - 85 %. These elements varied in lengths from 95 to 1044 bp and resided as far as 31 
kb up- and 7 kb downstream, respectively, from the translated part of MYOC (Fig. 4.4). H1, 
H2 and H8 - H10 were cloned in front of p313+67 into Luciferase-reporter constructs 
between the restriction enzyme overhangs NheI and XhoI (Fig. 4.2). The exact lengths of 
conserved distal regions, their %-homologies between human and mouse, as well as their 
positions within MYOC are listed in Table 4.2. The list also summarizes the lengths and 
positions of the true cloned amplicons. In order to compare the transcriptional enhancer 
capacity of distal conserved regions with the capacity of p313+67 to drive reporter gene 
expression, we transiently transfeceted the cloned reporter constructs into HTM-N cells and 
measured reporter gene expression in comparison to reporter gene expression in lysates that 
had been transfected with p313+67 alone. Repeated Dual-Luciferase
®
 assays as described in 
Materials and methods 3.2.5. showed that the 3´-downstream conserved regions H1 and H2 
enhanced the expression of reporter up to 2.9- and 2.4-fold, respectively, over the level than 
did p313+67 alone. The capacity of H1 to drive reporter gene expression over the basal 
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promoter level was significant (p = 0.037). The 5´-upstream conserved regions H8 and H9 
showed no effect on transcriptional gene regulation, whereas the most afield residing largest 
cloned region H10 showed a slight, but negligible, positive effect on reporter gene expression 
(Fig. 4.6). 
 
 
 
 
 
 
Figure 4.6: Dual-Luciferase
®
 Reporter assay measuring the capacity of conserved long-range MYOC elements 
to regulate reporter gene expression over human basal promoter (p313+67) level in cultured HTM-N cells. 
Reporter constructs bearing the human 5´-upstream regions H8 - H10, as well as the 3´-downstream regions H1 
and H2 in front of p313+67 were transiently transfected into HTM-N cells and a Dual-Luciferase
®
 Reporter 
assay was carried out after 72 h of expression. pGL3-Basic contains no eukaryotic promoter or enhancer 
sequences and was used as a background control. Reporter gene expression was measured as relative light units 
(RLUs) of the experimental reporter to the control reporter. Repeated assays confirmed that the 3´-downstream 
elements H1 and H2 enhance reporter gene expression up to 2.9- and 2.4-fold, respectively, over the basal 
promoter level in these cells. The 5´-upstream elements H8 - H10 had no noteworthy effect on gene regulation. 
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The graph shows an individual experiment, where duplicate samples were analyzed. Mean standard deviation (± 
SD) between duplicates are shown. Asterisks mark statistically significant differences of reporter gene activity 
between p313+67 and H (*p < 0.05).   
 
 
4.1.1.4. Expanded analysis of the 3´-UTR region 
 
Many genes are regulated by enhancer elements residing within their 3´-UTRs (Griffin et al., 
2002; Sun et al., 1998; Yochum et al., 2008). The discovery of microRNAs (miRNAs) 
(Chalfie et al, 1981; Ambros et al., 1989) has further corroborated the potential of the 3´-UTR 
to contribute to the complex network of gene regulation (reviewed by He and Hannon, 2004). 
Since both H1 and H2 showed a positive effect on reporter gene expression in cultured HTM-
N cells (Fig. 4.6), and since these elements both reside within the 3´-UTR of MYOC, we 
expanded our analysis of this region. Inter-species alignment of the 3´-UTR of MYOC by 
VISTA Browser 2.0 revealed that H1 and H2 reside within a larger area of conservation that, 
when comparing the human and mouse genes, extend as far as 13.5 kb downstream of exon 3. 
In addition to H1 and H2, this region contains at least four more peaks with a homology of ~ 
70 % (Fig. 4.7). 
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4.1.1.5. Analysis of GC responsiveness of conserved nc MYOC regions 
 
It has been well documented that myocilin expression is highly up-regulated in TM cells after 
treating these with the GC dexamethasone (Polansky et al., 1997; Nguyen et al., 1998; Tamm 
et al., 1999). Sequence analyses of the 5´-promoter region of MYOC have revealed that there 
are many potential functional GREs (Nguyen et al., 1998; Polansky et al., 1997; Adam et al., 
1997). However, attempts to analyze the 5´-promoter region of MYOC for its direct GC 
response have been without success (Kirstein et al., 2000), indicating that the GC response of 
MYOC is an indirect secondary response (Shepard et al., 2001). We wanted to expand the 
search for functional GREs within the MYOC locus to encompass also intronic, as well as 
long-range 5´- and 3´-UTR regions. We transiently transfected HTM-N cells with our cloned 
reporter constructs containing intronic, as well as distal 5´- and 3´-UTR regions of MYOC 
(Tables 4.1 and 4.2) in front of p313+67 (Fig. 4.2). Dexamethasone treatment (10
-7
 M) during 
expression did not have any effect on reporter gene expression in any of the samples (data 
shown only for DCRia, DCRi2b5´, DCRi2b3´and DCRi2c in Fig. 4.3). This indicates that 
none of our analyzed conserved regions contain functional elements that directly or indirectly 
are able to respond to dexamethasone.    
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4.2. Creation of ß-galactosidase overexpression mouse  
 
4.2.1. Search for artificial enhancer elements with strong activity within the TM 
 
In the attempt to better understand the molecular interactions that lie behind an elevated AH 
outflow resistance in the TM, it would be of great value to be able to direct high expression of 
interesting, possibly for POAG relevant proteins, into this tissue in vivo. The fact that there 
are additional regions within MYOC that contribute to its transcription rate above basal 
transcription level in cultured TM cells (Figs. 4.3 and 4.6), indicates that the MYOC basal 
promoter alone would not be sufficient to drive protein overexpression in this tissue in vivo. 
We wanted to create and identify an artificial enhancer element that, in combination with 
p313+67, would drive high protein expression in cultured HTM-N cells. The final aim of the 
project was to be able to use the identified element to drive overexpression of protein in the 
TM of a mouse model.     
 
We created a set of artificial enhancer elements that were made up of different combinations 
of repetitive binding sites for the evolutionary conserved transcription factors PITX (paired-
like homeodomain transcription factor) and FOX (forkhead box),  known to be pivotal in 
anterior eye development in human and in mouse (reviewed by Cvekl and Tamm, 2004; Matt 
et al., 2005). As members of the paired-class of homeodomain proteins, PITX transcription 
factors can bind the core DNA sequence TAATNN in both the major and minor grooves, 
where the two last nucleotides of the core sequence are specified by the recognition helix 
itself (Wilson et al., 1993). Chaney et al. (2005) showed a solution structure of PITX2 protein 
bound to its consensus DNA site TAATCC. We created an 87 bp element, with three 
recurring TAATCC PITX binding motives, interspaced by 15 nucleotides (Table 4.3). The 
FOX family of proteins contain a unique ~ 100 bp conserved winged-helix FOX domain that 
is essential for DNA binding (Kaestner et al., 2000). It has been shown that the FOX 
transcription factors can recognize variations of the DNA core motive (T/C)(A/C)AA(C/T)A, 
and that the less conserved regions of the proteins are able to regulate the DNA binding 
specificity of the conserved DNA binding regions (Tsai et al., 2006). Pierrou et al. (1995) 
showed that in vivo derived FOXC1 binds the DNA motive GTAAATAAA with high affinity 
in vitro. We created an 87 bp element, with three recurring GTAAATAAA FOX binding 
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motives, interspaced by 12 nucleotides (Table 4.3). To test for the possibility that a co-effect 
of both PITX and FOX would lead to a cumulative effect of reporter gene expression, we 
created an element that combined the repetitive consensus binding motives of PITX and FOX 
(Table 4.3). RA signalling is thought to control anterior eye development and morphogenesis 
by regulation of key transcription factors (Matt et al., 2005). The signals affect gene 
expression by nuclear RAR dimers that bind retinoic acid response elements (RAREs) in the 
genome. One of these elements, a direct repeat of the nucleotide motif GTTCAC, was 
originally discovered in the promoter of the mouse RARß2 gene. The GTTCAC repeat is 
separated by five nucleotides and is able to confer RA responsiveness via all three RAR 
subtypes (Sucov et al., 1990). To test for if an element that combines the repetitive binding 
sites for the transcription factors PITX and FOX, as well as for RAR dimers, would confer 
overexpression of reporter gene, we created an 150 bp artificial enhancer that combined the 
RARE GTTCAC repeat with the recognition motives for PITX and FOX transcription factors 
(Table 4.3). E-boxes (enhancer boxes) with the consensus sequence CANNTG are recognized 
by helix-loop-helix transcription factors (Funk et al., 1991). Human MYOC contains a 
canonical E-box at the nucleotide position -152-(-146) (the numbers depict the nucleotide 
position before the by Nguyen et al. (1998) published second possible start ATG). This site 
was shown to be of prime importance in conferring MYOC basal promoter activity by the 
binding of USF (Kirstein et al., 2000). We created a 32 bp enhancer element of the MYOC 
promoter region -171-(-140) that contains the conserved E-box CACGTG (reviewed by Corre 
and Galibert 2005) (Table 4.3).  
 
 
Element: Sequence (5´ → 3´) and length: 
PITX3 gtcatggctagcccttgggtaatccagcatgggccttgggtaatccagcatgggccttgggtaatccagcatgggctcgaga
cgtgt (87 bp) 
FOX gtcatggctagcgccaaaGTAAATAAAcaacaggccaaaGTAAATAAAcaacaggccaaaGTAAATAA
Acaacagctcgagacgtgt (87 bp) 
PITX3/ 
FOX 
gtcatggctagcccttgggtaatccagcatggggccaaaGTAAATAAAcaacagccttgggtaatccagcatggggc
caaaGTAAATAAAcaacagctcgagacgtgt (108 bp) 
RAREß/ 
PITX3/ 
FOX 
gtcatggctagcggttcaccgaaagttcactcgccttgggtaatccagcatggggccaaaGTAAATAAAcaacagg
gttcaccgaaagttcactcgccttgggtaatccagcatggggccaaaGTAAATAAAcaacagctcgagacgtgt 
(150 bp) 
MYOC E-
box 
gcacagccccacccagcctcacgtggccacct (32 bp) 
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Table 4.3: List of created artificial enhancer elements that had been cloned in front of p313+67 between the 
restriction enzyme overhangs KpnI and XhoI, or for human MYOC E-box between the restriction enzyme 
overhangs NheI and XhoI, to elicit an overexpression of the reporter gene firefly luciferase (Fig. 4.2). The 
sequence and the lengths of the elements are indicated. Repetitively ocurring evolutionary conserved binding 
sites for respective transcription factors are highlighted as underlined, capital letters, in bold and boxed for PITX, 
FOX, RAR and basic helix-loop-helix proteins, respectively.      
 
 
To direct the activity of the artificial enhancers PITX3, FOX, PITX3/FOX and 
RAREß/PITX3/FOX to the TM, they were cloned in front of p313+67 and the reporter firefly 
luciferase between the restriction enzyme overhangs KpnI and XhoI. The MYOC E-box was 
cloned into the same site via the restriction enzyme overhangs NheI and XhoI (Fig. 4.2). To 
analyze if the artificial elements had the capacity to induce an overexpression of protein in 
cultured HTM-N cells, we transfected the reporter constructs transiently into HTM-N cells 
and carried out a Dual-Luciferase
®
 assay as described in Materials and methods 3.2.5. 
Repeated experiments showed that a combination of the binding sites for RAR, PITX and 
FOX transcription factors did elevate the expression up to 11.8-fold, highly significant, above 
the level of basal expression (Fig. 4.8). None of the other tested elements did have an effect 
on gene expression over MYOC basal promoter level (data not shown). 
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To investigate if the characteristic of HTM-N cells to activate RAREß/PITX3/FOX-p313+67 
to drive a ~ 10-fold elevation of reporter gene expression compared to basal expression level 
is specific to these cells, we wanted to look at the activity of RAREß/PITX3/FOX-p313+67 in 
another cell line. We transiently transfected RAREß/PITX3/FOX-p313+67-Firefly Luciferase 
into HEK-293 cells and analyzed reporter gene expression compared to the expression elicited 
by p313+67 alone. Repeated Dual-Luciferase
®
 Reporter assays as described in Materials and 
methods 3.2.5 confirmed that HEK-293 cells do not offer the proper intracellular composition 
of transcription factors needed for RAREß/PITX3/FOX-p313+67 to activate gene expression 
(Fig. 4.9). This indicates that the capacity of RAREß/PITX3/FOX-p313+67 to activate 
reporter gene expression is not a general characteristic of cultured cells. In this regard and 
when comparing these two cultured cell lines, the capacity of RAREß/PITX3/FOX-p313+67 
in activating high reporter gene expression is specific for HTM-N cells. 
 
 
 
 
   
Figure 4.9: Dual-Luciferase
®
 Reporter assay to find out if the activating effect of RAREß/PITX3/FOX-p313+67 
on reporter gene expression in cultured HTM-N cells (Fig. 4.8) is a characteristic of these cells. As a 
comparison, we transiently transfected RAREß/PITX3/FOX-p313+67-Firefly Luciferase into HEK-293 cells and 
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analyzed reporter gene expression after 72 h of expression. pGL3-Basic contains no eukaryotic promoter or 
enhancer sequences and was used as a background control. Repeated assays confirmed that 
RAREß/PITX3/FOX-p313+67 could only confer minimal reporter gene activity in HEK-293 cells. The graph 
shows an individual experiment, where duplicate samples were analyzed. Mean standard deviation (± SD) 
between duplicates are shown.  
 
 
4.2.2. Cloning of ß-galactosidase overexpression construct 
 
Since cultured HTM-N cells had approved to offer the proper molecular machinery needed to 
activate the enhancer RAREß/PITX3/FOX-p313+67 to drive high reporter gene expression in 
these cells, we wanted to test if the activity of the element would also be sufficient to drive the 
expression of the reporter ß-galactosidase. We cloned an overexpression construct, where the 
gene for ß-galactosidase, LacZ, was driven by p313+67, as well as the artificial enhancer 
RAREß/PITX3/FOX. It has been shown that a reiteration of the SV40 large T-antigen nuclear 
localization signal (NLS) significantly increases the efficiency of nuclear polypeptide 
transport in mammalian cells (Fischer-Fantuzzi and Vesco, 1988). To ensure that the mature 
ß-galactosidase would be effectively imported into the nucleus, a repetitive NLS, 3 X NLS, 
was cloned in frame with the LacZ ORF, just behind the codon for the start ATG (Fig. 4.10). 
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4.2.4. Purification of ß-galactosidase overexpression construct for pronuclear injection 
 
Since HTM-N cells proved to have the required molecular machinery to activate 
RAREß/PITX3/FOX-p313+67 to drive high protein expression in these cells in vitro (Fig. 
4.8), a characteristic not seemed to be general among cell lines (Fig. 4.9), and since our 
cloned ß-galactosidase overexpression construct was able to direct expected blue staining into 
the nuclei of cultured HTM-N cells (Fig. 4.11A, B), we decided to test our ß-galactosidase 
overexpression construct in an in vivo mouse model. We wanted to create a TG mouse line 
that would express visible RAREß/PITX3/FOX-p313+67-driven ß-galactosidase in the TM. 
We released the 4041 bp linear transgene from the ß-galactosidase overexpression construct 
by restriction with KpnI. To facilitate separation of the transgene from the rest of the plasmid 
by agarose gel electrophoresis, the backbone was further restricted into smaller fragments by 
the restriction enzymes SapI, XmnI, AclI and SacII (Fig. 4.10). After complete separation of 
the transgene from the backbone, it was cut out from the gel and purified as described in 
Materials and methods 3.1.2.2 for mouse male pronuclear injection. 4.45 µg of purified 
transgene was sent to Max Planck Institute (MPI) for Neurobiology in Martinsried, Münich, 
for microinjection by standard protocols into male pronuclei of fertilized mouse oocytes of a 
FVB/N background.  
 
 
4.2.5. Screening for founder animals 
 
48 tail biopsies from possible founder mice bearing the transgene were sent back to us from 
MPI. We screened for these biopsies by PCR using a primer pair that binds LacZ within the 
transgene (LacZ fw. and LacZ rev), and that results in an amplicon of 524 bp (Materials and 
methods 3.3.3. and Fig. 4.10). We identified three animals, animal numbers 8387, 8388 and 
8390, that had integrated RAREß/PITX3/FOX-p313+67-3 X NLS-LacZ into their genomes 
(Fig. 4.12). 
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Figure 4.14: LacZ-staining of sagittal cryosections of eye (A) and heart (B), as well as a transverse cryosection 
of sciatic nerve (C) of an adult TG ß-galactosidase overexpression mouse of the line 8388. No LacZ-staining was 
seen in these organs, indicating that RAREß/PITX3/FOX-p313+67 could not be activated to drive visible ß-
galactosidase expression in these adult organs. Organs from a Pax6
lacZ/+
-mouse (St. Onge et al., 1997) were 
stained as a positive control (data not shown). For better visualization of fine structures, sections of heart and 
sciatic nerve were counterstained by haematoxylin-eosin staining. The images were taken by an Axio Imager Z1 
microscope at 5 X and 20 X magnifications for A, B and C, respectively.    
 
 
4.2.8. LacZ-staining of embryos 
 
4.2.8.1 Analaysis of LacZ-staining of eyes 
 
As it is known that RA-dimers, PITX- and FOX-transcription factors are pivotal in anterior 
eye development in human and in mouse at around E12.5 (reviewed by Cvekl and Tamm, 
2004; Matt et al., 2005), we wanted to analyze if the artificial enhancer element 
RAREß/PITX3/FOX, in combination with p313+67, is able to drive visible ß-galactosidase 
expression in the developing mouse eye at this time point. TG and WT E12.5 embryos of the 
ß-galactosidase overexpression lines 8388 and 8390 were LacZ-stained and analyzed for 
visible blue staining of the eyes. LacZ-stained E12.5 Pax6
lacZ/+
-embryos (St. Onge et al., 
1997) served as positive control. Repeated staining experiments showed that 
RAREß/PITX3/FOX-p313+67 was not activated to drive visible expression of ß-
galactosidase in the eyes of TG ß-galactosidase overexpression mice at this time point in 
either of the TG lines. As in the eye of the WT embryo of line 8390 (Fig. 4.15C), only 
background staining could be observed in the TG eyes of both lines (Fig. 4.15A and B). 
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Figure 4.18: Overview of haematoxylin-eosin stained coronal sections showing brain ventricles and ependyma. 
A) In mammals, the vascular CP can be found within the CSF-filled ventricular system (boxed and shown in 
higher magnification for the right lateral ventricle). The specialized epithelial lining of the CP secretes CSF into 
the ventricles and is responsible for filtration of metabolites and waste products between the blood and CSF. B) 
Despite this specialization, the epithelium is continous with the ependymal lining of the brain tissue. Source: 
http://neuromedia.neurobio.ucla.edu/campbell/nervous/wp_images%5C199_brain_ependyma.gif. 
 
 
Various approaches using antibodies against ependymal myocilin in brain sections of 
newborn mice did not confirm our suggestion about endogenous myocilin expression in this 
tissue (data not shown). There are generally problems by using anti-myocilin antibodies 
against mouse myocilin (reviewed by Ezzat et al., 2008), and by experience we know that our 
available myocilin antibodies may not work well, or may be associated with background 
staining in mouse tissues. Thus, we wanted to test these antibodies against rat myocilin 
ependymal cells. Immunohistochemistry of sections of 6 week old rats confirmed our 
suggestion of endogenous myocilin expression in mammalian ependyma (Fig. 4.19A, C and 
E). 
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Figure 4.20: Immunohistochemistry of transverse paraffin sections of 6 week old rat brain sections using a 
rabbit-derived  primary antibody against myocilin and a secondary green fluorescent anti-rabbit antibody. 
Endogenous myocilin expression was observed within neurons and glial cells of the PVZ of the lateral ventricle 
(A and B), whereas only faint background labelling is seen in the control (C). The positive myocilin labelling 
locates to perikarya, as well as to bundles of axons as exemplified in B).  DAPI staining shows the nuclei (A – 
C). Immunofluorescent images were made by an Axio Imager Z1 fluorescent microscope at a 20 X 
magnification.  
 
 
4.3.2. Analysis of myocilin expression in human CSF by Western blot 
 
Together with the ependymal lining of the ventricles, the ependymal cells of the CP secrete 
about 450 - 600 ml CSF/day into the ventricles. The CSF offers mechanical protection to and 
regulates homeostasis of the central nervous system (CNS) (Bob and Bob et al., 2007). 
Drainage of CSF through the arachnoid granulations into the venous system or directly into 
the lymphatic vessels clears the CNS from waste products. The rate of secretion into and 
drainage out of the brain ventricles of CSF thus regulates the intraventricular CSF volume, 
which in turn regulates intracranial pressure and blood flow perfusion (reviewed by Kapoor et 
al., 2008).  
 
Since we detected myocilin expression in the ependymal cells of the CP and the lining of the 
lateral ventricle in rat (Figs. 4.19A and C), we wanted to analyze if myocilin is secreted into 
the CSF in mammals. As the volume of CSF that can be obtained from rat is limited in 
comparison to volumes that can be obtained from human patients during lumbar puncture, and 
since we had access to CSF samples collected from patients during this procedure (PD Dr. 
med. Andreas Steinbrecher, Department of Neurology, University of Regensburg), we had 
earlier analyzed the expression of myocilin within human CSF by Western blot. Analysis of 
CSF samples from 18 patients showed that myocilin is secreted into human CSF. An antibody 
directed against myocilin detected it as the typical 55 - 57 kD double band (Nguyen et al., 
1998; Clark et al., 2001) in most of the samples and, in some samples (4, 7, 8, 10, 19 and 12) 
as a single ~ 56 kD band. The band intensities varied in intensity between the two bands of 
the double band, as well as between samples (Fig. 4.21),  
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Figure 4.21: Western blot of CSF samples collected from 18 human patients (numbered 1 – 18) during lumbar 
puncture. 30 µl of CSF was loaded on a polyacrylamide gel, transferred to a nitrocellulose membrane and blotted 
against myocilin with a goat-derived antibody against myocilin. Visualization of bound primary antibody was 
carried out by using a chemiluminescent secondary antibody directed against the primary antibody. In most 
samples myocilin was detected at varying intensity as a 55 – 57 kD double band, whereas it in some samples was 
detected as a single 56 kD band (samples 4, 7, 8, 10, 19 and 12). Std = standard. Blotting was carried out by Dr. 
Markus Kröber.      
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4.4. Creation of myoc knock-in mouse line 
 
Since RAREß/PITX3/FOX, in combination with the MYOC basal promoter, was not able to 
drive visible ß-galactosidase expression above background level in mouse TM in vivo (Figs. 
4.14A and 4.15), we made a second effort to target in vivo gene expression into this tissue. 
Myocilin shows a strong expression at both mRNA and protein level in human and mouse 
TM (Adam et al., 1997; Karali et al., 2000; Takahashi et al., 1998; Knaupp et al., 2004) and 
gene expression profiling of human TM confirmed that myocilin is the third most abundant 
message expressed in this tissue (Tomarev et al., 2003). A conditional knock-out by the 
Cre/lox system (reviewed by Sauer, 1998) in the TM would offer the possibility to study a 
wide spectrum of molecular interaction and function contexts in this tissue, and should be of 
immense value in unravelling the mechanisms that build up an elevated IOP. This prompted 
us to use the endogenous mouse myoc promoter to direct the expression of Cre recombinase 
into the TM of an in vivo mouse model.  
 
 
4.4.1. Cloning of myoc knock-in construct 
 
We designed a myoc knock-in construct, which would allow the integration of the gene for 
Cre recombinase in frame at the myoc locus by homologous recombination (Tymms and Kola, 
2001; Ch. 3). Details to amplification of homologous flanks, as well as to cloning of the 
construct, are described in Materials and methods 3.1.3.1. Sequencing of amplified 3072 bp 
homologous 5´-flanks revealed that all screened colonies contained point mutations. The 
clone of choice carried two mutations: - 1670 G → A and – 897 T → C, where the numbers 
depict respective nucleotide position before mouse myoc start ATG (Tomarev et al., 1998). 
Sequencing of amplified 2268 bp 3´-homologous flanks revealed that all screened colonies 
contained point mutations. The clone of choice carried one mutation: + 2129 T → C, where 
the number depicts the nucleotide position after mouse myoc start ATG (Tomarev et al., 
1998). Inter-species comparison of the mutated regions did not show conservation, suggesting 
that the point mutations would not interfere with transcriptional regulation of the construct. 
The 5´-homologous flank was ligated into the backbone vector pTV-0 between the restriction 
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4.4.2. Linearization and purification of myoc knock-in construct for electroporation into 
mouse ESCs   
       
The myoc knock-in construct was linearized by cutting it with NotI and purified for 
electroporation into mouse ESCs by phenol/chloroform/isoamylalcohol extraction as 
described in Materials and methods 3.1.3.2. 200 µg of linear purified construct was sent to 
MPI for Neurobiology in Martinsried, Münich, to be electroporated into mouse ESCs of a 
FVB/N background by standard protocols. 
   
    
4.4.3. Screening of electroporated ESCs for homologous recombination of the knock-in 
construct at the myoc locus by Southern blot   
 
Clones of electroporated ESCs were positively and negatively selected for the knock-in 
construct as described in Tymms and Kola 2001; Ch. 3. Clones that had passed this selection 
were lysed in a 96-well plate by standard methods (Tymms and Kola 2001; Ch. 5). The 
lysates were screened for proper homologous recombination at both flanks by Southern blot 
with radioactive probes directed against the myoc locus. The Southern blot strategy had been 
made up in combination with the cloning stategy by carefully choosing restriction enzymes 
that would cut WT and knock-in alleles differentially and yield fragments with a size 
difference of at least 1000 bp. Based on database data (Ensembl Genome Browser) for the 
myoc sequence, a restriction with XbaI should result in band sizes of 5432 and 7203 bp for 
WT and knock-in alleles, respectively, after correct homologous recombination of the 5´-end 
of the construct. After correct homologous recombination of the 3´-end of the construct, a 
restriction with HindIII should result in band sizes of 6743 and 4665 bp for WT and knock-in 
alleles, respectively (Fig. 4.23). 
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4.5. Analysis of corneal gene expression in TGF-ß1 overexpression mice   
 
A second focus in our attempts to investigate gene regulation during pathologic processes in 
the anterior eye was the fibrotic cornea. Scar formation in the cornea elicits a wound healing 
process that can lead to inflammation, neovascularisation and ECM accumulation, reducing 
the transparency of the cornea and impairing vision (reviewed by Fini, 1999). Since activated 
TGF-ß enhance the fibrotic reactions in the eye, actual efforts to counter this negative side 
effect of wound healing concentrate on targeting signalling pathways downstream of TGF-ß 
(reviewed by Saika, 2006; reviewed by Saika et al., 2008). Flügel-Koch et al. (2002) 
generated a mouse model that overexpress active TGF-ß1 in the lens and that show a fibrotic 
corneal phenotype including elevated migration and proliferation and of fibroblast-like 
stromal mesenchyme cells, neovascularisation, as well as abnormal ECM accumulation. To 
learn more about which corneal gene regulatory networks that are affected upon an 
overexpression of TGF-ß1, and thus to find out possible genes that may be involved in the 
loss of corneal transparency in these mice, we carried out gene expression profiling and 
subsequent quantitative RT-PCR of corneas from TGF-ß1-overexpression mice and compared 
the data against those of corneas from WT mice.  
 
 
4.5.1. Selection of genes of interest 
 
In order to get a better understanding of the signalling networks that may lie behind the 
fibrotic corneal phenotype seen in ßB1-crystalline-TGF-ß1 mice (Flügel-Koch et al., 2002), 
we earlier compared the corneal gene expression between newborn WT and TGF-ß1-
overexpression mice by cDNA microarrays (Affymetrix
®
 430.0 Mouse Arrays). Comparison 
of 4 TG and 4 WT animals showed that 98 and 163 genes were at least two-fold up- and 
down-regulated, respectively in TG corneas. Out of these genes we chose 7 and 5 genes that 
were up- and down-regulated, respectively, to be confirmed for by quantitative RT-PCR. 
Criteria for the selection of genes were the presence of mRNA transcript in all arrays, as well 
as an abundance of transcript that gave a signal of more than 50. Based on the literature, we 
further selected the genes for those that were known to be regulated by TGF-ß1, or that were 
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known to be found in the eye or the cornea. Tables 4.4 and 4.5 show the selected genes, their 
detection p-values, as well as their fold change compared to WT animals in the microarrays. 
 
Gene bank: Gene Symbol: Gene name: p-
Value 
Fold change to 
WT 
NM_010118 Egr2 early growth response 2 
 
0.0203 2.811 
 
NM_008046 Fst 
 
Follistatin 
 
0.0184 
 
2.645 
 
NM_008125 Gjb2 
 
gap junction membrane channel 
protein beta 2 
0.0245 
 
2.933 
 
NM_016958 Krt14 (Krt1-14) 
 
keratin complex 1, acidic, gene 14 
 
0.0133 
 
2.656 
 
NM_008484 
 
Lamb3 
 
laminin, beta 3 
 
0.04 
 
2.404 
 
X84014 
 
Lama3 laminin, alpha 3 0.0151 
 
2.356 
 
NM_008607 
 
Mmp13 
 
matrix metallopeptidase 13 0.047 
 
6.156 
 
 
Table 4.4: Based on our previous microarray data, as well as a profound literature search, the following up-
regulated genes were selected to be confirmed for by quantitative RT-PCR.   
 
 
Gene bank: Gene Symbol:  Gene name: p-Value Fold change 
to WT 
NM_008344 Igfbp6 
 
insulin-like growth factor binding 
protein 6 
0.0365 
 
0.42 
 
NM_021879 
 
Oca2 (pink-
eyed dilution) 
oculocutaneous albinism II 0.0268 
 
0.0916 
 
NM_018752 
 
Trpm1 
 
transient receptor potential cation 
channel, subfamily M, member 1 
0.0261 
 
0.0991 
 
NM_020265 
 
Dkk2 
 
dickkopf homolog 2  
 
0.00479 
 
0.452 
 
NM_008963 
 
Ptgds 
 
prostaglandin D2 synthase  
 
0.0389 
 
0.198 
 
 
Table 4.5: Based on our previous microarray data, as well as a profound literature search, the following down-
regulated genes were selected to be confirmed for by quantitative RT-PCR.   
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4.5.2. Primer design and testing of reference genes  
 
Primer pairs for quantitative RT-PCR that spanned intron boundaries of the mouse genome 
were designed by the Universal ProbeLibrary System from Roche (https://www.roche-
applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000) for the selected genes as described 
in Materials and methods 3.1.4.4. To find the most suitable reference genes with no changes 
in corneal gene expression between WT and TG animals, we designed primer pairs for the 
following 6 candidate genes as above (Table 4.6): 
  
 
Gene name (gene symbol, gene 
bank):  
Primer sequence: Position in 
mouse 
genome: 
Product 
size: 
ribosomal protein L32 (Rpl32, 
NM_172086.2)  
fw.: 5´-gctgccatctgttttacgg-3´ 
rev.: 5´-tgactggtgcctgatgaact-3´ 
 
29 - 47 
107 - 126 
 
98 bp 
glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh, 
NM_008084.2)   
fw.: 5´-tgtccgtcgtggatctgac-3´ 
rev.: 5´-cctgcttcaccaccttcttg-3´ 
763 - 781 
818 - 837 
 
75 bp 
 
guanine nucleotide binding protein, 
beta polypeptide 2 like 1 (Gnb2l1, 
NM_008143.3) 
fw.: 5´-tctgcaagtacacggtccag-3´ 
rev.: 5´-gagacgatgatagggttgctg-3´ 
 
 
514 - 533 
584 - 604 
 
91 bp 
ribosomal protein S9 (Rps9, 
NM_029767.2) 
 
fw.: 5´-atccgccaacgtcacatta-3´ 
rev.: 5´-tcttcactcggcctggac-3´ 
 
437 - 455 
555 - 572 
 
136 bp 
tubulin, beta 1 (Tubb1, 
NM_001080971.1) 
fw.: 5´-actgtgggacgtctgctctc-3´ 
rev.: 5´-gcggcacatacttcttaccg-3´ 
 
157 - 176 
215 - 234 
 
78 bp 
 
hypoxanthine guanine 
phosphoribosyl transferase 1 
(Hprt1, NM_013556.2) 
fw.: 5´-tcctcctcagaccgctttt-3´ 
rev.: 5´-cctggttcatcatcgctaatc-3´ 
 
 
104 - 122 
173 - 193 
 
90 bp 
 
Table 4.6: Primer pairs for listed 6 candidate reference genes were designed by the Universal ProbeLibrary 
System from Roche. The list summarizes the target gene names, primer sequences, positions of the primer 
binding sites within mouse genome and product sizes.   
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Comparison of the expression of above candidate reference genes in 4 TG corneas vs. 4 WT 
corneas in several parallel quantitative RT-PCR experiments confirmed that Gnb2l1 and 
Rpl32 were expressed equally in TG and WT animals (data not shown). These two genes were 
used as reference genes in all experiments.  
 
 
4.5.3. Differential gene expression in ßB1-crystalline-TGF-ß1 mouse corneas  
 
Since transgenic TGF-ß1 mRNA levels decrease after day P1 in ßB1-crystallin-TGF-ß1 
mouse eyes (Flügel-Koch et al., 2002), and because RNA from P0 mice had been used for the 
cDNA microarray studies, we chose P0 as the day of preparation of corneal RNA. cDNA was 
synthesized from RNA and used as template for the quantitative RT-PCR experiments. The 
gene expression level of the above selected genes was compared between a minimum of 4 
WT and 4 TG animals by relating the levels to those of the reference genes. All experiments 
were assembled by the Gene Study function of the iQ Optical System Software version 2.0. 
Microarray data showed that in TG corneas Egr2, Fst, Gjb2, Krt14, Lamb3, Lama3 and 
Mmp13 had fold changes of 2.811, 2.645, 2.933, 2.656, 2.404, 2.356 and 6.156, respectively, 
when compared to WT corneas (Table 4.4). In our quantitative RT-PCR experiments the 
expression levels of these genes were 5.68, 3.45, 3.17, 3.04, 2.21, 1.51 and 53.66 times higher 
in TG corneas than in WT corneas (Figs. 4.26 and 4.27). Thus, we confirmed the previous 
microarray data that showed that an over-expression of TGF-ß1 in the mouse eye leads to an 
up-regulation of above genes in the cornea. 
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Microarray data showed that Igfbp6, Oca2, Trpm1, Dkk2 and Ptgds had fold changes of 0.42, 
0.0916, 0.0991, 0.452 and 0.198, respectively, in the corneas from TG mice in comparison to 
WT corneas (Table 4.5). In our quantitative RT-PCR experiments the expression levels of 
these genes in TG corneas were 0.38, 0.08, 0.25, 0.46 and 0.13 of that of their expression 
levels in WT corneas (Fig. 4.26). Thus, we here confirmed the previous microarray data that 
showed that an over-expression of TGF-ß1 in the mouse eye leads to a down-regulation of 
these genes in the cornea. 
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5. Discussion 
5.1. Characterization of MYOC 
Since only few studies focused on the transcriptional regulation of myocilin, and since earlier 
attempts to characterize MYOC are restricted to its near 5´-UTR, resulting in definition of just 
the immediate proximal promoter that is responsible for myocilin basal transcription (Kirstein 
et al., 2000), we wanted to characterize human MYOC more thoroughly by analysing also 
intronic and long-range nc regions. 
 
5.1.1. Analysis of conserved nc MYOC regions 
Being important for protein function, exon coding sequences have been highly conserved 
between species through evolution. Based on same principle, inter-species alignment can 
reveal nc sequences that are important for the regulation of a gene over its basal promoter 
level (reviewed by Visel et al., 2007). We started our characterization of human MYOC by 
searching for possible regulatory sequences within the human MYOC transcript, as well as 
within its immediate 3´-UTR. Inter-species alignment of the myocilin gene, subsequent 
cloning of conserved regions and reporter gene expression studies revealed that two regions 
within MYOC intron 1, DCRi2b5´ and DCRi2c, induced a 3.7- and 2.3-fold expression (both 
statistically highly significant) of reporter gene over MYOC basal promoter level in TM cells 
in vitro. DCRi2b3´and the 5´-most intronic region DCRi2a had slight inhibitory effects on 
basal transcription level (Fig. 4.3). 
Since we in our deletion studies confirmed that deletion of the flanking sequences of 
DCRi2b5´ and DCRi2c resulted in only a modest elevation of reporter gene expression over 
MYOC basal promoter level (Fig. 4.5), confirms that the positive effect on reporter gene 
expression raised by DCRi2b5´ and DCRi2c is not elicited by shorter enhancer elements 
represented by the sharp homology peaks residing within DCRi2b5´ or DCRi2c (viewed in 
Fig. 4.4), and suggests that the whole sequences spanned by the intronic regions DCRi2b5´ 
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and DCRi2c are important in the elevation of gene expression over basal transcription level in 
TM cells.  
Interestingly, a deletion of the flanking sequences of the 5´-most intronic region DCRi2a, 
which had a slightly negative effect on basal transcription (Fig. 4.3), resulted in a significant 
induction of reporter gene expression over MYOC basal promoter level (Fig. 4.5). This could 
mean that the flanking sequences may in some way repress or inhibit the positive effect that 
the conserved peak region H7 has on transcriptional regulation. Theoretically, this could 
occur through binding of an inhibitory factor to the flanking deleted part. Such factors may 
indirectly repress the action of positively acting factors by e.g. re-organizing chromatin 
structure to a more packed form that hinders the access of transcription enhancing proteins to 
neighboring DNA (reviewed by Latchman, 1996). An example of this kind of indirect 
repression of transcription occurs in Drosophila melanogaster, where the Polycomb-group of 
proteins bind to specific elements of the DNA, thereby inducing heterochromatin formation 
and inactivating transcription (Zink and Paro, 1995). It illustrates the complexity of regulatory 
networks present in eukaryotes that allow a fine-tuning of gene regulatory processes to meet 
the needs of a specific developmental or pathological state. 
 
5.1.2. Analysis of conserved long-range distal elements 
To test for the possibility that MYOC could be regulated by long-range distal elements, we 
analysed three and two distal conserved regions within the 5´- and 3´-UTRs of MYOC, 
respectively, for their capacities to regulate gene expression beyond basal promoter level in 
cultured human TM cells. We confirmed that both distal 3´-UTR regions, H1 and H2, which 
reside 7 kb downstream of the 3´-end of the transcribed region of MYOC (viewed in Fig. 4.4), 
regulated reporter gene expression 2.9 (statistically significant) and 2.4 fold, respectively, 
over basal promoter level (Fig. 4.6). Even though these two elements reside only ~ 1600 bp 
apart from each other, and within a wide 8 kb area of conservation (viewed in Fig. 4.7), our 
experiments did not confirm a cumulative effect of H1 and H2 on reporter gene expression. 
However, it does not rule out that other untested elements within the 8 kb conserved 3´-UTR 
region could participate in the transcriptional regulation of MYOC. 
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The fact that none of the conserved cloned 5´-upstream MYOC regions showed any effect on 
reporter gene expression over basal promoter level in cultured human TM cells (Fig. 4.6), 
indicate that these regions are not important for the transcriptional regulation of myocilin over 
basal promoter level. It still raises the question, why these regions (H8 – H10) show such an 
extent of conservation over such a wide region (in the case of H10 there is 85 % homology for 
a distance of over 1000 bp between MYOC and Myoc (Table 4.2). The fact that these regions 
did not show any effect on transcription efficiency in our human TM culture model, does not 
rule out that H8 – H10 could be important regions for accessory protein binding in vivo or in 
other tissues where myocilin is normally expressed. Even though our culture model is an 
established line to be used as a model in the analysis of molecular mechanisms of the TM 
(Pang et al., 1994), cultured cells are not in contact with neighbouring tissue as in an 
organism, and thus do not receive extracellular molecular signals. A culture model is thus 
solely a simplified generalization of the in vivo situation. H8 – H10 could therefore be 
important regions for accessory proteins important for transcriptional regulation in vivo or in 
other tissues, where these factors may be present. 
 
5.1.3. Search for functional GREs within MYOC 
Myocilin expression is highly activated by GC treatment in TM cell cultures (Polansky et al., 
1997; Tamm et al., 1999). Even though there are many putative GREs within 5 kb of the 5´-
UTR of MYOC (Nguyen et al., 1998), no functional GREs have been found within its close 
5´-upstream region (Kirstein et al., 2000; Shepard et al., 2001). Our search for functional 
GREs within our cloned conserved and analysed MYOC intronic and distal 5´- and 3´-UTR 
regions, did not corroborate that these regions would encompass functional GREs (Fig. 4.3 
and data not shown). The fact that myocilin induction by GCs often requires days of treatment 
(Tamm et al., 1999), has led to a hypothesis that myocilin is a delayed secondary GC 
responsive gene (Shepard et al., 2001), i.e. a gene that is activated upon binding of another, 
first to be expressed, primary GC responsive gene. The fact that we did treat our transfected 
cells with dexamethasone for 3 d, also excludes the possibility that our cloned MYOC regions 
encompass binding sites for factors that are synthesized upon a primary GC response. 
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Since some authors have shown that high elevation of myocilin expression may not occur 
until 7 - 10 d of GC treatment (Nguyen et al., 1998), our results do not exclude that the cloned 
regions could respond to dexamethasone after a longer than 3 d treatment. Available data 
about GC- induced myocilin expression mainly are derived from experiments using primary 
TM cell cultures from human or monkey (Nguyen et al., 1998; Tamm et al., 1999; Clark et al., 
2001), whereas we used an immortalized human TM cell line (Pang et al., 1994). Since the 
molecular GC response of a cell usually works by interactions with other accessory proteins 
present in the cell (e.g. chromatin remodeling factors) (reviewed by Liberman et al., 2007), 
we can not exclude that our tested MYOC regions could respond to GCs in primary lines, 
tissue culture or in vivo.   
 
5.1.4. Future aspects 
The fact that there are conserved regions within intron 1 and the 3´-UTR of MYOC that 
elevate reporter gene transcription over MYOC basal promoter level, suggests that these 
regions may be important in pre-mRNA processing, affecting the efficiency of transcription. 
By using bioinformatic and subsequent biochemichal (e.g. DNase footprinting and chromatin 
immunoprecipitation) tools it would be interesting to closer analyse the sequences 
encompassed by DCRi2b5´, DCRi2c, H1 and H2 to find out how and through what accessory 
factors these regions could be involved in enhancing the transcription of MYOC. Since none 
of our conserved 5´-UTRs did have any effect on transcription level in cultured human TM 
cells, it could be interesting to look at the effect of these regions in other systems like in 
astrocyte- or podocyte cell cultures, since myocilin is known to be expressed in these cell 
types (Obazawa et al., 2004; Goldwich et al., 2005). 
It is possible that there are regulatory regions still far beyond those that we analysed above 
(the farthest analyzed 5´- and 3´-UTR reside 31 and 7 kb, respectively, beyond the transcript 
coding region of MYOC). Examples of genes whose expression is affected by far distal 
regulatory elements within their 5´- and 3´-UTRs are Pax6, FOXL2 and Bmp2. Within PAX6 
a 35 kb long distant regulatory region that is responsible for endogenous Pax6 expression in 
parts of the brain and the developing eye resides ~ 150 kb downstream of the transcribed 
region, within the intron of the neighbouring gene ELP4 (Kleinjan et al., 2006). Long-range 
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extragenic deletions of wide regions of 5´- and 3´-UTRs of the gene FOXL2 have been found 
to be responsible in 14 % of patients suffering from blepharophimosis syndrome (BPES) 
(Beysen et al., 2005), a rare disease with complex inheritance that is characterized by eyelid 
malformation and in some cases premature ovarian failure. Bmp2, an important signalling 
ligand during osteoblast differentiation and bone formation, is transcriptionally regulated by a 
conserved 656 bp enhancer element that resides 156.3 kb downstream of the Bmp2 promoter 
(Chandler et al., 2007).  
The genomic landscape responsible for the endogenous expression pattern of Pax6 has been 
resolved by cloning a 420 kb region encompassing the human PAX6 locus into a yeast 
artificial chromosome (YAC). Approaches using bacterial artificial chromosomes (BACs) or 
YACs would make it possible to analyze much wider regions for their participation in the 
transcriptional regulation of myocilin, as than is possible by simple cloning. Since GCs can 
exert their transcription enhancing effect not only by binding to GREs or nGREs, but also by 
affecting and reqruiting accessory protein/transcription or chromatin remodelling factors 
(reviewed by Liberman et al., 2007), it may be possible that the molecular enhancement of 
MYOC transcription by GCs encompass much wider regions around the MYOC transcribed 
region than tested here. Approaches using BACs or YACs would allow for screening of huge 
areas at and around the MYOC locus for their ability to regulate transcription over basal 
transcription level, as well as to test for their GC responsiveness, in TM. 
 
5.1.5. The complexity of eukaryotic gene regulation  
Classically, basal transcriptional regulation is considered to occur by binding of transcription 
factors and auxiliary proteins to the 5´-promoter. Binding to far and near enhancer or 
inhibitory elements by cell- and developmental stage specific factors then can modulate the 
promoter driven basal transcription (Nelson and Cox, 2001). Critical cell- and developmental 
stage-specific enhancer or inhibitory elements may reside thousands of kb away from the 
transcribed region, within other loci (Kleinjan et al., 2006), within introns (Aruga et al., 2007) 
or even on other chromosomes (reviewed by Bartkuhn and Renkawitz, 2007). Transcriptional 
regulation in eukaryotes is a complex process that, in addition to the RNA polymerase II 
complex, is dependent on accessory factors that can bind the complex, as well as the DNA 
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(reviewed by Hartzog, 2003). In order to enable effective elongation of pre-mRNA transcript, 
accessory protein- and DNA binding factors are needed for the modulation of the chromatin 
structure (reviewed by Sunders et al., 2006). Transcriptional regulation is closely interwoven 
in time and space with pre-mRNA processing and mRNA decay (reviewed by Moore and 
Proudfoot, 2009). Increasing data show that regulation of gene expression occur both at the 
DNA and RNA levels. Through complex regulation of the processing of pre-mRNA by RNA 
binding proteins, a fine-tuning of the repertoire of mRNA species in time and space can be 
reached (reviewed by Licatalosi and Darnell, 2010). This means that also protein non-coding 
(nc) regions, like introns and 3´-UTRs, may contain regions that are targets for binding of 
important RNA processing factors. 
 
5.1.5.1. Possible role of DCRi2b5´and DCRi2c as long ncRNA 
The facts that DCRi2b5´and DCRi2c both are able to elicit gene expression highly significant 
over the human MYOC basal promoter level in cultured human TM cells (Fig. 4.3), and that 
they reside only ~ 50 bp apart (viewed in Fig. 4.1), suggest that they both, as one 2353 bp 
stretch, may be important for the transcriptional regulation of MYOC over basal transcription 
level. Usually, intronic enhancers have lengths of a few hundred bp, are extremely conserved 
and have the potential to elevate gene expression considerably over basal level. Examples of 
such intronic enhancers are the spinal cord-specific enhancer element of PAX6 (Xu and 
Saunders, 1998) and the oligodendrocyte-specific enhancer of the myelin gene Opalin (Aruga 
et al., 2007). This raises the possibility that the nc intronic regions DCRi2b5´and DCRi2c, 
rather than being enhancers, may serve as template(s) for or produce a so called long ncRNA. 
Usually, ncRNAs are coded by moderately conserved, larger than 200 bp, nc regions of a 
gene. They may be coded by the sense, antisense (as), or by both strands of the DNA. They 
can overlap with exons, be interspersed between genes or reside within introns (reviewed by 
Mercer et al., 2009). They serve various gene regulatory functions e.g. during chromatin 
remodeling, as exemplified by the long as ncRNA HOTAIR, derived from the human 
homeobox HOXC locus, and which recruits the chromatin remodeling complex PRC2 to the 
HOXD locus (Rinn et al., 2007). During transcription, long ncRNAs can modulate the activity 
of RNA polymerase II or recruit RNA binding regulatory proteins into the transcriptional 
program (reviewed by Mercer et al., 2009). Post-transcriptional and translational regulation 
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by long ncRNAs is exemplified by the intronic long ncRNA of the homeobox gene Zeb2, that 
during epithelial-mesenchymal transition masks a splice site on the pre-mRNA, leading to 
retention of an intronic internal IRES with subsequent efficient translation and expression of 
Zeb2 (Beltran et al., 2008). Annealing of long ncRNAs can result in their processing into 
small interfering (si)RNAs, which then can silence or regulate gene expression (reviewed by 
Amaral and Mattick, 2007). An example for siRNA induced silencing is X-chromosome 
inactivation by siRNAs produced from a duplex of the long ncRNA Xist (Ogawa et al., 2007). 
Transcribed long ncRNAs have been found within genes of many transcription factors that are 
important for eye development and function. During development, so called natural as 
transcripts (NATs) are transcribed from 5´-UTR, intronic or 3´-UTR regions of genes like 
Pax6, Six3, Otx2, Crx, Vax2, Six6 and Rax. These NATs co-express with, as well as co-
localize with the gene they are transcribed from. Since a corresponding NAT expression 
pattern has been observed in human, it suggests that regulation of important eye development 
genes by NATs is important in the pathogenesis of developmental eye diseases (Alfano et al., 
2005).  
In addition to being processed to siRNAs, long ncRNAs may be processed to micro 
(mi)RNAs, ~ 22 nucleotide ss RNA molecules that bind to target sequences by imperfect base 
pairing. One miRNA can regulate hundreds of targets, usually in a negative way, by binding 
of the 3´-UTR of a gene, thus directing mRNA degradation or disturbing the translation 
process. As other ncRNAs, miRNAs can have a wide variety of other regulatory functions 
(reviewed by Amaral and Mattick, 2008). In the eye, there is a repertoire of tissue- and cell-
specific miRNAs, suggesting that they may be important regulators of gene expression during 
eye morphogenesis and differentiation (Ryan et al., 2006). 
 
5.1.5.2. Possible role of DCRi2b5´and DCRi2c during pre-mRNA processing 
Rather than serving as a template for, or being processed into ncRNA, NAT, si or miRNAs, 
DCRi2b5´ and DCRi2c could be important for pre-mRNA processing. Since transcription and 
pre-mRNA processing, as well as termination of transcriptional elongation, are both 
physically and in time integrated processes, the efficiency of pre-mRNA processing affects 
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the efficiency of transcription (Pandit et al., 2008). A large number of pre-mRNA processing 
factors are in contact with the RNA polymerase II complex during elongation in eukaryotic 
cells (Das et al., 2007) and many of these factors contact the DNA (Listerman et al., 2006; 
Brès et al., 2004). Such accessory factors can regulate splicing of introns, mRNA surveillance 
and mRNA export (Moore et al., 2006). DCRi2b5´ and DCRi2c may contain recognition 
motifs that are important for some accessory factors critical in mRNA processing. Another 
theory is that these regions encompass motifs that are recognized by accessory factors that aid 
in resolving transcription bubbles (Li and Manley, 2005), a process that is critical for efficient 
transcriptional elongation (Pandit et al., 2008), or that are involved in chromatin remodeling.         
 
5.1.5.3. Possible role of H1 and H2 
In addition to the possibility that H1 and H2 could act as enhancer elements that bind 
accessory factors that aid in transcription, elongation and/or internal pre-mRNA processing, 
these 3´-UTR elements could be important in the termination of MYOC transcription. It is 
known that the immediate 3´-UTR of MYOC contains three polyadenylation signals, of which 
two are used (Nguyen at al., 1998). Classically, cleavage of transcript occurs 10 – 30 bp 
downstream of a polyadenylation signal, from where the polyadenylation polymerase 
synthesizes an 80 – 250 bp long poly(A)-tail (Nelson and Cox, 2001). Termination of 
transcription by RNA polymerase II is coupled to 3´-end and pre-mRNA processing, and is 
not determined by any conserved site in the 3´-UTR of a gene. Thus, termination can occur a 
few bp to several kb downstream of the polyadenylation cleavage site (reviewed by Richard 
and Manley, 2009). This is shown e.g. for the globin genes ß and ε, where transcription 
continues far downstream of the poly(A) cleavage site, and where cleavage at the poly(A) site 
is then induced by termination and cleavage at more downstream sites of transcription 
termination (Dye and Proudfoot, 2001). It is possible that H1 and H2 code for sites that are 
recognized by factors that facilitate termination of MYOC transcription by RNA polymerase II 
and subsequent cleavage at one of its poly(A) sites. Chromatin remodelling proteins have 
been shown to associate to genomic regions downstream of the mRNA coding region 
(Venkataraman et al., 2005), and it is generally thought that chromatin remodelling factors are 
crucial for effective termination and subsequent cleavage of transcript at the poly(A) site 
(reviewed by Richard and Manley, 2009). An explanation for the inducing effect on 
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transcription by H1 and H2 can be that these regions bind important chromatin remodelling 
factors, which in turn could facilitate the binding of other factors that assist termination and 
subsequent cleavage of the MYOC transcript. 
 
5.1.6. Envisions 
Even though an elevated amount of myocilin within the TM  has been shown to be related to 
POAG in some patients (Lütjen-Drecoll et al., 1998; Konz et al., 2009), an overexpression of 
myocilin in the mouse TM do not result in a phenotype (Gould et al., 2004; Zillig et al., 
2005). In contrast to most mice strains, dogs, cats (Brooks, 1990) and horses (Wilcock et al., 
1991) do develop secondary glaucoma, and it has been reported that myocilin levels are 
elevated in the TM (Samuelson et al., 2007), as well as in the AH (MacKay et al., 2008), of 
glaucomatous dog eyes. Inter-species comparison of the myocilin genes for dog and horse 
reveals that these genes are much more conserved to human MYOC than is mouse Myoc. 
Beyond the sequences that we tested, there are still more peaks of conservation within the 
introns and the 3´-UTR when comparing human MYOC against dog, cat and horse myocilin 
genes. In the case of intronic conservation, there is eminent conservation within exon 2 that is 
not found when comparing human MYOC with mouse Myoc (Fig. 5.1A: grey shaded box). 
The same is true when looking at the 3´-UTR of MYOC. The area of conservation between 
human, dog, and horse myocilin genes reaches as wide as 28 kb beyond the transcribed region 
of MYOC, while conservation between human MYOC and mouse Myoc reach only 13 kb 
beyond the transcribed region (Fig. 5.1B). 
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Figure 5.1: Inter-species alignment and comparison of sequence homology of dog, horse and mouse myocilin 
genes with human MYOC by using the VISTA Browser 2.0 bioinformatic software. A) Comparison of intronic 
nc sequences reveals that dog and horse myocilin genes show many more regions of > 70 % homology to human 
MYOC, as does mouse Myoc. Vertical arrows depict our analyzed regions. The grey shaded box highlights 
conserved regions within intron 2 that are not conserved when comparing human and mouse genes. B) 
Comparison of 3´-UTR sequences reveals that dog and horse myocilin genes show a much wider region (that 
reaches as far as 28 kb beyond the transcribed region) of homology to human MYOC (grey shaded box), as does 
mouse Myoc (that reaches only 13 kb beyond the transcribed region). Vertical arrows depict our analyzed 
regions. Exons and proximal UTRs are shown in blue and turquoise, respectively. Conserved nc sequences that 
show a consensus homology of at least 70 % for a length of at least 100 bp are shown in pink. 
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Since dog, cat and horse suffer from glaucoma, and since in fact the expression of myocilin is 
elevated in the eyes of glaucomatous dogs (Samuelson et al., 2007; MacKay et al., 2008), the 
conservation of wide nc regions between MYOC and the myocilin genes for these species may 
reflect an important role of the transcriptional regulation of myocilin in causing glaucoma in 
human and in these species. It would be interesting to test the illustrated regions (grey boxes) 
that are conserved between human, dog, cat and horse for their capacity to regulate 
transcription in cultured human TM cells.  
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5.2. Search for and analysis of an artificial enhancer element for TM directed 
overexpression of protein 
 
5.2.1. Search and testing of a candidate element in vitro 
 
So far, there are no glaucoma animal models that show targeted overexpression of protein to 
the TM, which would be of value in the achievement to better understand the molecular 
mechanisms that build up an AH outflow resistance too high for the physiology of the eye. 
Increasing microarray data derived from TM offer a valuable source in the search for potential 
molecular factors involved in POAG pathology, and may serve as a guideline on which 
further molecular biological studies can be designed.  
 
We wanted to approach this topic by using the MYOC basal promoter (Kirstein et al., 2000) to 
target expression of protein to the TM. Since it is known that myocilin is one of the most 
highly expressed protein within TM (Tomarev et al., 2003), whose expression can still be 
markedly augmented upon GC treatment (Rozsa et al., 2006), and since myocilin is expressed 
at much lower levels in some tissues outside the, we found the MYOC basal promoter to be a 
good candidate for TM-directed expression of protein. Since our characterization of MYOC 
indicates that the basal proximal promoter alone is not sufficient to drive endogenous 
myocilin expression (Figs. 4.3; 4.6), we wanted to find an enhancer element that would 
“boost” the activity of the MYOC basal promoter to drive gene expression far beyond basal 
level in the TM. Since it is known that repetitive binding sites for transcription factors are 
more effective enhancers of transcription than a single site (Schatt et al., 1990), we had earlier 
cloned repetitive binding motifs for transcription factors that are known to be pivotal in 
anterior eye development (Table 4.3) (reviewed by Cvekl and Tamm; Matt et al., 2005), in 
front of the human MYOC basal promoter. The fact that one of our tested cloned artificial 
enhancer elements, a 150 bp sequence made up of repetitive binding motifs for the 
transcription factors RAR, PITX and FOX, in combination with the human MYOC basal 
promoter, did elevate reporter gene expression up to 11.8 fold (statistically highly significant) 
over the level than did the MYOC basal promoter alone (Fig. 4.8) in human TM cells in 
culture, encouraged us to analyze this enhancer further, as a candidate element for directing 
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expression of protein to the TM in vivo. Our data, which confirmed that our artificial enhancer 
is not a ubiqutous enhancer (Fig. 4.9) prompted us to clone a ß-galactosidase overexpression 
construct driven by this element and the MYOC basal promoter (Fig. 4.10). The ability of our 
element to drive visible reporter gene expression in TM cells in vitro (Fig. 4.11) finally 
encouraged us to generate a mouse line that would enable the analysis of the capacity of our 
enhancer to drive and target visible reporter protein expression to the TM in vivo.  
 
 
5.2.2. Creation of a mouse model for the analysis of our candidate element in vivo 
 
Since the context of transcriptional regulation in vitro may differ significantly from that in 
vivo, a mouse model would confer the most comprehensive information about the usefulness 
of RAREß/PITX3/FOX as a TM-specific enhancer element. For this purpose, we generated a 
transgenic mouse line that had integrated a transgene, which would drive ß-galactosidase 
expression under the control of RAREß/PITX3/FOX and the human MYOC basal promoter, 
into its genome. Screening for founder animals revealed that three animals had integrated the 
transgene into their genomes (Fig. 4.12). Subsequent genotyping of progeny, affirmed that 
only two of these founder animals transferred the transgene to the next generation in a 
Mendelian fashion.  
 
Since DNA synthesis and replication in one-cell stage fertilized mouse oocytes begin already 
12 – 14 h after fertilization, it may happen that the microinjected transgene integrates into an 
already replicated chromosome. If this happens, the developing embryo is a mosaic, where 
not all cells have integrated the microinjected transgene. In these cases, the transfer of 
transgene to the next generation is ineffective, i.e. the frequency of transgene transmission is 
25 % or less (Pinkert, 2002). This may explain the fact that only two of our three founder 
animals had TG offspring. Since TG embryos of one of our established lines frequently did 
not get born, and when, was always a female that showed a physically retarded phenpotype 
concerning size, incidence of hair coat and fertility (Fig. 4.13), suggests that the transgene had 
integrated unfavorable into the genome of this line, affecting transcriptional regulation of 
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other genes (position effect). Due to the rarity of born TG animals of this line, we had 
difficulties in stabilizing this breed, with the consequence of limited experimental material.  
 
 
5.2.3. Analaysis of our candidate element in vivo 
 
We started our analysis of ß-galactosidase expression by LacZ-staining of adult eye, heart and 
sciatic nerve, since myocilin is known to be expressed in these tissues in adult mouse and 
human (Karali et al., 2000; Knaupp et al., 2004; Ohlmann et al., 2003; Ortego et al., 1997; 
Swiderski et al., 1999). Since we did not detect any staining of these organs prepared from TG 
mice (Fig. 4.14), and since it is known that RAR, PITX and FOX are crucial regulators of 
embryonic anterior eye development (reviewed by Cvekl and Tamm; Matt et al., 2005), we 
wanted to analyze ß-galactosidase expression in TG mouse embryos. LacZ-staining of whole 
E12.5 embryos revealed that there was no staining within TG eyes above background level 
(Fig. 4.15). Since we used standardized protocols for fixation and staining, and since the 
staining procedure was successful in Pax6
LacZ/+
 embryos (St. Onge et al., 1997), the lack of 
staining in the eyes of our TG ß-galactosidase overexpression mice could not be due to 
shortcomings during these procedures.  
 
The fact that our candidate element had proven to be active in human TM cells in culture 
(Figs. 4.8; 4.11), whereas we could not observe any ß-galactosidase expression in the eyes of 
adult or embryonic mice (Figs. 4.14A; 4.15), may be explained by the fact that the molecular 
context involved in gene regulation in the mouse TM may differ from that within human TM. 
In addition, since the gene regulatory networks in vivo are much more complex than those in 
vitro, it is not a rule that a promoter with capacity to drive protein expression in cultured cells 
will be active also in a living system. Liton et al. (2006) showed that Ch3L1 (chitinase 3-like), 
a gene coding for a glycoprotein member of the glycosyl hydrolase 18 family, involved in e.g. 
inflammation  and tissue remodeling (Bernardi et al., 2003; Vind et al., 2003), is one of the 
few genes that is equally expressed in cultured human TM cells and in TM tissue. In addition, 
the same authors showed that Ch3L1 is differentially expressed in TM cells, when compared 
to SC cells. However, their approach to express visible ß-galactosidase expression in cultured 
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human TM cells and anterior eye segments under the control of the Ch3L1 promoter, resulted 
in ß-galctosidase expression in only a subset of the TM cells, suggesting that the TM may be 
more complex than earlier thought, being composed of two different cell types (Liton et al., 
2005). If  the TM really is composed of two different cell types with differing characteristics, 
and if this is true also for the mouse, it could make it more difficult to observe unambigous 
expression of reporter in this tissue. 
 
In addition to the explanation that the living TM is, concerning gene regulation, much more 
complex than cultured cells, the lack of ß-galactosidase expression in mouse eyes in vivo 
could be due to the relative weak enhancer character of RAREß/PITX3/FOX. Even though it 
has been shown that an enhancer composed of repetitive RAR motifs alone is able to drive ß-
galactosidase expression in the eyes of developing mouse embryos (Rossant et al., 1991; 
Balkan et al., 1992), it can not be presumed that our combination of successive binding motifs 
for three different transcription factors also should act similarly in a living system. The 
complexity of our element could lead to unexpected interactions between the transcription 
factors binding to the element, resulting in a totally different effect on gene regulation than 
seen in vitro. In fact, we observed that RAREß/PITX3/FOX induced ß-galactosidase 
expression in only a portion of the cultured human TM cells, when compared to positive 
control cells that had been transfected with a plasmid, where LacZ was driven by the 
cytomegalovirus (CMV) promoter, a known strong promoter used to drive ubiqutous 
overexpression of protein. Even though we showed that RAREß/PITX3/FOX could elevate 
reporter gene expression in human TM cell cultures > 11-fold over the level of the MYOC 
basal promoter (Fig. 4.8), our comparison of its activity to that of the CMV promoter in Dual-
Luciferase
®
 Reporter assays showed that the CMV promoter was hundreds of thousands of 
folds more capable in driving reporter gene activity than our candidate element (data not 
shown). Thus, we had interpreted the small amount of ß-galctosidase expressing cultured cells 
as a consequence of the relative weak promoter capacity of RAREß/PITX3/FOX, when 
compared with the CMV promoter. Or, we had explained the few blue cells as being a 
consequence of low transfection efficiency. 
 
Even though the 377 bp human MYOC basal promoter is sufficient in driving reporter gene 
expression in primary human TM, mouse TM and mouse astrocyte cultures (Kirstein et al., 
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2000), as well as in cultured immortalized human TM cultures as seen in our experiments 
(Figs. 4.3; 4.5; 4.6; 4.8), it may not be capable of driving gene expression in the mouse, since 
there may be differences between the molecular network active in human vs. mouse TM. Or, 
the MYOC basal promoter may in general be too weak to drive expression in vivo. This theory 
is supported by our MYOC promoter studies that showed that even in culture, there are nc 
elements within MYOC that are required for expression of reporter over basal promoter level 
(Figs. 4.3; 4.6), suggesting that a larger endogenous region of MYOC may be needed to drive 
expression of protein in vivo in TM. In fact, Kim et al. (2001) showed that the whole 
endogenous Myoc locus was able to drive visible myocilin mRNA expression in adult mouse 
TM.  
 
A third explanation to the lack of ß-galactosidase expression within eyes in vivo, may be 
wrong time point of investigation. In the case of the MYOC basal promoter, there is no doubt 
that our decision to analyze adult eyes would not be appropriate, since myocilin mRNA and 
protein can be detected within the mouse eye already at P9 (whole eye) and P12 – 14 (TM), 
respectively (Knaupp et al., 2004). The decision to analyze ß-galactosidase expression in 
mouse embryos was based on the fact that RAR, PITX and FOX are known to be pivotal 
regulators of anterior eye development, concretely this can be observed in the range of ASDs, 
which rely on mutations in PITX and FOX (reviewed by Cvekl and Tamm, 2004; Matt et al., 
2005). Matt et al. (2005) confirmed that in the developing mouse eye the target of action of 
RA is the NC crest-derived anterior eye mesenchyme, from which also the CB stroma, TM 
and SC are derived (reviewed by Cvekl and Tamm, 2004). Based on these facts, there is no 
doubt that these transcription factors are present and active at our embryonic stages of 
analysis. As mentioned above, the complex design of our element may lead to unexpected 
interactions between the binding transcription factors, resulting in a totally different effect on 
gene regulation in vivo than observed in vitro. Moreover, the facts that the binding 
transcription factors are predominantly active at embryonic stages, exemplified by the fact 
that overall RARE-driven ß-galactosidase expression decreases in later embryonic stages 
(Rossant et al., 1991), and that the Myoc basal promoter is not active in the anterior mouse 
eye until P10 (Knaupp et al., 2004), may rise the possibility that the enhancer and promoter 
can not co-operate in the anterior eye at the same time point.  
 
Discussion  143 
 
5.2.3.1. Unexpected expression of ß-galactosidase outside the eye 
 
Unexpectedly, we observed ß-galactosidase expression within the ependymal lining of the 
lateral ventricle (Fig. 4.16) and within epithelial cells of intestinal glands (Fig. 4.17) in TG 
embryos of our instabile transgenic line. Due to limited material from this line, we only had 
the opportunity to analyze two TG embryos. Both TG embryos showed staining within the 
intestinal glands, whereas the ependymal staining was observed only in one of the TG 
animals. The positive staining within the ependyma could be observed in the transverse cut 
embryo, but not in the other embryo that was cut sagittal. It can be, that staining within the 
ependymal lining of the lateral ventricles can be better detected in transverse sections, 
whereas the plane of a sagittal section could affect detection of ependymal staining. Another 
theory is, as already discussed, that our used enhancer may not be strong enough to invariably 
drive expression of LacZ to an extent that turns cells blue. In fact, our observed staining was 
rather turquise that deep blue (Fig. 4.16), which was true also for the expression colour in our 
transfected culltured TM cells (Fig. 4.11). The probably too weak character of 
RAREß/PITX3/FOX to drive uniform reporter gene expression in vivo, may thus explain why 
we did not observe any in vivo expression within the complex eye. 
 
The ependymal ß-galactosiadse expression correlates with the fact that components of the RA 
signalling pathway, RAR-ß and the RA acid synthesis facilitating cellular retinol binding 
protein type I, are both expressed in developing neural structures in mouse, including the 
neuroepithelium of the neural tube, as well as in the from neuroepithelium originating 
ependymal lining and CP, suggesting that RA-signalling is important in the development of 
these structures (Ruberte et al., 1993). In fact, improper concentrations of RA has been shown 
to result in congenital hydrocephalus in human infants (Lammer and Armstrong, 1992) and in 
calves (Okamoto et al., 1962), reflecting the role of RA in the developing ependymal lining 
and CP, the sites that secrete CSF.      
 
PITX and FOX proteins are likewise involved in the regulation of brain CNS development. 
Pitx2 is expressed in the developing mouse neuroepithelium, where it controls differentiation 
of neural progenitors into differentiated neuronal phenotypes (Martin et al., 2002). 
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Homozygous mutations in PITX3 may affect CNS development in humans (Bidinost et al., 
2006). It is also interesting to note that mutations in Mf1, the mouse homologue to FOXC1, 
leads to congenital lethal hydrocephalus in mice, suggesting that this gene may be involved in 
the regulation of CSF secretion or filtration (Hong et al., 1999). In fact, human patients that 
suffer from Axenfeld-Rieger syndrome, a subtype of ASD that relies on mutations or 
deletions in the ocular mesenchyme-derived transcription factors FOXC1 and PITX2 
(reviewed by Cvekl and Tamm, 2004), also may show pehotypes that affect the CNS, 
including hydrocephalus (Maclean et al., 2005; Moog, 1998). All these facts indicate that 
RAR, PITX and FOX isoforms may be active in the developing ependyma of the lateral 
ventricle, explaining the visible ependymal ß-galactosidase expression observed in our 
embryonic TG mice (Fig. 4.16).   
 
ß-galctosidase expression within the epithelial cells of intestinal gland (Fig. 4.17) in TG mice 
of the same instabile ß-galactosidase overexpression line, correlates with the fact that RA-
synthesizing enzymes are present differentially in time and space within the outer 
mesenchyme, lamina propria and epithelial layers of the developing mouse intestine 
(Niederreither et al., 2001), suggesting that regualted RA expression in these tissues is 
important for differentiation of the different layers of the intestinal mucosa. Due to limited 
material of TG mice of this line, we could not closer analyze in which parts of the mucosa ß-
galactosidase was present. Since the epithelial expression of ß-galactosidase in our 
experiments is only based on visual interpretion of our sections, the observed blue colour may 
likewise be expression within the whole mucosal layer, including the outer mesenchyme, 
lamina propria and epithelial layer. 
 
Differential expression of Pitx2 within the mesenchyme of the embryonic mouse small 
intestine affects protein expression in a way that results in asymmetries of the ECM and cell-
cell adhesion throughout the mesentery, resulting in correct looping of the intestine (Kurpios 
et al., 2008). Also forkhead transcription factors have been shown to be involved in the 
development of the intestine. FOXC1 cDNA has been derived from intestine (NCBI 
UniGene). Subfamilies of FOX-proteins usually show overlapping functions during 
embryogenesis, whereas they may have diverse specific functions in the adult (Cirillo and 
Barton, 2008). FOXC2, which belongs to the same subclass as the eye mesenchyme-derived 
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FOXC1, is expressed in the intestinal mesenchyme adjacent to the developing epithelium. 
From here, it regulates morphological changes of the becoming overlying intestinal 
epithelium, including the definition of the zone occupied by crypts of Lieberkühn and the 
lengths of the villi (Kaestner et al., 1997). The above facts that describe expression of RAR, 
PITX and FOX isoforms within the embryonic intestine thus may explain the visible intestinal 
ß-galactosidase expression observed in our embryonic TG mice (Fig. 4.17).   
  
If the observed intestinal ß-galctosidase expression is due to the activity of the MYOC basal 
promoter, the data would correlate with the fact that Fingert et al. (1998) showed that MYOC 
mRNA is found within intestine at comparable amounts as within skeletal muscle and heart. 
Since also other genes that code for olfactomedin-domain containing proteins have been 
shown to be expressed within the human intestine, it suggests that olfactomedin-related 
glycoproteins in general may have a role in regulating the extracellular environment of 
mucus-lined tissue (Kulkami et al., 2000). Interesting is also that the intestinal mucosal cells, 
together with the protruding tubular crypts of Lieberkühn, akin to the CB and TM, are 
involved in secretion and absorption/drainage, respectively. If myocilin is expressed within 
the intestine, the attempt to clarify its function within this organ will be a topic of future 
research. 
 
The answer to the question why ß-galactosidase expression was observed only in one of our 
two transgenic lines, may be the fact that this line has more copies of the transgene inserted 
into its genome, a possibility that we never tested. Another explanation may be a positional 
effect, where our transgene may have integrated into a position in the genome that favors 
expression, e.g. into a site that is affected by a nearby promoter or enhancers. Since this line 
was the one that had proven to be instabile, we already discussed the possibility of a 
positional effect in this line (see section 5.2.2 for discussion). 
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5.3. Analysis of myocilin expression in mammalian brain 
 
5.3.1. Expression of myocilin within the ependymal lining of the CP and the lateral 
ventricle 
 
The fact that the MYOC basal promoter, in combination with our constructed artificial 
enhancer element RAREß/PITX3/FOX, directed visible ß-galactosidase expression to the 
ependymal lining of the lateral ventricle in the embryonic mouse brain (Fig. 4.16A), prompted 
us to investigate if myocilin is endogenously expressed at protein level in this tissue in 
mammals. Swiderski et al. (1999) already showed that myocilin mRNA is expressed in 
widespread regions of the adult mouse brain, including the ependymal lining of the third and 
fourth ventricles and the CP, and within regions that are involved in vision, hearing, olfaction, 
regulation of visceral activity, salt-water balance and emotional behaviour. 
 
Our immunohistochemical data for the first time showed that myocilin protein is 
endogenously expressed in the ependymal lining of the lateral ventricle (Fig. 4.19E) and the 
CP (Figs. 4.19A, B). Since the ventricles in mammals are connected, and since Swiderski et 
al. (1999) showed that myocilin mRNA is expressed in the ependymal lining of the third and 
fourth ventricles, suggests that myocilin is endogenously expressed within the ependymal 
lining of the whole inner ventricular system in mammals. 
 
 
5.3.2. Expression of myocilin within the CSF 
 
Together with the ependymal lining of the ventricles, the ependymal cells of the CP secrete 
about 450 - 600 ml CSF/day into the ventricles, making up the so called blood-CSF barrier. 
Normally, CSF is clear, containing tiny amounts of protein (15 – 45 mg/dl within the lumbar 
region and even lower levels within the ventricles, which corresponds to ca 1 % of the 
concentration in blood), glucose and lymphocytes (Bob and Bob, 2007). CSF offers 
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mechanical protection to, and regulates homeostasis of, the CNS (Bob and Bob, 2007). The 
fact that myocilin is expressed in CSF secreting epithelial ependymal cells of the CP and the 
lining of the ventricular system in mammals (Fig. 4.19), prompted us to analyze if myocilin is 
also secreted into the CSF. As the volume of CSF that can be obtained from rodents is limited 
in comparison to volumes that can be obtained from human patients during lumbar puncture, 
and since we had access to CSF samples collected from patients during this procedure (PD 
Dr. med. Andreas Steinbrecher, Department of Neurology, University of Regensburg), we had 
earlier analyzed the expression of myocilin within human CSF by Western blot. The fact that 
all 18 analyzed human CSF samples expressed myocilin (Fig. 4.21) confirmed our suggestion 
that myocilin is secreted from ependymal cells into the CSF in mammals.  
 
 
5.4. Pathology and architecture of the ventricular ependyma 
 
Improper functioning of the CP due to atrophy of the ependyma, thickening of the basement 
membrane and decrease in enzymatic activity, often seen during ageing, reduce CSF secretion 
rate up to 50 %, affecting brain activity (reviewed by Serit et al., 2003). The process may 
impair the blood-brain barrier and result in pathological states like neurological and infectious 
disorders, as well as tumours. Multiple sclerosis, a neuroimmunological disease where the 
immune system attacks the myelin sheath of the CNS, is caused by entry of lymphocytes into 
the normally, due to the blood-CSF barrier, immune privileged CSF/CNS. Infections are 
triggered by viruses or bacteria that invade the CNS via the fenestrated vessels of the CP, 
where they activate cytokines, resulting in damage of the ependyma. Concerning prion 
diseases, it has been shown that the scrapie agent can escape the blood-CSF barrier (Banks et 
al., 2004). In Alzheimer´s disease neurotoxic plaques of the fibrous insoluble amyloid-ß, as 
well as tangles of neurofibrils and so called Bondi rings, accumulate within the CP ependyma 
(reviewed by Wolburg and Paulus, 2010). One theory to the accumulation of amyloid-ß in the 
brain is that the CP produces and secretes substances into the CSF that bind and sequester 
amyloid-ß (Choi et al., 2007). Ischemia in neighbouring tissue may impair blood flow to the 
CP, resulting in disruption of the blood-CSF barrier and subsequent neuronal death (Ennis et 
al., 2006). Following ischemia, there is an increase in the expression and release of 
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vasopressin from the CP, which may affect vascular resistance and induce edema formation 
(reviewed by Kozniewska and Romaniuk, 2008). 
 
The ependymal lining of the ventricles is continous with the epithelial layer of the CP and it 
is, similarly to the ependymal lining of the central canal of the spinal cord, of 
neuroectodermal origin. Since the ependymal epithelial cells are non-neuronal cells of the 
brain, they are classified as a type of macroglial cells. The CP is the primary source of CSF 
secretion. It consists of ependymal epithelial cells, fenestrated arterial blood vessels and an 
ECM-rich stroma. In the CP, the CSF is produced by the ependymal cells from blood that 
leaks through the fenestrated blood vessels, and which then is transported to the ventricular 
space by a combination of passive diffusion and active transport (reviewed by Wolburg und 
Paulus, 2010). The epithelial ependymal cells are ciliated. It has generally been assumed that 
these motile cilia circulate CSF through the ventricular spaces, though more up to date studies 
show that the ependymal cilia can act as sensitive chemosensors to regulate CSF production 
(Narita et al., 2009). The ependymal cilia are of the motile primary type. Other cilia of the 
primary type are the ciliated photoreceptors of the retina and the cilia of principal cells of the 
kidney nephron. Defects in primary cilia in the ependyma, the photoreceptor and nephron 
(called primary ciliary dyskinesia), cause diseases like hydrocephalus (Ibanez-Tallon et al., 
2004), retinitis pigmentosa and cystic kidney (reviewed by Eley et al., 2005), respectively.  
 
 
5.4.1. Possible ependymal role of myocilin 
 
Our finding that myocilin is expressed within ciliated ependymal cells of the CP and the 
ventricular lining (Fig. 4.19), correlates with the fact that myocilin is expressed in the 
connecting cilia of the axoneme, which connects the outer and inner segments of 
photoreceptors (Kubota et al., 1997). By assisting in molecular turnover and by transporting 
molecules between the diverse segments, the microtubular connecting cilium in the 
photoreceptor axoneme participates in morhogenesis and maintenance of the diverse segments 
(reviewed by Insinna and Besharse, 2008). Topics of future research are to find out, where 
exact within the ependymal cells myocilin is expressed, and to then analyze, if myocilin also 
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in these cells has a role in the maintenence of morphology and proper function of the 
ependymal cells. Such an analysis would be of great value in deciphering the molecular 
mechanisms that help maintain the normal function of ependymal cells. Since many 
neurological and infectious diseases, as well as CP tumours, are generally thought to rely on 
dysfunction of the CP epedyma, and since ischemia may result in dysfunction of the barrier 
capacity of the CP (reviewed by Wolburg and Paulus, 2010), a charachterization of the 
molecular mechanisms that maintain normal function of the ependyma would be of clinical 
relevance. 
 
 
5.4.2. Possible correlation between amount of and extent of post-translational 
modification of myocilin and disease 
 
CSF collection by lumbar puncture is routinely used to detect different forms of 
inflammation, like meningitis, or disease, like multiple sclerosis, of the brain and spinal cord. 
An interesting observation was that the overall myocilin expression between CSF samples 
varied significantly (Fig. 4.21). This may reflect differing pathological conditions of the 
patients at the time of CSF collection, and suggests that myocilin may be present in different 
amounts depending on disease or a pathological state thereof. Thus, the amount of myocilin 
within CSF may be relevant in the pathology of a certain disease. To clear this, it would be 
informative to get data about the disease, and pathological state thereof, that respective patient 
suffered from at the time point of lumbar puncture.     
 
In most samples myocilin was detected as the typical 55 - 57 kD double band (Nguyen et al., 
1998; Clark et al., 2001), of which the two bands are thought to be a result of post-
translational modifications like glycosylation (Nguyen at al., 1998; Fingert et al., 1998). 
Normally, the two bands of the double band appear at same intensity. Our results showed 
different expression of the two myocilin isoforms, whereby the heavier 57 kD isoform was 
more abundant than the light 55 kD form. Appropriate glycosylation of a protein is important 
for correct folding, quality control, stability, enzymatic activity and molecular interactions. It 
is a general fact that aberrant glycosylation of a protein is involved in disease. Since myocilin 
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contain many putative glycosylation sites (Nguyen et al., 1988), and since it is known that the 
glycosylation status of a protein regulates its function, as exemplified for integrins and 
cadherins (reviewed by Zhao et al., 2008), the higher expression of the heavier 57 kD 
myocilin isoforms relative to the lighter 55 kD form in CSF samples from patients, may 
indicate that a higher degree of glycosylation of myocilin could be responsible for the 
respective pathologies.  
 
 
5.4.3. A general function for myocilin in regulating drainage of fluid? 
 
After circulation of CSF through the ventricles, most of it is drained through the arachnoid 
granulations into the venous system. The drainage of CSF through this so called CSF-blood 
barrier clears the CNS from waste products. Minor CSF volumes are thought to escape the 
ventricles through lymphatic capillaries, as well as the ependymal lining. The rate of CSF 
secretion into, and drainage out of, the brain ventricles thus regulates the intraventricular CSF 
volume, which in turn regulates intracranial pressure and blood flow perfusion. As already 
discussed, failure of the CSF secretory-drainage system may lead to hydrocephalus, or 
neurological and infectious diseases, as well as tumours of the CNS. Failure of the secretory-
drainage system can also be induced by ischemia (reviewed by Wolburg and Paulus, 2010; 
reviewed by Kapoor et al., 2008). 
 
In the same way as the balance between secretion and drainage of CSF in the CNS is 
important for the proper functioning of the CNS, the balance and proper interplay between 
secretion of AH by the CB and subsequent drainage through the TM is crucial in maintaining 
a physiological IOP (reviewed by Coca-Prados and Escribano, 2007). The secretion-drainage 
system between ependyma and the arachnoid granulations closely resembles that of the CB 
and TM in the following aspects. 1) Both secreting tissues, the ependyma and the CB, are of 
neuroectodermal origin. 2) Both the ependyma and the CB express myocilin. 3) Myocilin is 
found in both secretes, the AH and the CSF. 4) In both systems a balance between inward 
secretion and outward drainage are important for respective physiological intraocular and 
intracranial pressures. 5) Defects in both systems are associated with disease. 
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 The facts that both the ependyma and CB express myocilin suggests that myocilin may be 
involved in the maintenance of structure and/or proper function of these neuroectodermal 
tissues, or in the secretion process itself. Concerning CNS this would link myocilin to 
neurological and infectious diseases, CNS tumours and hydrocephalus. Future studies are 
needed to clarify if myocilin is involved in the secretion process, or in the maintenance and 
function of both CB and ependyma. Very interesting is that both the ependyma and the CB 
secrete myocilin. Even though the function of myocilin within the AH is unknown, there are 
data that support that bacterially expressed recombinant myocilin accumulate in the TM, 
thereby increasing outflow resistance and IOP, when perfused through human anterior eye 
segments. Perfusion with high concentrations of various control proteins corroborated that the 
observed effect on outflow resistance and IOP is not due to the amount of overall protein, but 
rather due to a specific property of myocilin (Fautsch et al., 2000). These data were specified 
by the same experiment using recombinant eukaryotically expressed myocilin, which 
confirmed that an increase in outflow resistance and IOP occurs only when myocilin is first 
incubated with AH. Interaction studies showed that myocilin formed a complex with another 
unknown protein in the AH. At maximum outflow resistance, myocilin located to the JCT 
(Fautsch et al., 2006), the region within TM that is responsible for the generation of most of 
the AH resistance (reviewed by Johnson, 2006). The different data between these studies 
indicate that post-translational modifications, which are possible only in eukaryotic systems, 
may alter the ability of myocilin to interact with other proteins within the AH and the TM, 
thus affecting changes in hydrodynamics. In fact, it was already shown that AH is able to 
obstruct filter pores with diameters corresponding to the smallest flow dimensions in the JCT 
(Johnson et al., 1986). Later, it was shown that AH myocilin is able to block filters with pores 
of the same diameter. Most AH myocilin had a molecular weight of ~ 66 kD, suggesting post-
translational modifications, most probably glycosylation (Russell et al., 2001).  
 
Interestingly, our experiments showed that within human CSF the higher MW 57 kD myocilin 
isoform predominated over the 55 kD form (Fig. 4.21), suggesting that there may be more of 
glycosylated than non-glycosylated forms of myocilin within human CSF. This resembles the 
data from Russell et al. (2001), where AH myocilin was mostly found in its glycosylated 
form, and may indicate that a possibly glycosylated form of myocilin, as within the TM, may 
affect drainage hydrodynamics within the arachnoid granulations. The fact that the amount of 
myocilin varied between CSF samples from patients in our experiment (Fig. 3.21), may 
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indicate that the amount of myocilin within the CSF affected CSF drainage and pathology in 
these patients. Thus, in addition to being involved in the elevation of AH outflow resistance 
and IOP in the eye, which leads to glaucoma, myocilin may have a role in the regulation of 
CSF drainage out of the CNS. All these data suggest that myocilin may be involved in 
diseases caused by an inappropriate function of CSF secretion and drainage structures, as seen 
in neurological or infectious diseases, CNS tumours and hydrocephalus (reviewed by Kapoor 
et al., 2008), or after ischemia (Ennis et al., 2006).   
 
 
5.4.4. Expression of myocilin within nerve cells of the PVZ 
 
Adjacent to the ependymal layer is the SVZ of the PVZ, which separates the ependyma from 
the caudate nucleus that is involved in memory and learning. The SVZ is made up of a layer 
of mainly astrocytes, neuronal progenitor cells, as well as of a layer of myelinated fibers 
(reviewed by Curtis et al., 2007). During brain development, most of the neurons are 
generated from the SVZ and recent findings about populations of cells within the SVZ that 
can serve as adult neuronal stem cells (reviewed by Chojnacki et al., 2009), have given this 
tissue much clinical interest. In fact, during neurodegenerative diseases like Alzheimer´s or 
Parkinson´s disease there is a down-regulation of proliferative cells within the SVZ (reviewed 
by Curtis et al., 2007).  
 
The observation that myocilin was, in addition to the ependyma, also expressed within axons 
and perikarya of nerve cells of the PVZ of 6 week old rat brain (Fig. 3.20) correlates with data 
that show that myocilin is expressed in astrocytes of adult rat brain (Jurynec et al., 2003), in 
ONH astrocytes, retinal perikarya and axons in human (Karali et al., 2000), as well as within 
the oligodendrocyte myelin sheath of human and primate optic nerve axons (Ricard et al., 
2001). Myocilin expression within the peripheral nervous system has been observed in the 
Schwann cell myelin sheath of rat sciatic nerve (Ohlmann et al., 2003). The function of 
myocilin within nerve cells is unclear, though since the commence of expression within the 
myelin sheaths of optic nerve axons in human fetuses (Ricard et al., 2001), as well as of rat 
sciatic nerve (Ohlmann et al., 2003), correlate with respective time points of myelin sheath 
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formation, it is thought that myocilin may have a supporting role in the formation and/or 
maintenance of the myelin sheath of neurons. A supporting maintaining neuronal function of 
myocilin is supported by the fact that the expression of MYOC mRNA and protein decreased 
in glaucomatous human and monkey ONHs, when compared to controls (Ricard et al., 2001). 
In contrast to primates, elevation of IOP in rats resulted in an increase of ONH Myoc mRNA 
(Ahmed et al., 2001), suggesting that myocilin may be differentially regulated between 
primates and rodents. 
 
Injury to the CNS induces a response that activates astrocytes, resulting in a so called glial 
scar, a characteristic of neurological diseases (Eng et al., 2000). The activation of astrocytes 
induces expression of specific glycosylated ECM proteins that inhibit regeneration of the 
CNS, including axonal regeneration (Fitch and Silver, 1999: Bradbury et al., 2002). It has 
been documented that myocilin is upregulated in activated astrocytes of glial scars in vivo, 
whereby the glycosylated 66 kD form predominated (Jurynec et al., 2003). As a possible 
extracellular matricellular protein, myocilin may be secreted and bind to other molecules 
needed for regeneration/maintenance of the CNS, thereby inhibiting their function. In vitro, 
myocilin interacts physically with flotillin-1 (but not when mutated) (Joe et al., 2005), a lipid-
raft protein that is found within the same fraction of bovine CNS myelin sheath as the 
cytoskeletal proteins actin and tubulin, as well as the plasma membrane protein caveolin 
(Arvanitis et al., 2005). Also within the peripheral nervous system myocilin was expressed 
within regions of the myelin sheath that is enriched in proteins having structural and/or 
signalling roles (Ohlmann et al., 2003). Thus, myocilin might support neuronal function 
structurally and/or through signalling, thereby maintaining proper myelin sheath 
characteristics and/or interacations. Since astrocytes, the most common and largest glial cell 
of the CNS, akin to oligodendrocytes are supportive nerve cells, the increase of myocilin 
expression in glial scar may indicate a response to restore structure and function of the 
astrocyte. Thus, myocilin could have a general role in maintaining structure and function of 
glial cells. 
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4.4.5. Possible periventricular role of myocilin 
 
Since we did not label our brain sections, we can not exactly define the area of the PVZ where 
myocilin expression was present. If it is the adjacent SVZ, the expression of myocilin is an 
interesting fact, since this area is the origin of most neurons in development, and it maintains 
a pool of progenitor cells, which replace neurons in the olfactory bulb in adulthood. In 
neurological diseases, like Alzheimer´s, Huntington´s or Parkinson´s, the regulation of 
progenitor cell proliferation is disturbed (reviewed by Curtis et al., 2007). There has been 
debate about the identity of the SVZ progenitor cells, which may be of ependymal, astocytic 
or of neural stem cell origin (reviewed by Chojnacki et al., 2009). If future experiments show 
that myocilin is expressed within the SVZ, it would bring our ependymal myocilin expression 
data (Fig. 4.19) into a new light, regarding a possible role of myocilin in the differentiation of 
e.g. myelinating oligodendrocytes. If the myocilin expression turns out to reside within a 
more distal site of the PVZ, myocilin anyhow seems to have some neuronal supporting role in 
that it seems to generally be expressed within nerve cells (Fig. 4.20A), most probably glial 
cells and neuronal axons (Fig. 4.20B). Concerning neurons, the role could be a cytoskeletal 
role, as seen within the connecting cilium of photoreceptors (Kubota et al., 1997). The role of 
myocilin in glial cells suggests an involvement in myelination and/or in the support and 
maintenance of the myelin sheath (Ricard et al., 2001; Ohlmann et al., 2003), as well as a 
supporting role in the function of astrocytes, as exemplified by the fact that the expression of 
myocilin is increased during glial scar formation (Jurynec et al., 2003), probably in an attempt 
to restore astrocyte function. As a matricellular protein myocilin may be secreted by glial cells 
to the ECM, thereby affecting ECM interactions and function of the nervous system.  
 
 
5.5. Outcome 
 
In summary, our attempt to target protein expression into the TM in vivo opened totally new 
aspects concerning the function of myocilin. Our results have brought more evidence for a 
neuronal supporting function of myocilin, which is in accordance with its assumed role as a 
matricellular protein, since these proteins do not by themselves show to have any specific 
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functional role, in contrast, matricellular proteins act by modulating other proteins (reviewed 
by Bornstein et al., 2000). In fact, astrocytes are known to secrete matricellular proteins that 
regulate developmental processes, as well as CNS repair after injury in adulthood. In 
concordance with matricellular proteins in general, knock-out within the CNS do not evoke 
any observable phenotype (reviewed by Eroglu, 2009), which matches the fact that myocilin 
knock-out mice seem to be normal (Kim et al., 2001). Despite the absence of an obvious 
phenotype, there is however evidence that deletion of CNS matricellular proteins modulate 
synaptic transmission (Eroglu, 2009). In addition to showing evidence for a suggested general 
function in supporting and/or modulating the function of nerve cells, our data suggest a 
possible role of myocilin in the drainage of CSF in the brain, which also in this context links 
myocilin to new areas of clinical interest.  
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5.4. Creation of an animal model that would allow a TM directed conditional knock-out 
 
The Cre/lox system is the most widely used (and perhaps the most effective) system by which 
a conditional gene knock-out can be achieved in mammals. A mouse line that expresses Cre 
recombinase in a tissue-specific manner allows this mouse line to be used as a tool to generate 
a conditional tissue-specific knock-out of a desired gene in TG offspring. This is of huge 
advantage, since classical germ-line knock-outs usually may be associated with embryonic 
lethality (reviewed by Sauer, 1998). 
 
Whereas there have been many attempts to conditionally knock-out genes in the posterior eye, 
only few reports involve the anterior eye (reviewed by Kao, 2006). TM-directed expression of 
Cre would open the possibility to study the effect that deletion of a desired gene has on the 
hydrodynamics of AH outflow, without the need to create a germ-line knock-out line for 
every gene of interest. The growing microarray data from normal, glaucomatous and 
dexamethasone-treated TM (Tomarev et al., 2003; Rozsa et al., 2006; Vittal et al., 2005; 
Diskin et al., 2006) makes it necessary to create a straightforward strategy to analyze potential 
candidate glaucoma genes. To approach this topic, we wanted to create a mouse-line that 
drives the expression of Cre specifically in the TM. Since myocilin is abundantly expressed at 
both mRNA and protein levels in adult mouse TM (Takahashi et al., 1998; Knaupp et al., 
2004), and since Kim et al. (2002) already showed that the endogenous Myoc locus can be 
targeted by homologous recombination, and that this knock-out of the myocilin gene did not 
have any effect on the viability or phenotype, we wanted to use the endogenous Myoc 
promoter to drive the expression of Cre in the TM. Our data that showed that the MYOC basal 
promoter, even though acting in combination with an enhancer element, was too weak to 
drive gene expression in vivo (Fig. 4.15), further prompted us to this time use the whole 
endogenous myocilin promoter for expression of protein in the living TM. 
 
We designed and cloned a knock-in construct that would be able to integrate at the Myoc 
locus by homologous recombination in mouse ESCs, and that as well would later enable for 
screening of properly integrated ESCs by Southern blot. (Chapter 4.4.1; Figs. 4.22, 4.23). 
Linearization, purification and electroporation of the knock-in construct into mouse ESCs 
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resulted in > 600 clones expressing our construct. Screening of these colonies for correct 
homologous recombination at the Myoc locus by Southern blot revealed that one of the clones 
had integrated the 3´-flank of the knock-in construct correctly at the Myoc locus (Fig. 4.24). 
Screening for the 5´-flank of the construct revealed that also this flank had integrated, 
however, the expected band size after restriction digestion did not show the calculated size 
(Fig. 4.25). Since the ESC lysate was limited, we could not repeat the experiment. Since the 
band was smaller than the expected 7203 bp, showing a size of ~ 4 kb, we first thought about 
a possible deletion that may have occurred during the recombination process. To exclude this, 
we amplified the whole 5´-flank, beginning from the 5´-upstream region of the genome and 
ending downstream of the flank within the gene for Cre (data not shown). This indicates that 
the whole 5´-flank promoter region was present but, since we did not further clone and 
sequence the amplified region, we can´t exclude that the amplicon was an artefact.  
 
If a deletion of a part of the 5´-flank had occurred, it probably arose during the meiotic 
homologous recombination process, which may be affected by processes like gene conversion 
(whereby a part of a recombinating sequence do not recombinate, but retains the sequence 
from the other strand, resulting in two identical alleles) or some of the DNA proof-reading 
mechanisms that inhibit crossing-over of e.g. improperly aligned homologous sequences 
(Alberts, 2004). Since we by sequencing detected that we only had two point mutations in our 
amplified 3072 bp 5´-homologous flank (Chapter 4.4.1), it is though unlikely that improper 
alignment of the 5´-flank sequences would have, due to non-complementarity, interrupted the 
recombination event at this end of the construct. The unexpected too short size resulting from 
our 5´-end restriction could theoretically be a consequence of a novel restriction enzyme site 
due to a naturally occurring small nuclear polymorphism in the 5´-homologous region, or due 
to a nucleotide exchange during amplification. However, based on our sequencing data, this 
theory seems to be unlikely. A third theory concerning the restriction, and which could have 
resulted in the unexpected restriction pattern, may be star activity of our enzyme. 
 
Contamination problems in the ESC facility finally resulted in the death of our analyzed 
clone, thus we could not proof this clone further for it possibly having a correct integration of 
our knock-in construct at the Myoc locus. Further attempts by a biocompany to target the 
Myoc locus of ESCs, destined to become germ-line cells, by our knock-in construct failed, 
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indicating that the Myoc locus in general may not be easy to manipulate. This correlates with 
the fact that we earlier had to screen over 600 colonies until we detected possibly one positive 
clone. Even though Kim et al. (2001) targeted the Myoc locus successfully, they did not 
mention how many ES clones they screened for. Homologous recombination is a rare process, 
occurring once per 10
5
 – 10
7
 electroporated cells (Sargent and Wilson, 1998), whereby the 
propability of a crossing over increases proportionally with the lengths of the homologous 
flanks (Hasty et al., 1991). Since a conditional knock-out in the TM would offer an immense 
spectrum of possibilities to study the role of molecular factors thought to be involved in an 
elevated IOP, we at the moment are in the process of elongating our homologous flanks, 
aiming later to send our elongated knock-in construct for electroporation. Future projects 
beyond this Ph.D. Thesis aim to analyze the Cre knock-in mouse in its ability to conditionally 
knock out sequences in the TM. Crosses with reporter lines like Z/EG (LacZ/EGFP) (Novak 
et al., 2000) and Z/AP (LacZ/human placental alkaline phosphatase (Lobe et al., 1999) will 
give an insight into the spatial pattern of Cre activity, whereas analysis of eGFP expression 
will show the temporal pattern of Cre expression. Then, our Cre mouse line can be crossed 
with lines that carry loxP-flanked genes to generate double TG progeny with knock-out in a 
Cre expression pattern dependent fashion.  
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5.5. Analysis of corneal gene expression in TGF-ß1 overexpression mice 
 
Earlier microarray analysis of our TGF-ß1 overexpression mice, which have eye defects like a 
thick opaque cornea, due to a stroma with undifferentiated and excessively proliferated 
mesenchyme cells, vascularisation and an unorganized ECM, and which show an up- and 
downregulation of  fibronectin, perlecan, α-smooth muscle actin and type VI collagen 
expression, respectively (Flügel-Koch et al., 2002), revealed that there were 98 and 163 genes 
that were differentially up- and down-regulated, respectively, in the corneas of these mice (not 
yet published). Since the corneal defects in these mice in many aspects resemble a fibrotic 
corneal phenotype, knowledge of the TGF-ß1-induced differential gene expression may be of 
clinical relevance, not at least in finding out which genes that may be responsible in 
maintaining the transparency of this tissue. Thus, we wanted to extend our earlier microarray 
data to be validated for 12 genes that are known, based on literature, to be regulated by TGF-
ß1 or to be expressed in the cornea, by RT real-time PCR. 
 
The microarray data showed that the expression of many genes that are important for the 
maintenance of normal characteristics of the cornea was altered in response to an 
overexpression of TGF-ß1 (Tables 4.4; 4.5). Cytoskeletal and ECM proteins, and their 
interplay via integrins, are pivotal in the maintenance of an ordered cell-ECM architecture, a 
criterion that is crucial for the for transparency responsive corneal stroma (Maurice, 1957). 
Proteins that serve as connectors and communicators between cells (e.g. junction-forming 
proteins) are important for tissue integrity, not at least for the as barriers functioning 
epithelium and endothelium (reviewed by Lu et al., 2001). Enzymes and signalling molecules 
are finally the ones that maintain basic metabolic functions and regulate growth, migration 
and differentiation during development or disease. In addition, high expression of some 
general enzymes are thought to also have a second crystallin role in the corneal stroma 
(reviewed by Jester, 2008). Our microarray data showed that the expression of proteins from 
all above described classes were affected in TG corneas, indicating that the observed 
phenotype in these mice is a result of a complex alteration in protein expression and 
molecular signalling that affect both intra- and extracellular molecular mechanisms. Changes 
in gene expression of cytoskeletal, extracellular and junction-forming proteins, as well as of 
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enzymes and signalling molecules can also generally be observed during wound healing, 
making our study relevant also in this aspect.  
 
5.5.1. Differential expression of genes coding for ECM proteins 
 
Our real time PCR data confirmed that the genes for the extracellular Mmp13, as well as the 
basal lamina proteins Lama3 and Lamb3 were up-regulated in TG corneas, indicating a 
remodelling of ECM and cell-matrix contacts. MMP13, a secreted proteinase with a wide 
substrate specificity ranging from various collagens to adhesion molecules like tenascin C and 
fibronectin (Knäuper et al., 1997), was originally cloned from human breast carcinoma tissue 
(Freije et al., 1994), and is a critical regulator of cartilage formation and ossification during 
development (Inada et al., 2004). MMPs are generally known to be involved in ocular surface 
diseases like corneal wound healing (Ye et al., 2000), corneal erosions (Dursun et al., 2001), 
corneal ulcers (Fini et al., 1998) and corneal inflammation and neovascularisation (Kvanta et 
al., 2000), though the regulation of the MMPs in these diseases are unclear. The expression of 
MM13 was induced in neovascularized rabbit corneas (Huang et al., 2001), which correlates 
with the fact that our TGF-ß1 overexpressing mice showed a vascularised corneal stroma. 
MMP13 expression is up-regulated in keratoconus human corneas (Mackiewicz et al., 2006). 
Even though keratonus corneas are thinner than normal, in contrast to the too thick than 
normal corneas of our TG mice, it may not exclude that Mmp13 may be involved, through 
remodelling of the ECM, in the regulation of corneal thickness. MMP13 was shown to be 
active in embryonic chick corneal stroma, where it by degrading ECM facilitated NC cell 
migration (Huh et al., 2007). The increased cellularity of our TG corneas may be, in addition 
due to an increased proliferation, due to an increased migration of NC-derived mesenchyme 
cells into the stromal space during development. Migration of cells is dependent on adhesive 
ECM molecules, like fibronectin, on which to migrate (reviewed by Perris and Perrissinotto, 
2000), and Mmp13 may facilitate this migration by digesting excess ECM. Up-regulation of 
MMP13 in wounded rat corneas (Ye et al., 2000) and its role in mediating fibrosis and 
inflammation in hepatic stellate cells (Uchinami et el., 2006), finally shows that our TG mice 
show fibrotic characteristics also at the gene expression level, underscoring that these mice 
may be a good model to study fibrotic molecular mechanisms. 
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Since MMP13 was originally found to be a protease that digests fibrillar collagens (Freije et 
al., 1994), and since the corneal transparency is dependent on a highly ordered structure of 
abundant fibrillar collagens (Maurice, 1957), the opaque corneas of our TG mice may be due 
to digestion of the stromal fibrous collagens by Mmp13, resulting in disturbances of both 
homeostasis and the ordered architecture normally present in a healthy cornea. Since MMP13 
has a central role in the network of MMPs and their inhibitors tissue inhibitor of matrix 
metalloproteinases (TIMPs), in that it activates and is activated by many of them, the high 
expression of MMP13 in our analyzed TG corneas is likely to be accompanied by a 
differential expression of also other MMPs and TIMPs.  
 
MMP13 is differentially regulated by various signalling cascades, depending on cellular 
environment and developmental or pathological state. Even though MMP13 contains a TGF-ß 
inhibitory element in its promoter (Pendas et al., 1997), its mRNA and protein levels, as well 
as its activity, can be increased by TGF-ß1 treatment, from barely detectable levels under 
normal conditions (Li et al., 2003), in a dose-dependent manner in cultured human corneal 
epithelial cells (Kim et al., 2004), indicating that the inhibitory element is not used in the 
cornea. This correlates with the fact that our TGF-ß1 overexpressing mice showed a 6.156 
and > 53-fold elevation in Mmp13 expression in the microarray and real-time PCR (highly 
significant), respectively, when compared to WT corneas (Table 4.4, Fig. 4.27), and reflects 
the fact that our TGF-ß1 overexpression mice showed a high, > 7-fold over that of WT eyes, 
expression of TGF-ß1 mRNA at P0, the time point of preparation of our analyzed corneas, as 
well as an effective translation of the TGF-ß1 mRNA into protein (Flügel-Koch et al., 2002). 
Since TGF-ß can, in addition to via Smad2/3, signal via different arms of the MAPK pathway 
(reviewed by Saika, 2006), and since it has been shown that MMP13 is activated via p38 
MAPK upon TGF-ß1 treatment in transformed human keratinocytes (Johansson et al., 2000), 
Mmp13 could be activated by TGF-ß1 via the MAPK signalling pathway also in our TG 
corneas. Since all MAPKs, MAPK, JNK and p38, are able to phosphorylate Smad2/3 
(reviewed by Saika, 2006), a TGF-ß1 induced activation of MAPKs could result in a positive-
feedback loop of TGF-ß1 expression. 
 
Basal lamina proteins are synthesized by the cells that rest on it, i.e. in the case of the cornea 
by the epithelium and endothelium. These proteins bind integrin, as well as other ECM 
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molecules, thus connecting the cytoskeleton of a cell to the ECM. Thus, they are involved in 
structural organization of both intra- and extracellular architecture, cell migration during 
development and wound healing, as well as in cell signalling via integrins. The basal lamina 
multidomain adhesive glycoprotein laminin is one of the first ECM proteins synthesized in a 
developing embryo (Alberts et al., 2004). Lama3 and Lamb3 are subunits of laminin 5 and 
normally expressed in the basal lamina (Bowman´s membrane) of the corneal epithelium, 
whereas they in diseased corneas are also expressed in the corneal stroma (Byström et al., 
2007). In wounded rat corneas TGF-ß and its receptors were induced in the regenerating 
epithelium, as well as in the stroma, which showed hypercellularity and fibrotic 
characteristics. The expression of laminin and fibronectin were as well up-regulated in the 
stroma. The authors suggest that TGF-ß may be responsible for the stromal ECM formation 
and cell reqruitment (Mita et al., 1997). In vitro data confirmed that TGF-ß1 physically 
interacts with laminin (Kumar et al., 1995), and that the Lama3 promoter contains a TGF-ß1 
responsive element that is responsible for reporter gene expression in keratinocytes (Virolle et 
al., 1998). These data correlate with the fact that the expression of Lama3 and Lamb3 was up-
regulated (for Lamb3 highly significant) in corneas of TGF-ß1 overexpressing mice (Fig. 
4.26). Since TGF-ß1 is known to regulate the expression of both integrin and laminin subunits 
in rat alveolar cells, indicating that TGF-ß1 is involved in differentiation of this tissue through 
the regulated expression of these proteins (Kumar et al., 1995), the TGF-ß1 induction of 
Lama3 and Lamb3 in our analyzed TG corneas may have influenced the differentiation and/or 
migration of mesenchyme cells into the stroma in these mice. Or, as basal lamina proteins are 
known, together with integrins, to co-ordinate incoming extracellular signalling (Alberts et al., 
2004), Lama3 and Lamb3 may have structurally been involved in accumulating extracellular 
growth signalling at the cell surface, leading to the excess proliferation of stromal 
mesenchyme cells seen in our TG mice. It would be interesting to analyze if also integrins are 
differentially expressed in the corneas of our TGF-ß1 overexpressing mice.  
 
 
5.5.2. Effect of TGF-ß1 on the cytoskeleton 
 
Krt14 makes up intermediate filaments (IFs) of the cytoskeleton primarily in the epidermis, 
where it in its mutated form is associated with skin fragility and blistering diseases 
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(Coulombe et al., 1991). Our data that showed that Krt14 was up-regulated significantly upon 
TGF-ß1 overexpression in mouse corneas (Fig. 4.26) correlate with earlier data that showed 
that TGF-ß1 induces the expression of Krt14 in cultured human keratinocytes and cutaneous 
wounds in mice (Jiang et al., 1995; Werner et al., 2000). Embryonic mouse corneal epithelial 
cells express Krt14, whereas it in adult is limited to mitotically active basal cells (Kurpakus et 
al., 1994). The facts that Krt14 is thus considered a marker for mitotically active basal cells, 
and that Krt14 was up-regulated in our TG corneas, correlates with the observed excessive 
cellular proliferation of the corneal stroma in these mice (Flügel-Koch et al., 2002). The fact 
that there is normally a switch from the keratin pair Krt5/Krt14 to Krt3/Krt12 as the cornea 
differentiates (Schermer et al., 1986) correlates with the fact that the corneas of our TGF-ß1 
overexpression mice had an immature character (Flügel-Koch et al., 2002).  
 
During wound-healing, activated cells alter their composition and architecture of IFs, which 
may alter their viscoelastic properties, facilitating proliferation and migration (reviewed by 
DePianto and Coulombe, 2004). In addition, IFs are able to bind and modulate the activities 
of receptors, enzymes, and adaptor molecules, whereby they organize and assemble activities 
of the cell to maintain proper metabolism and homeostasis (reviewed by Green et al., 2005). It 
is also known that IFs can sequester regulators of signalling pathways, resulting in changes in 
cell size, migration and survival (reviewed by Pallari and Eriksson, 2006). Thus, in addition to 
contributing to changes in viscoelastic properties of the cells of the corneal stroma in our TG 
mice, which could have affected the excessive migration of mesenchyme cells into the stroma 
(Flügel-Koch et al., 2002), the up-regulation of Krt14 could have affected growth signals in a 
positive way to enhance proliferation of these cells. Patients with posterior polymorphous 
endothelial dystrophy show abnormalities of the corneal endothelium and the Descemet´s 
membrane, including opacities. Jirsova et al. (2007) showed novel expression of Krt14 in the 
diseased endothelium of these patients, indicating that there is an epithelialization of this 
tissue. Interestingly, our analyzed TGF-ß1 overexpression mice do not either have a defined 
normal corneal endothelium. The fact that the corneas of these mice are opaque (Flügel-Koch 
et al., 2002), also suggests that there may be an epithelialization of this tissue. In fact, the 
microarray data showed that also other epidermal-specific keratins were up-regulated in the 
microarray, including Krt16 and Krt23 (data not shown). 
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5.5.3. Changes in cell-cell communication and cation permeability 
 
Gjb2 is an epithelial integral membrane protein of the connexin proteinfamily, it also called 
connexin 26. Connexins build up a connexon and connexons from adjacent cells form gap 
junctions (Alberts et al., 2004). Mutations in GJB2 cause keratitis-ichthyosis-deafness 
syndrome, a disease that depending on mutation may cause deafness, thickening of the 
epidermis and corneal defects, incuding opacity, scarring, inflammation, neovascularisation 
and absence of sensation (Bale et al., 1999; Richard et al., 2002, Sonoda et al., 2004). 
Connexins show a spatially regulated pattern of expression in the cornea, suggesting that they 
have important roles in proliferation, differentiation and maintenance of this tissue. Gjb2 was 
found in epithelial basal and intermediate cells, as well as between endothelial cells in rat 
cornea (Laux-fenton et al., 2003). In vitro data showed that GJB2 mediates gap junction 
communication in well differentiated human corneal epithelial cells, whereas undifferentiated 
cells were uncoupled, and that mutant GJB2 was not capable of forming gap junctions in 
these cells (Shurman et al., 2005). These data show that a proper expression of GJB2 is 
inevitable for proper development and function of the cornea, and may indicate that the 
observed up-regulation of Gjb2 in our TG corneas (Fig. 4.26) may have disturbed normal 
communication between the cells.  
 
Also for this gene there is a parallel to the wound healing process, since Gjb2 has shown to be 
transiently up-regulated and to re-locate in wounded rabbit corneas, indicating that cell-cell 
communication is important during corneal wound healing (Ratkay-Traub et al., 2001). 
Epidermal wounding also up-regulated Gjb2 in hyperproliferative cells proximal to the 
wound, and these cells showed an altered intercellular communication (Goliger and Paul, 
1995). This correlates with the fact that stromal cells of our analyzed TG corneas showed 
hyperproliferation (Flügel-Koch et al., 2002). Interstingly, connexin 43, which is the most 
prevalent connexin within the cornea (Shurman et al., 2005) directed embryonic NC cell 
migration in the heart and the proliferation of neighbouring non-NC tissue (Huang et al., 
1998). Even though it has not yet been shown that Gjb2 can do the same, it is interesting that 
our TG corneas also had an increase of NC migration into the corneal stroma (Flügel-Koch et 
al., 2002). The facts that FGF-2 up-regulated TGF-ß1 and GJB2 in human ESCs, suggesting 
that GJB2 was induced by TGF-ß1 (Greber et al., 2007), and that TGF-ß1 up-regulated 
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connexin expression in cultured bovine aortic endothelial cells, correlate with our microarray 
and real-time PCR data. On the other hand, Flügel-Koch et al. (2002) assumed that TGF-ß1 
would indirectly act via FGF-2 to cause the phenotype seen in our analyzed TGF-ß1 corneas. 
Thus, Gjb2 could have been either directly by TGF-ß1 or indirectly via FGF-2 up-regulated in 
our analyzed TG corneas.   
 
Trpm1, which was highly significant down-regulated in our real-time PCR experiments (Fig. 
4.26), codes for a transient receptor potential cation channel protein, originally discovered in 
benign metastatic melanomas, where its expression inversely correlated with tumour thickness 
(Duncan et al., 1998; 2001) and thus is regarded as a possible tumour suppressor. Since 
transient receptor potential cation channel proteins are permeable for e.g. Ca
2+
 and Mg
2+
, and 
thus involved in the regulation of intracellular Ca
2+ 
and Mg
2+
 levels that in turn regulate 
signalling and stabilization of enzymes (Stryer, 1995; Wolf and Cittadini, 1999), respectively, 
dysfunction in these proteins can affect proliferation, differentiation and growth. These 
channel proteins are reported to be associated with a diverse spectrum of diseases called 
channelopathies, including systemic diseases like asthma, pulmonary disease and 
neurodegenrative disorders (reviewed by Nilius et al., 2007). The facts that cations like Ca
2+ 
and Mg
2+
 are important in maintaining the health of the corneal epithelium (Bachman and 
Wilson, 1985), that the chelation of Ca
2+ 
and Mg
2+
 by sodium citrate reduces corneal 
ulceration after injury in rabbit eyes (Haddox et al., 1996), and that these cations decreased 
bovine stromal swelling (Hogan et al., 2008), indicate that proper regulation of intra- and 
extracellular Ca
2+ 
and Mg
2+
 concentrations are important for corneal homeostasis. In fact, 
improper Ca
2+
 homeostasis in the cornea may lead to band keratopathy, a disease where 
calcium deposits in the cornea and which may be accompanied by inflammation and 
impairment of vision (Galor et al., 2008). The down-regulation of Trpm1 in our experiments 
could thus, due to an abnormal cation homeostasis, have resulted in the corneal phenotype 
observed in our analyzed TG mice. Or, the reduced amount of Trpm1 transcript could be a 
result of the immature character of the cornea in these mice, i.e. be a consequence rather than 
cause of the phenotype. It is interesting to note that TRPM1 is a direct target for 
micropthalmia-associated transcription factor (MITF) in diverse human melanoma cell lines, 
and its mRNA location corresponds to that of MITF in the mouse eye (Miller et al., 2004), 
suggesting that it is a downstream target of MITF. This correlates with the fact that Mitf was 
2.6-fold down-regulated in our analyzed TG corneas compared to WT corneas (data not 
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shown) and suggests that the down-regulation of Trpm1 in our experiments may be a result of 
TGF-ß1 induced down-regulated Mitf. 
 
5.5.4. Differential regulation of enzymes/transporters 
 
Oca2, or pink-eyed dilution, is a melanosomal transmembrane protein involved in the 
processing and trafficking of tyrosinase in the melanogenesis process (Chen et al., 2002), 
and/or it mediates neutralization of melanosomal pH, which favors melanogenesis (Ancans et 
al., 2001). Mutations in OCA2 cause oculocutaneous albinism type 2, a disease that show a 
phenotype that results from defects in melanogenesis, i.e. hypopigmentation of skin, hair and 
the pigmented parts of the eye (Rinchik et al., 1993). Mutations in OCA2 may cause 
symptoms like nystagmus, foveal dysplasia, as well as affect vision (reviewed by Grønskov et 
al., 2007). Since only the pigmented part of the retina and the iris contain melanosomes, the 
role of OCA2 within the cornea suggests another, not with melanogenesis associated function. 
Since the exact function of OCA2 in the melanogenesis process is not defined, and since Oca2 
has been suggested to act as an ion transporter (Puri et al., 2000) and been shown to modulate 
glutathione metabolism (Staleva et al., 2002), the role of Oca2 in the cornea may be to 
generally maintain homeostasis by e.g. ion transport or detoxification. If Oca2 has a general 
homeostatic role, the highly significant down-regulation of this gene in our analyzed TG 
corneas (Fig. 4.26) could have affected normal development of these corneas by generally 
disturbing e.g. homeostasis or protein folding. It is interesting that Oca2 is mutated in the 
cavefish Astynax, whose eye primordia degenerate by apoptosis of the lens (Jeffery, 2009). In 
fact, the lenses of our TG mice were apoptotic (Flügel-Koch et al., 2002). Even though the 
severe phenotype seen in the cavefish relies on mutations that cause total loss of function of 
Oca2, as well as due to additional mutated genes (reviewed by Jeffery, 2009), it suggests that 
this protein could have an important eye developmental function. 
 
The down-regulation of Mitf in our microarray of corneas from TGF-ß1 overexpressing mice 
(data not shown) correlates with data where TGF-ß1 was shown to down-regulate MITF and 
melanin synthesis in cultured mouse melanocytes via a delayed activation of ERK MAPK 
signalling (Kim et al., 2004). Since MITF is known to regulate melanogenesis associated 
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genes (Cheli et al., 2010), the down-regulation of Oca2 in our experiments could thus be a 
consequence of by TGF-ß1 down-regulated Mitf.  
 
Another gene that showed a highly significant down-regulation in TG vs. WT corneas was the 
gene coding for dual function brain protein Ptgds (Fig. 4.26). Intracellularly Ptgds acts as an 
enzyme that converts prostaglandin H2 (PGH2) to prostaglandin D2 (PGD2), a potent 
endogenous somnogen, nociceptive modulator, anti-coagulant, vasodilator, 
bronchoconstrictor and allergic and anti-inflammatory mediator, whereas it extracellularly 
acts as a lipophilic ligand binding protein (rewiewed by Urade and Hayaishi, 2000). The 
down-regulation of Ptgds due to an overexpression of TGF-ß1 in our experiments correlates 
with data that show that TGF-ß1 can modulate the expression of cyclooxygenase, the enzyme 
that converts arachidonic acid to the prostaglandin precursor PGH2, in human bronchial 
epithelial cells in a time- (Liu et al., 2007) and in neurons and astrocytes of rat CNS in a dose-
dependent manner (Luo et al., 1998), respectively. PTGDS was shown to be the most 
abundant transcript in human corneal endothelium (Sakai et al., 2002) and PGD2 is a major 
prostanoid in ocular tissues. However, is the enzymatic activity of PTGDS in the cornea 
negligible (Goh et al., 1987), suggesting that this protein may have another than an enzymatic 
role in this tissue. Indeed, since rat and human PTGDS bind RA and retinaldehyde, as well as 
RA and retinal, respectively, with high affinity (Tanaka et al, 1997; reviewed by Urade and 
Hayaishi, 2000), PTGDS could have a role in the transport of RA and its derivatives 
throughout the cornea. During mouse development NC cells of the ocular mesenchyme are 
target for RA signalling (Matt et al., 2005), which affects other important (including Pitx- and 
Fox-mediated) signalling pathways, resulting in the required determination of the conjunctiva-
corneal border (Gage et al., 2008). Thus, indirectly, RA signalling is involved in directing 
cues for the establishment of corneal transparency, and a possible disturbed RA transport, due 
to a down-regulation of Ptgds, could have resulted in the observed corneal phenotype of our 
analyzed TG corneas.  
 
Cultured bovine keratocytes were shown to express Ptgds as a keratan sulphate proteoglycan 
(KSPG) (Berryhill et al., 2001), the type of post-translationally modified ECM proteoglycans 
that, in addition to collagens, are important for the maintenance of corneal transparency 
(Michelacci, 2003). This is evidenced by the facts that there is an increase in corneal KSPG 
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content during development, which correlates with the time point of acquisition of 
transparency (Coulombre and Coulombre, 1958), and that KSPGs are absent in opaque 
corneal scars (Hassell et al., 1983). If PTGDS has a role in conferring transparency, the down-
regulation of Ptgds in our analyzed TG corneas could thus be one of the reasons that lead to 
corneal opacity in these mice. It is a general fact that abundantly occurring enzymes involved 
in basal metabolism can have a second crystalline role, conferring transparency, in the cornea. 
Such enzymes are e.g. aldehyde dehydrogenase 1A1 and transketolase (reviewed by Jester, 
2008). In fact, transketolase was down-regulated in our analyzed TG corneas in the 
microarrays (data not shown). It is tempting to speculate that Ptgds would also, in addition to 
its enzymatic role, have a crystallin transparency conferring function in the cornea. 
 
 
5.5.5. Modulation of signalling pathways 
 
Egr2, or Krox-20 which was significantly up-regulated in our real-time PCR experiments 
(Fig. 4.26), codes for a zink finger immediate-early transcription factor. Egr-2 is up-regulated 
early, without de novo protein synthesis, and transiently in the G0/G1 transition of the cell 
cycle (Chavrier et al., 1988). Egr-2 activates Hox genes, necessary for the morphological 
segmentation of the hindbrain (Seitanidou et al., 1997). In mouse, Egr2 is also involved in the 
myelination of PNS (peripheral nervous system) Schwann cells, where it activates genes 
necessary for proper myelination (Topilko et al., 1994). In human, mutations in EGR lead to 
sensory neuropathies including axonal atrophy and disability, as well as defects in axonal 
transport (reviewed by Berger et al., 2006). Egr-2 expression increases as development 
proceeds in chick corneas (Conrad et al., 2009). EGR-2 could thus have a role in the 
myelination of nerves also in the cornea. The facts that only the peripheral/limbal corneal 
stroma contains myelinated nerves, whereas the central and transparent corneal stroma only 
contains unmyelinated nerve fibers (Müller et al., 1996), may be a sign of conjunctivalization 
of our analyzed TG corneas. This suggestion is supported by the fact that Dkk2 was highly 
significant down-regulated in our experiments (Fig. 4.26) (discussed later in this chapter), 
which in turn suggests an up-regulation of Wnt signalling. Data from Gage et al. (2008) 
showed that down-regulation of the Wnt signalling in the central cornea is necessary for the 
development of corneal over conjuctival fates, including the acquisition of transparency.  
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In embryonic and adult wounds Egr-2 was rapidly and transiently up-regulated, suggesting 
that it is involved in the initiation of the wound healing process by activating other genes 
(Grose et al., 2002). Our data that showed that TGF-ß1 overexpression induced the expression 
of Egr-2 in mouse corneas correlate with earlier data where TGF-ß1 induced an almost five-
fold up-regulation of Egr-2 in primary mouse embryonic maxillary mesenchyme cells (Pisano 
et al., 2003). TGF-ß1 also induced the expression of Egr2 in both mouse fibroblast and 
epithelial cells, which were growth-stimulated and growth-inhibited by the treatment, 
respectively (Koskinen et al., 1991). This is interesting, since our analyzed TG corneas had 
proliferation of the stroma, whereas the epithelium was degenerated, covering only a part of 
the stroma (Flügel-Koch et al., 2002). 
 
Fst, which codes for a secreted ubiquitous autocrine glycoprotein that originally was 
identified as a follicle-stimulating hormone suppressing protein (Ueno et al., 1987), was 
significantly up-regulated in our real-time experiments (Fig. 4.26). Fst binds and inhibits 
downstream signalling of the TGF-ß superfamily members activin in rat ovary (Nakamura et 
al., 1990), as well as BMP4 (Fainsod et al., 1997) and myostatin (Amthor et al., 2004) in the 
embryonic frog and chick mesoderm, respectively. Activin is also known to be an embryonic 
morphogen, determining cell fate in a concentration dependent manner (Alberts et al., 2004). 
You and Kruse (2002) showed that activin and its receptors are transcribed in human corneal 
fibroblasts, and that activin mediates differentiation of cultured human keratocytes. The fact 
that the activin mediated effect on differentiation was inhibited by Fst in these cells indicates 
that the activin-Fst system may be present in the cornea. This correlates with the up-regulation 
of Fst in (Fig. 4.26), as well as the disturbance of keratocyte differentiation of (Flügel-Koch et 
al., 2002), our analyzed TG corneas. In vivo, in the rabbit cornea, Fst was shown to have an 
angiogenic effect. The angiogenic effect of Fst was increased sharply in combination with 
FGF-2 (Kozian et al., 1997). Thus, since Flügel-Koch et al. (2002) proposed that FGF-2 may 
be up-regulated by TGF-ß1 overexpression in the eyes of our analyzed TG mice, and since 
these mice show neovascularisation, the up-regulation of Fst in these mice could act in 
concert with FGF to induce the observed neovascularisation.  
 
The activin-Fst system is important in regulation of fibrosis during wound healing, and an 
overexpression of activin reduced scar formation in mice in a concentration dependent 
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manner (Bamberger et al., 2005). An Fst-mediated inhibition of activin could thus be 
responsible for the fibrotic phenotype observed in our analyzed TG corneas. TGF-ß1 activates 
activin in embryonic mesoderm and endothelial cultures (van der Kruijssen et al., 1993), and 
activin is known to induce, via Smad2/3 signalling, the expression of Fst both at mRNA and 
protein levels in liver cell cultures, suggesting a negative feedback of Fst on activin signalling 
(Bartholin et al., 2002). Thus, TGF-ß1 may have induced the expression of activin in the eyes 
of our TG mice, which then could have activated Fst via Smad2/3. Or, since Fst can be 
activated via Smad2/3, as shown by Bartholin et al. (2002), and since TGF-ß1 also signals via 
these proteins, TGF-ß1 could have directly activated Fst. 
 
BMP4, which can be inhibited by Fst during frog mesodermal development (Fainsod et al., 
1997), is expressed at the protein level in all cell types of fresh frozen human cornea. In 
addition, mRNA for BMP receptors were found to be expressed in cultured human corneal 
cells, and further analysis showed that BMP4 regulated keratocyte proliferation and apoptosis 
(Mohan et al., 1998). Thus, the significant up-regulation of Fst in our analyzed TG corneas 
may have had an impact on BMP4-mediated signalling, resulting in observed stromal cell 
proliferation and/or lens epithelial apoptosis, and/or in apoptosis of peripheral corneal 
epithelium (Flügel-Koch et al., 2002). Keratoconus corneas are thinner than normal, probably 
due to apoptosis of keratocytes (Wilson et al., 1996). Interestingly, BMP4 was shown to be 
up-regulated in human keratoconus fibroblasts, suggesting that this protein mediates 
keratocyte apoptosis during keratoconous (Lee et al., 2009). Thus, the up-regulation of Fst, 
and possible subsequent inhibition of Bmp4, in our analyzed TG corneas could have led to the 
observed excess proliferation of corneal stromal cells, causing the three-fold than normal 
thick cornea (Flügel-Koch et al., 2002). Moreover, deletions of BMP4 resulted in congenital 
corneal opacity in a human patient (Hayashi et al., 2008) and haploinsufficient Bmp4-null 
mice showed corneal defects including neovascularisation, irregular collagen bundle 
architechture of the stromal ECM, scarring, scleralization and opacity (Chang et al., 2001). 
Most of these corneal phenotypes were also observed in our analyzed TG mice (Flügel-Koch 
et al., 2002), suggesting that overexpression of TGF-ß1 may have resulted in defect Bmp4 
signalling, possibly via the up-regulation of Fst.  
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Igfb6, significantly down-regulated in our real-time PCR experiments (Fig. 4.26), codes for an 
extracellular protein which preferentially binds the insulin-like growth factor II (IGF-II), over 
IGF-I, with high affinity, (Kiefer et al., 1992), thus inhibiting IGF-II mediated downstream 
signalling normally involved in cell survival, cell metabolism and cell proliferation (Alberts et 
al., 2004). There is also some evidence that IGFBP6 may have IGF-independent activity in 
cell growth or apoptosis, or as an intracrine effector modulating transcriptional activity after 
nuclear entry (reviewed by Bach, 2005), and Fu et al. (2007) showed that IGFBP6 was 
independently able to induce migration of colon cancer cells via phosphorylation and 
activation  of the p38 MAPK. It is possible that the down-regulation of Igfbp6 in our 
experiments could have elevated IGF-II mediated signalling, resulting in e.g. the observed 
excess proliferation of TG corneal stromal cells or, if acting in an IGF independent way, 
resulting in modulation of e.g. transcriptional regulation or migration. The fact that other 
proteins that also modulate IGF signalling, i.e. IGFBP3 and IGFBP5, have been shown to be 
significantly differentially regulated in keratoconus keratocytes (Ha et al., 2004), suggests that 
proper regulation of IGF signalling, possibly also by Igfbp6, may be important for the 
regulation of stromal thickness. The fact that IGF-II is present in bovine corneal stroma, 
where it activates keratocytes to proliferate in vitro and counteracts TGF-ß-induced gene 
expression changes that affect corneal transparency (Musselmann et al., 2008), further 
indicates that proper regulation of IGF-II signalling is important in regulating stromal 
development and differentiation. IGF signalling has been shown to stimulate the expression of 
collagens in cultured keratocytes (Lelbach et al., 2005; Hassell et al., 2008) and neonatal 
mouse keratocytes were shown to express high amounts of IGF-I/II and collagens (Kane et 
al., 2009). Thus, the possible elevated IGF signalling, due to down-regulation of Igfbp6, in 
our analyzed TG corneas may have influenced development of the abnormal ECM structure 
observed in these mice (Flügel-Koch et al., 2002). The fact that TGF-ß1 down-regulated 
Igfbp6 in our analyzed TG corneas correlates with earlier data that showed that TGF-ß1 is 
able to down-regulate the expression of IGFBP6 in fibroblast cultures (Nik et al., 2007) and in 
rat osteoblasts (Gabbitas and Canalis, 1997).  
 
Dkk2, which was highly significant down-regulated in our real-time experiments (Fig. 4.26), 
codes for a secreted glycoprotein that belongs to an evolutionary conserved ancient protein 
family, originally discovered to being responsive for head induction in Xenopus by 
antagonizing Wnt signalling (Glinka et al., 1998). Dkk proteins are expressed throughout 
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development in a tissue- and stage-specific manner in tissues where epithelial-mesenchymal 
interactions occur (Monaghan et al., 1999), and where they modulate Wnt-signalling mediated 
developmental processes like cell fate, polarity and proliferation. Dkk2 binds to the frizzled 
co-receptor LDL-receptor related protein 6 (LPR6) with high affinity and, depending on cell 
context, the binding either promote or inhibit downstream canonical Wnt signalling. If the 
transmembrane receptor protein Kremen 2 also binds LRP6, the effect of Dkk on Wnt 
signalling will be negative (Mao et al., 2002). Dkk2 mRNA showed a strong expression in the 
developing murine cornea at E11.5 (Monaghan et al., 1999), whereas DKK2 was not found to 
be expressed in the mature human cornea (Turner et al., 2007), indicating that this gene is 
important for corneal development. As a modulator of Wnt-signalling through ß-catenin, 
Dkk2 may alter NC induction and cell differentiation, as well as NC cell migration, since ß-
catenin, in addition to translocating to the nucleus affecting gene expression, also can affect 
cytoskeletal architecture, cell shape and cell adhesion via binding to α-catenin and E-cadherin 
(reviewed by Jamora and Fuchs, 2002). In fact, Dkk2 down-regulates Wnt signalling in the 
NC-derived stroma and overlying surface ectoderm-derived corneal epithelium in the mouse. 
RA-signals originating from the retina activate Pitx2 in the developing stroma (Kumar and 
Duester, 2010). Here, Pitx2 activates Dkk2 which, via down-regulation of Wnt- signalling, 
can down-regulate Pitx2. Thus, Dkk2 is an integration-node between RA- and Wnt signalling 
in the developing ocular mesenchyme. The down-regulation of Dkk2 in our TG corneas could 
thus have led to an excess Wnt signalling, which could have led to the observed defects in 
corneal stromal architecture, including the abnormal shape of the cells and the irregular ECM, 
as well as to observed excessive proliferation and/or migration of NC-derived stromal 
mesenchyme cells  (Flügel-Koch et al., 2002).  
 
The crucial role of Dkk2 in the developing cornea could be observed in Dkk2-deficient mice, 
which showed a phenotype with hypomorphic eyes, ectopic eyelashes, abnormally thick 
corneal epithelium, irregular stromal ECM, immature stellate-shaped keratocytes, ectopic 
corneal stromal blood vessels, conjunctivalization of the corneal ectoderm, as well as 
epidermal characteristics of the conjunctiva/limbus. In another study Dkk2
-
/
-
 mice showed a 
phenotype where the cornea was opaque and where the corneal epithelium and conjunctiva 
showed characteristics of epidermis, including expression of epidermal-specific 
differentiation markers, hair growth, sebaceous glands and pigment granules. In both of these 
studies, the absence of Dkk2 led to an up-regulation of Wnt-signalling in ocular mesenchyme 
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(Gage et al., 2008; Mukhopadhyay et al., 2006). Many of the above mentioned corneal defects 
resemble the defects seen in our analyzed TG corneas, including hypomorphic eyes, opacity, 
irregular stromal ECM, immature stellate-shaped keratocytes and ectopic blood vessels 
(Flügel-Koch et al., 2002). Additionally, our microarray data showed that there was an up-
regulation of many epidermal-specific keratins in our analyzed TG corneas (discussed in 
Chapter 4.5.2). Down-regulation of Dkk2 in our analyzed TG corneas could thus be, via an 
up-regulation of Wnt-signalling, responsible for some of the observed corneal defects. Gage 
et al. (2008) suppose that NC-derived stromal RA and Pitx2 activated Dkk2 is needed to fine-
tune Wnt signalling in the stroma, as well as in the overlying epithelium. Wnt signalling is 
known to be high in conjunctival epithelium, whereas it is down-regulated in the developing 
corneal ectoderm (Liu et al., 2003). Thus, Wnt signalling could be important in the 
determination of corneal vs. conjunctival fate of ocular ectoderm. Since our analyzed TG 
corneas were opaque, and since Dkk2 in these corneas was highly significant down-regulated, 
Wnt signalling could be a factor that is involved in the development of corneal opacity in 
these mice.  
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6. Conclusion 
 
Since the normal and pathologic function of myocilin is unknown, we aimed to characterize 
MYOC, and thus to learn more about the way the gene is regulated, a topic of clinical interest, 
since myocilin expression has been found to be elevated in glaucoma patients (Lütjen-Drecoll 
et al., 1998; Konz et al., 2009). In addition, characterization of MYOC may give insight into 
the molecular networks that are linked to myocilin, thus enhancing the understanding of its 
function. The fact that we found elements within near nc regions of MYOC that enhanced 
gene expression over the level of the known MYOC basal promoter (Kirstein et al., 2000), 
indicates that MYOC may be subject of extensive pre-mRNA processing. Since these 
elements yet did not elevate gene expression level more than up to 3.7-fold over basal 
transcription level, there may be more important regions residing far beyond those analyzed. 
Future biochemical studies will be required to learn more about the mechanisms that are 
involved in pre-mRNA processing of MYOC and to find out what functional role and 
consequence an eventual processing of MYOC mRNA has on the molecular networks active 
in TM. 
 
Our aim to create a TM-specific enhancer element for targeted protein expression in this 
tissue, an aim that also is of clinical relevance in the attempt to treat POAG, gave unexpected 
novel information about the possible functions of myocilin in the brain. Unexpected and novel 
in vivo expression in the ependymal lining of the ventricular system, CP and CSF suggest that 
myocilin may have a function in the drainage of CSF, possibly in the way it acts in the CB 
and TM. Unexpected and novel myocilin expression within nerve cells of the CNS, 
suggesting a supporting, maintaining and/or modulating role, accentuates the known role of 
myocilin as a matricellular protein. Future molecular biological and histological studies aim 
to learn more about the function and possible clinically relevant role of myocilin within the 
CNS. 
 
Our project that aimed to create a mouse line that would able conditional knock-out of genes 
within the TM, which would help to resolve the molecular networks that are active in 
maintaining normal TM homeostasis and architecture, and thus a normal AH outflow 
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resistance, is still going on and intend to elongate the homologous flanks required for 
homologous recombination. Future projects aim to analyze the usefulness of the Myoc knock-
in mouse in its ability to conditionally knock out genes in the TM. 
 
Our aim to find genes that are differentially regulated upon TGF-ß1 overexpression in the 
mouse cornea intended to get an insight into the molecular networks that are active in corneal 
scar formation, and thus to find possible candidate genes that are responsible for corneal 
transparency, a clinically relevant area of interest, since corneal scar formation affects vision. 
Our analysis revealed that excess TGF-ß1 affects corneal development and integrity by 
affecting both extra- and intracellular molecular mechanism. Differential expression of genes 
coding for proteases, junction- and channel-forming proteins, cytoskeletal proteins, enzymes 
and transporters was observed in TG corneas. Additionally, several genes coding for proteins 
that affect elemental signalling pathways important in growth and differentiation were 
differentially regulated. Our findings might be of value for designing further future 
experiments that intend to resolve the molecular mechanisms that are active in scar formation, 
as well as intend to learn more about the molecular basis that maintain corneal transparency.  
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7. Summary 
 
The main focus of the thesis was set on approaches that aim to clarify molecular mechanisms 
that are responsible for an elevated aqueous humour (AH) outflow resistance in the trabecular 
meshwork (TM), leading to an elevated intraocular pressure (IOP) and primary open-angle 
glaucoma (POAG), an optic neuropathy that if uncured leads to blindness. Myocilin is, when 
mutated, responsible for autosomal dominant forms of POAG, which account for about 3 % of 
all cases. In addition, there is evidence that patients with other forms of POAG may express 
higher than normal amounts of TM myocilin. The normal and pathological function of how 
myocilin affects AH outflow resistance is unknown. By characterizing the human myocilin gene 
(MYOC) by reporter gene analysis, we wanted to get knowledge about how myocilin expression 
is regulated, and thus which elements within MYOC are responsible for its higher than normal 
expression in POAG cases. Our results indicate that intronic, as well as non-coding (nc) 3´-
downstream regions, are important for effective expression of myocilin, probably by being 
important during pre-mRNA processing.   
 
In a second animal model approach, we aimed to generate an artificial enhancer element for in 
vivo TM-directed protein expression. For this approach, we combined the MYOC basal promoter, 
since myocilin is abundantly and primarily expressed in the TM in human, with a tested artificial 
enhancer element that had been shown to drive effective reporter gene expression in TM cells in 
vitro. Unexpected activity of this combination in the tissues that regulate secretion and drainage 
of cerebrospinal fluid (CSF) in a mouse model, as well as expression of myocilin in these tissues 
and in CSF in rat and human, respectively, opened totally new insights about the function of 
myocilin, and confirmed that myocilin may have a function in regulating CSF secretion and 
drainage in the central nervous system (CNS) in mammals, much like it is involved in the 
drainage of AH in anterior eye in human. Expression of myocilin in nerve cells of rat CNS 
further confirmed earlier data about a neuronal function of myocilin.  
 
The third approach concerning POAG aimed to create a mouse model that would allow for 
conditional knock-out of genes in the TM by the Cre/loxP system, and which thus would offer 
immense possibilities in analyzing the effect that candidate POAG-causing genes has on AH 
Summary   177 
 
drainage resistance through the TM. For this purpose we successfully cloned a knock-in 
construct that would enable Cre recombinase to be expressed under the control of the 
endogenous myocilin promoter after homologous recombination at the Myoc locus in mouse 
embryonic stem cells (ESCs), and which thus would offer the possibility to generate a mouse-
line that would express Cre recombinase highly in the TM.  
 
Another focus was set on clarifying molecular mechanisms that are active during corneal wound 
healing, a process that may lead to loss of transparency of this tissue and thus impairment of 
vision. As a model for our analysis we used a mouse model that, due to an overexpression of the 
key wound healing processes regulator transforming growth factor (TGF)-ß1 in the lens, shows a 
phenotype that resembles corneal fibrosis, including corneal opacity. Microarray and real-time 
PCR data of transgenic (TG) corneas confirmed that TGF-ß1 induces differential regulation of 
several genes that code for proteins that regulate extra- and intracellular homeostasis and 
integrity, as well as code for proteins that modulate signalling cascades that are pivotal in growth 
and differentiation. The identified genes may be candidate genes that are important in 
maintaining corneal transparency. Our data serve as a basis on which further experiments 
concerning corneal scar formation and corneal transparency can be designed.    
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9. Appendix 
 
9.1. Recipes for buffers, solutions and media 
 
10 X annealing buffer: 
 
Ingredient: Final concentration: 
MgCl2  10 mM 
Tris-HCl, pH 8.0  200 mM 
 
 
Denaturation solution: 
 
Ingredient: Final concentration: 
NaOH     0.5 M 
NaCl     1.5 M 
 
 
50 X Denhardt´s solution: 
 
Ingredient: Final concentration: 
BSA  10 mg/ml 
Ficoll 400 10 mg/ml 
PVP K-30 10 mg/ml 
 
 
HEK-293-medium: 
 
DMEM + GlutaMAX-™ -II + 4.5 g/l D-Glucose, - Pyruvate containing from Invitrogen. 
Addition of 10 % (final concentration) sterile FCS. 
 
 
 
 
Fill up with nuclease-free H20. 
Fill up with H20 and autoclave. 
Fill up with H20, filter sterilize and store proper 
aliquots at – 20 °C. 
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High-salt buffer (500 ml): 
 
NaCl  29.22 g 
Tris-base 1.21 g 
0.5 M EDTA, pH 8.0 1 ml 
 
 
HTM-N-medium: 
 
DMEM + GlutaMAX-™ -II + 4.5 g/l D-Glucose, - Pyruvate from Invitrogen. 
Addition of 10 % (final concentration) sterile fetal calf serum (FCS) and 1 % (final 
concentration) sterile penicillin (10 000U/ml)/streptomycin (10 mg/ml)-mix.  
 
Injection buffer (100 ml): 
 
Tris-base 0.121 g 
0.5 M EDTA, pH 8.0 40 µl 
 
 
LacZ-fixation buffer (50 ml): 
 
Ingredient: Stock solution: ml/50 ml buffer: 
Glutaraldehyde  25 % 0.4 ml 
EGTA, pH 7.3 0.25 M 1.0 ml 
MgCl2  1 M 0.1 ml 
 
 
LacZ-staining solution 50 ml): 
 
Ingredient: Add: Final concentration: 
X-gal (dissolved in DMF)  2 ml (25 mg/ml in DMSO) 1 mg/ml 
Potassium ferrocyanide 106 mg 5 mM 
Potassium ferricyanide 82 mg 5 mM 
 
Fill up volume to 50 ml with LacZ-wash buffer. 
Adjust pH to 7.4, fill up with H20 to 500 ml and filter 
sterilize. 
Adjust to pH 7.5, fill up with ultrapure H20 to 
100 ml and filter sterilize. 
Fill up to 50 ml with 0.1 M 
NaPO4 buffer. 
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LacZ-wash buffer (500 ml): 
 
Ingredient: Stock solution: ml/500 ml buffer: 
MgCl2 1 M 1 ml 
Sodium deoxycholate  1 % 5 ml 
Nonidet-P40  2 % 5 ml 
 
 
LB (lysogeny broth)-medium and agar plates (1 l): 
 
NaCl     10 g 
Bacto tryptone        10 g 
Bacto yeast extract 5 g 
 
Adjust to pH 7.0, fill up with H20 to 1 l, autoclave and store at + 4 °C. For agar plates, let LB-
medium cool down to ~ 55 °C after autoclaving and add antibiotic for selection. In case of 
blue/white screening add also X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside)        
and IPTG (isopropyl-ß-D-thiogalactopyranoside). Pour plates and store at + 4 °C. 
  
Additives to LB-medium and LB-agar plates: 
 
Antibiotic: Stock solution: ml/1 l LB-medium: 
Ampicillin    100 µg/ml 1 ml 
Kanamycin         50  µg/ml 1 ml 
 
Additives for blue/white screening: 
 
Additive: Stock solution: ml/1 l LB-medium: 
IPTG   23.83 mg/ml 1 ml 
X-gal  20 mg/ml in dimethylformamide 1 ml 
 
 
 
 
 
Fill up volume with 0.1 M 
NaPO4 buffer. 
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Low-salt buffer (500 ml): 
 
NaCl  5.84 g 
Tris-base 1.21 g 
0.5 M EDTA, pH 8.0 1 ml 
 
 
0.1 M NaPO4 buffer (500 ml): 
 
1 M NaH2PO4 11.5 ml 
1 M Na2HPO4 38.5 ml 
H20 450 ml 
 
 
Neutralization solution: 
 
Ingredient: Final concentration: 
Tris-HCl          0.5 M 
NaCl    1.5 M  
 
 
(Pre-)hybridization solution (~ 20 ml): 
 
Formamide       10 ml 
 20 X SSC          5 ml 
50 X Denhadt´s solution            2 ml 
15 % SDS      2 ml 
Sheared salmon sperm (10 mg/ml)   200 µl 
 
Use this total of 19.2 ml for pre-hybridization. Just before hybridization, add 2 ml of 50 % 
dextransulphate (dissolved in H20), as well as the radioactively labelled probe to the pre-
hybridization solution (end volume 21.25 ml).  
 
 
 
Adjust pH to 7.4, fill up with H20 to 500 ml and 
filter sterilize. 
Adjust to pH 7.3.  
Fill up with H20, adjust to pH 7.4 and 
autoclave. 
 
Appendix  203 
 
Proteinase K lysis buffer: 
 
Ingredient: Final concentration: 
KCl  50 mM 
Tris-HCl, pH 8.3 10 mM 
MgCl2  2 mM 
Gelatine 0.1 mg/ml 
Nonidet P-40 0.45 % 
Tween-20 0.45 % 
 
 
20 X SSC (saline-sodium citrate) (1 l): 
 
NaCl    175.3 g 
Sodium citrate     88.2 g 
 
 
50 X TAE (Tris-acetate-EDTA (1 l): 
 
Tris base 242 g 
Acetic acid 57.1 ml 
0.5 M EDTA, pH 8.0 100 ml 
 
 
10 X TBE (Tris-borate-EDTA (1 l): 
 
Tris base 108 g 
Boric acid 55 g 
0.5 M EDTA pH 8.0 40 ml 
 
 
 
 
 
 
Store at – 20 °C. Tie up just before use and 
add 50 µl/ml of Proteinase K (stock 
concentration 10 mg/ml).  
Adjust to pH 7.0, fill up with H20 to 1 l and autoclave. 
Fill up with H20 to 1 l and filter sterilize. 
 
Fill up to 1 l with H20, autoclave. 
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9.2. Oligonucleotides  
 
Tables 9.1A – D summarize primers used in the creation of a myoc knock-in mouse line 
(Materials and methods 3.1.3 and Results 4.4.1).  
 
 
Primer: Sequence (5´→ 3´): 
Cre fw 1 GCTGGTTCCCACACTTCTC 
Cre fw 2 GGAGACAATGGTTGTCAACAGAG 
Cre fw 3 GGCGCTCTTGAAGAAGTCGTG 
Cre rev. 1 AATGGCCATGGGACGTCGACCTG 
Cre rev. 2 CTGCCACGACCAAGTGACAG 
Cre rev. 3 AGTGAAACAGGGGCAATGGTG 
Cre rev. 4 GCCTCGGTGCACATGCTTTAC 
 
 
 
 
NotI- 5´-flank fw GCGGCCGCAGCTTGGGAATCAGGTTTTCC 
XhoI- 5´-flank rev. CTCGAGCTTGGGACCACAGCTGCAG 
5´-flank fw 1 CAGGAACCAGGAAGAGAGCAG 
5´-flank fw 2 CCTGCAGAAGCCAAGTAGTCC 
5´-flank fw 3 GACTTGCCAGGCAAGAGTGG 
5´-flank fw 4 CAGGTGAACGCAGATGCACAC 
5´-flank fw 5 GTACTTGGTTCTCCTGCTTGG 
5´-flank rev. 1 CGTCCTGTAGCAGAGACGAAG 
    
Table 9.1B: Primers and their 5´ → 3´ sequences used for amplification of, and sequencing through, the 5´-
homologous flank. The restriction enzyme recognition sites for cloning are underlined. Primers used for the 
amplification of template for radioactive 5´-probe used in Southern blot are listed.   
 
 
 
NheI- 3´-flank fw GCTAGCAGCATCCAGCATGCAGACC 
SalI- 3´-flank rev. GTCGACGGACCAGCAATCTCTCTGG 
5´-probe fw GAGTCTCTGTGTCCAGAAATCC 
5´-probe rev. CAGCCAAGTCAGAGAAACTACC 
3´-probe fw GTCAGCAGTATTCTGAGGGTC 
3´-probe rev. TGGTCTCTTGCCTTCTTGCTC 
Table 9.1A: Primers and their 5´ → 
3´ sequences used for sequential 
sequencing of NLS-Cre-IRES-eGFP. 
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Table 9.1C: Primers and their 5´ → 3´ sequences used for amplification of, and sequencing through, the 3´-
homologous flank. The restriction enzyme recognition sites for cloning are underlined. Primers used for the 
amplification of template for radioactive 3´-probe used in Southern blot are listed. 
 
   
5´-flank-NLS-Cre fw CTCTTGCTGGCAGTGTGAGTG 
3´-flank-Neo rev. TCCAGATCCCTGGTTTGGGTC 
Cre rev. 5 CCTGTTTTGCACGTTCACCG 
 
Table 9.1D: Primers and their 5´ → 3´ sequences used to check the integrity of the myoc knock-in construct. Cre 
rev. 5 was, together with 5´-probe fw. (Table 9.1C), used to check that no deletion of the 5´-flank had occured 
during homologous recombination.  
 
 
Tables 9.2A and B summarize primers that are used in the creation of a ß-galactosidase 
overexpression mouse (Materials and methods 3.1.2.1 and Results 4.2.2), as well as in 
screening of founder animals (Materials and methods 3.3.3 and Results 4.2.5).  
 
 
PstI- RAREß fw CTGCAGGGTACGGGAGGTACTTGG 
NcoI- p313+67 rev. CCATGGTGCAGAGGCTTGGTGAGG 
LacZ rev. 3 CACCAACGTAACCTATCCCATT 
 
Table 9.2A: Primers and their 5´ → 3´sequences used for amplification of RAREß/PITX3/FOX-p313+67 from 
the Firefly Luciferase-reporter construct, as well as for proving for correct annealing of long 3 X NLS oligos. 
Restriction enzyme recognition sites for cloning are underlined.  
 
 
 
LacZ fw ATTATTTGCCCGATGTACGC 
LacZ rev. ACATCCAGAGGCACTTCACC 
NLS fw GATCCAAAAAAGAAGAGAAAGG 
LacZ rev. 2 CTGCGCAACTGTTGGGAAG 
 
 
 
 
 
Table 9.2B: Primers and their 5´ → 3´ 
sequences used for screening of ß-
galactosidase overexpression founder 
animals, as well as for routine genotyping of 
TG animals.  
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NheI-H1 fw GCTAGCGTGCCGTGCTTACATAGTGG  
XhoI-H1 rev. CTCGAGTGCTTCAGCCTAGGCAACAG   
NheI-H2 fw GCTAGCTCCTTGAATGCACCAGGCAC 
XhoI-H2 rev. CTCGAGTTACAGGGCCCATGCAAGTC  
NheI-H3 fw GCTAGCGTTACATGGTTACCACAAGCC 
XhoI-H3 rev. CTCGAGCTGCAATCACATCTCCCAACC 
NheI-H4 fw GCTAGCCAGCATACATGGGAGGGTG 
XhoI-H4 rev. CTCGAGGTACTGTGCTGGGTGCTTG 
NheI-H5-6 fw GCTAGCACTATCTGACACAGTACAGCC 
XhoI-H5-6 rev. CTCGAGTTCTTCTAGGTCATGTCAGCC 
NheI-H7 fw GCTAGCCATGTGTGTATGTGGGTGTGG 
XhoI-H7 rev. CTCGAGGCTCATTAGGTCCCTTTCCAG 
NheI-H8 fw GCTAGCAATGCCAGGAGAGCAAATAATG 
XhoI-H8 rev. CTCGAGTAACATGACCTTCCTGAACTTG 
NheI-H9 fw GCTAGCCTGGACCAGAACTATAACCAC 
XhoI-H9 rev. CTCGAGGAGGGATTTCATGACTGGAAC 
NheI-H10 fw GCTAGCCAACAGCCATGGTGAGAGG 
XhoI-H10 rev. CTCGAGACCACAGGCTTCTTGCCTG 
 
 
 
 
9.3. DNA standards 
 
 
  
 
 
Fig. 9.1:  100 bp DNA ladder. 0.5 µg of 100 bp DNA 
ladder run on a 1.3 % agarose gel and visualized by EtBr 
staining (source: New England Biolabs). 
Table 9.3: Primers 
and their 5´ → 3´ 
sequences used for 
amplification of 
conserved MYOC 
regions. Restriction 
enzyme recognition 
sites for cloning are 
underlined.  
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Fig. 9.2: 1 kb DNA ladder. 0.5 µg of 1 kb DNA ladder run 
on a 0.8 % agarose gel and visualized by EtBr (source: New 
England Biolabs). 
Fig. 9.3: 1 µg of λ DNA marker, EcoRI/HindIII 
digest run on a 1 % agarose gel (source: New England 
Biolabs). 
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9.4. Laboratory supplies 
 
9.4.1. Bacteria, reagents and kits used for molecular biology  
 
In all reactions nuclease-free H20 of HPLC grade was used (ROTH). All used chemical 
substances were of p.A. quality or designated as "extra pure" and purchased from Merck or 
Roth. Buffers and enzymes for restriction digestion were purchased from New England 
Biolabs or Fermentas.  
 
 
Supply: Source: 
Ampicillin ROTH 
Antibody H130 anti-myocilin Santa Cruz Biotechnology 
BSA ROTH 
Competent one shot® TOP10 E. coli cells Invitrogen 
100 mM d(A/C/G/T/)P  Qiagen 
[α-32P]dCTP HARTMANN ANALYTIC GmbH 
DMSO ROTH 
EndoFree Plasmid Maxi Kit Qiagen 
Fluorescein Qiagen 
Gel Loading Dye, blue (6 X) New England Biolabs 
GoTaq® Green Master Mix Promega 
IPTG ROTH 
iScript™ cDNA Synthesis Kit Bio-Rad Laboratories 
Kanamycin ROTH 
25 mM MgCl2 Qiagen 
Mini Quick Spin™ Column Roche 
NucleoSpin® Extract II Macherey-Nagel 
NucleoSpin® Plasmid Macherey-Nagel 
10 X PCR Buffer  Qiagen 
PCR Cloning kit Qiagen 
Proteinase K Fermentas 
PureYield™ Plasmid Midiprep System Promega 
QIAfilter Plasmid Maxi Kit Qiagen 
Random Primers DNA Labeling System Invitrogen 
Secondary antibody Alexa Fluor® 488 Invitrogen 
SYBR-Green I Qiagen 
Taq DNA Polymerase Qiagen 
TRIzol® Reagent Invitrogen 
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9.4.2. Kits and reagents used for cell culture techniques 
  
Supply: Source: 
CASY®ton Roche Innovatis AG 
Dexamethasone Sigma 
Dual-Luciferase® Reporter Assay System Promega 
FCS Invitrogen 
Lipofectamine™ 2000 Invitrogen 
1 X PBS Invitrogen 
Penicillin/Streptomycin-mix  Invitrogen 
Plus™ Reagent Invitrogen 
Trypsin Invitrogen 
 
 
 
9.4.3. Reagents and media used for histological techniques 
        
Supply: Source: 
DePeX mounting medium SERVA Electrophoresis GmbH 
Diethyl ether ROTH 
EGTA ROTH 
Glutaraldehyde 25% SERVA Electrophoresis GmbH  
Nonidet™ P-40  Sigma 
Potassium ferricyanide Merck 
Potassium ferrocyanide Merck 
Sodium deoxycholate  Roth 
Tissue-Tek® Sakura Finetek Europe B.V. 
VECTASHIELD® Mounting Medium with DAPI  Vector Laboratories 
X-gal ROTH  
 
 
 
9.4.4. Labware 
 
Supply: Source: 
BAS-MS 2025 imaging plate FUJIFILM Germany 
Cell culture plate, 24-well Sarstedt 
Chamber slide (1.8 cm2) Nunc 
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Coverslips, 24 x 60 mm VWR 
Dialysis tubular membrane and clips ROTH 
EasYFlask™ Nunclon™ ∆ ( 75 cm2) Nunc 
Elutip-d® Purification Minicolumn Schleicher & Schuell 
Eppendorf tube (1.7 ml/2.0 ml) ROTH 
Falcon tube (15 ml/50 ml) Sarstedt 
(Filter) pipette tips Sarstedt 
Hybridization bottle and caps with seals  Biometra 
iCycler iQ™ PCR Real-Time PCR Plate, 96 well BioRad 
Injection canulae HEILAND 
Luminometer vials (5 ml) Sarstedt 
Microseal® "B" Adhesive Seal BioRad 
Nylon membrane, positively charged Roche 
Parafilm® M Barrier Film Pechiney Plastic Packaging, Inc. 
Phase Lock Gel™ (light) tube (2.0 ml) Eppendorf 
Single-use syringe (1/2/5/10/50 ml) HEILAND 
Sterile plastic pipette (1/2/5/10/25/50 ml) Sarstedt 
Sterilization filter, 0.22 µm ROTH 
SuperFrost Ultra Plus® microscope slide MENZEL-GLÄSER 
UV-Cuvette PLASTIBRAND® 
Whatman®-Blotting paper  NeoLab 
X-ray cassette Rego X-ray GmbH 
 
 
 
9.4.5. Laboratory equipment 
      
Equipment: Source: 
Agarose gel electrophoresis system PEQLAB Biotechnologie GMBH 
Analytical balance Kern & Sohn GmbH 
AutoLumat LB 953 Berthold Technologies 
Axio Imager Z1 microscope Zeiss 
Axioskop 40 microscope Zeiss 
Axiovert 40 CFL microscope Zeiss 
CASY® Cell Counter Roche Innovatis AG 
Centrifuge Biofuge 13 Heraeus 
Centrifuge (models: 5415D, 5415R, 5804R and 5810R) Eppendorf 
Centro XS3 LB 960 microplate luminometer Berthold Technologies 
Crosslinker CL-1 Herolab GmbH 
Eraser Raytest GmbH 
HB-1000 hybridization oven  UVP Laboratory Products 
HERAcell 150 incubator Heraeus 
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HERAsafe® safety cabinet Heraeus 
Hybridization oven for isotopes Bachofer 
IDA Gel Documentation System Raytest GmbH 
IKAMAG® heating magnetic stirrer IKA®Werke GmbH 
Innova® 4200 Incubator Shaker  New Brunswick Scientific 
inoLab®-pH Meter WTW GmbH 
iQ™5 Multicolor Real-time PCR Detection System + iCycler BioRad 
Julabo SW water-bath  Julabo Labortechnik GmbH 
LB 124 contamination monitor Berthold Technologies 
Mastercycler Gradient Eppendorf 
Mastercycler Personal Eppendorf 
Memmert water-bath Memmert GmbH 
Mettler AE163 analytical balance Mettler-Toledo 
Microcome HM 500OM cryostat Microm International 
Microtome Supercut 2050 Reichert-Jung 
OV3 hybridization oven Biometra  
Phosphoimager Fujifilm FLA-5000 FUJIFILM Germany 
PIPETMAN® Concept electronic pipettes Gilson International 
Promax 1020 platform shaker Heidolph Instruments GmbH 
Research pipettes Eppendorf 
Spectrophotometer  Eppendorf 
Sprout™ minicentrifuge Biozym Scientific GmbH 
Stemi 2000 CS + KL 1500 LCD stereomicroscope Zeiss 
Systec V-75 autoclave Systec GmbH 
Thermoblock Bioblock Scientific 
Thermomixer Eppendorf 
Vortex-Genie 2 Scientific Industries, Inc.  
     
 
 
 
9.5. Software 
 
Software: Provider/Source: 
Adobe® Photoshop®  Adobe 
Aida Image Analyzer V.3.28  Fuji 
BLAST Source: http://blast.ncbi.nlm.nih.gov/Blast.cgi 
CorelDRAW® Corel Corporation 
Corel PHOTO-PAINT® Corel Corporation 
iQ™5 Optical System Software Version 2.0 Bio-Rad 
Microsoft® Excel Microsoft 
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Microsoft® PowerPoint Microsoft 
Microsoft® Word Microsoft 
MicroWin 2000  Berthold Technologies 
Primo Pro 3.4: PCR Primer Design Chang Bioscience 
Universal ProbeLibrary System Roche 
Vector NTI® Invitrogen 
VISTA Browser Source: http://pipeline.lbl.gov/cgi-bin/gateway2 
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